Scientific Programme
Scientific Programme
Scientific Programme
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
eular berlin 2012<br />
<strong>Scientific</strong> <strong>Programme</strong><br />
13:00 – 14:30 Hall 6.2 A<br />
Satellite Symposium: Abbott<br />
13:00 – 14:30 Hall 5.2 A<br />
Satellite Symposium: Pfizer<br />
13:00 – 14:30 Hall 6.2 B<br />
Satellite Symposium: UCB Pharma<br />
13:00 – 14:30 Hall 4.1<br />
Satellite Symposium: Celgene Corporation<br />
13:00 – 14:30 Room Dublin<br />
Satellite Symposium: International Medical Press<br />
13:00 – 14:30 Room Paris 2<br />
Satellite Symposium: Menarini<br />
12:00 – 13:00 Exhibition opening cocktail<br />
within the exhibition area<br />
13:30 - 14:30 Room New York 3<br />
PARE Session<br />
Pre-conference outlook<br />
Learning Objectives:<br />
• The session will give an overview about the congress<br />
centre and relevant venues for PARE delegates and<br />
will introduce the PARE and Joint Sessions<br />
Chairperson(s):<br />
Neil Betteridge (United Kingdom)<br />
Maria Batziou (Greece)<br />
Ursula Faubel (Germany) 13:35<br />
General information and outlook on EULAR 2012<br />
Kate Llewelyn Betteridge (United Kingdom) 13:55<br />
Abstract N° SP0001<br />
Overview of the PARE programme and joint sessions<br />
Yolanda Marron (Spain) 14:15<br />
Standing Committee of PARE meeting and networking<br />
dinner<br />
14:30 – 15:00<br />
Coffee break within the exhibition area<br />
15:00 - 16:30 Hall 1.2<br />
What is New (WIN)<br />
WIN Session 1<br />
Iain B. McInnes (United Kingdom) 15:05<br />
Abstract N° SP0002<br />
Early arthritis<br />
Alberto Martini (Italy) 15:45<br />
Paediatric rheumatology<br />
15:00 - 16:30 Hall 1.1<br />
Clinical Science Session<br />
Health economics of RA in 2012: Can we<br />
afford to treat? Can we afford not to treat?<br />
Chairperson(s):<br />
Annelies Boonen (Netherlands)<br />
Hans Severens (Netherlands) 15:05<br />
Key concepts for understanding the health-economics<br />
of RA<br />
Martin Neovius (Sweden) 15:25<br />
Abstract N° SP0003<br />
The costs to society of RA - data from the Swedish<br />
national registries<br />
Arthur Kavanaugh (USA) 15:45<br />
Abstract N° SP0004<br />
The gains to society from RA treatments - data from<br />
randomized trials<br />
Bengt Jönsson (Sweden) 16:05<br />
Abstract N° SP0005<br />
An economist's long-term perspective on the pricing of<br />
drugs<br />
15:00 - 16:30 Hall 6.2 A<br />
Clinical Science Session<br />
Interstitial lung disease in rheumatic<br />
disease: an update<br />
Learning Objectives:<br />
• To better understand the epidemiology genetics/<br />
natural history/risk factors for the development of<br />
ILD in association with rheumatic disease<br />
• To better understand the histopathology of the ILD<br />
seen with rheumatic disease and how it<br />
compares/contrast in our diseases - PSS, RA, SLE- as<br />
well as with idiopathic ILD<br />
1<br />
Wednesday, 6 June 2012<br />
19
Wednesday, 6 June 2012<br />
20<br />
<strong>Scientific</strong> <strong>Programme</strong><br />
• To provide an understanding of benefits and deficiencies<br />
of present treatment protocols for ILD and<br />
potential new therapeutic approaches<br />
Chairperson(s):<br />
Daniel Furst (USA)<br />
Oliver Distler (Switzerland)<br />
Eric Matteson (USA) 15:05<br />
Abstract N° SP0006<br />
Epidemiology/genetic predisposition/natural history of<br />
ILD in rheumatic disease: what do we know?<br />
Athol Wells (United Kingdom) 15:30<br />
Abstract N° SP0007<br />
Histopathology of ILD in rheumatic disease - what clues<br />
does it provide re pathogenesis and treatment options<br />
Kevin Brown (USA) 15:55<br />
ILD in rheumatic disease: present and future management<br />
L. A. Saketkoo (USA) 16:20<br />
D. Khanna, D. Huscher, P. Dellaripa, K. Flaherty,<br />
E. Matteson, C. Oddis, A. Wells, C. Denton,<br />
O. Distler, O. Kowal-Bielecka, N. Sandorfi,<br />
R. Christmann, K. Phillips, D. Pittrow, V. Strand,<br />
K. Brown, J. Seibold<br />
Abstract N° OP0001<br />
Developing a disease activity and therapeutic response<br />
index in connective tissue disease - interstitial lung<br />
disease (CTD-ILD): results from a delphi exercise:<br />
consensus on domains<br />
15:00 - 16:30 Hall 5.2 A<br />
How to Manage/Treat (HOT)<br />
How to manage 1<br />
Tore K. Kvien (Norway) 15:05<br />
Osteoarthritis<br />
David M. Reid (United Kingdom) 15:45<br />
Abstract N° SP0008<br />
Osteoporosis<br />
15:00 - 16:30 Hall 5.2 B<br />
Outcomes Science Session<br />
Long-term outcomes of modern treatment<br />
Chairperson(s):<br />
Deborah Symmons (United Kingdom)<br />
Axel Finchk (Switzerland)<br />
Johan Askling (Sweden) 15:05<br />
Abstract N° SP0009<br />
Mortality<br />
William G. Dixon (United Kingdom) 15:25<br />
Cardiovascular morbidity<br />
Ingemar Petersson (Sweden) 15:45<br />
Abstract N° SP0010<br />
Economic outcomes: sick leave and work disability<br />
L. Gossec (France) 16:05<br />
C. Gaujoux-Viala, A.-C. Rat, B. Fautrel, A. Saraux,<br />
F. Guillemin, S. Paternotte, M. Dougados<br />
Abstract N° OP0003<br />
Are patient global and fatigue predictive of structural<br />
outcomes, 3 years later, in patients in remission in early<br />
arthritis? Results from the French ESPOIR cohort<br />
M. T. Nurmohamed (Netherlands) 16:15<br />
Y. Bao, J. Signorovitch, P. M. Mulani, D. E. Furst<br />
Abstract N° OP0002<br />
Use of anti-TNF therapy is associated with reduced<br />
cardiovascular event risk in rheumatoid arthritis<br />
15:00 - 16:30 Hall 6.2 B<br />
Challenges in Clinical Practice Session<br />
Seronegative rheumatoid arthritis<br />
eular berlin 2012<br />
Learning Objectives:<br />
• Wrong diagnosis may be a reason for poor response<br />
to anti rheumatic medications. We present seronegative<br />
cases who were treated as early rheumatoid<br />
arthritis and were later revealed various diagnoses<br />
• The objective of this session is to remind of the<br />
necessity to re-evaluate diagnosis of patients with<br />
persistent seronegative “RA”<br />
Chairperson(s):<br />
Diego Kyburz (Switzerland)<br />
Tuulikki Sokka (Finland)<br />
Milos Antic (Switzerland) 15:05<br />
Abstract N° SP0011<br />
Case 1 presentation: Arthritis with Parvovirus<br />
Diego Kyburz (Switzerland) 15:10<br />
Abstract N° SP0011<br />
Case 1 discussion<br />
Tuomas Rannio (Finland) 15:25<br />
Abstract N° SP0011<br />
Case 2 presentation: Hemachromatosis<br />
Tuulikki Sokka (Finland) 15:30<br />
Abstract N° SP0011<br />
Case 2 discussion<br />
Milos Antic (Switzerland) 15:45<br />
Abstract N° SP0011<br />
Case 3 presentation: Whipple's disease<br />
Diego Kyburz (Switzerland) 15:50<br />
Abstract N° SP0011<br />
Case 3 discussion<br />
Tuomas Rannio (Finland) 16:05<br />
Abstract N° SP0011<br />
Case 4 presentation: Polycystic lipomembranous<br />
osteodysplasia (Nasu-Hakola disease)<br />
Tuulikki Sokka (Finland) 16:10<br />
Abstract N° SP0011<br />
Case 4 discussion
eular berlin 2012<br />
<strong>Scientific</strong> <strong>Programme</strong><br />
15:00 - 16:30 Hall 6.1<br />
PReS Session<br />
Transition for teenagers and young adults<br />
with arthritis: what does it need?<br />
Learning Objectives:<br />
• Understand how arthritis clinical phenoptypes differ<br />
in the adolescent age range compared to children<br />
• Learn some key clinical imperatives of caring for<br />
young adults who had JIA as a child<br />
• Hear data about E-health approach to long term data<br />
and follow up among adolescents with arthritis<br />
Chairperson(s):<br />
Nico Wulffraat (Netherlands)<br />
Michael Hofer (Switzerland)<br />
John Ioannou (United Kingdom) 15:05<br />
Abstract N° SP0012<br />
ERA in the adolescent age: one or two diseases<br />
Helen E. Foster (United Kingdom) 15:30<br />
Abstract N° SP0013<br />
Young adults who had JIA - key clinical management<br />
issues to remember<br />
Kirsten Minden (Germany) 15:55<br />
Abstract N° SP0014<br />
Data collection for adolescents with arthritis: how to<br />
make it cool<br />
N. Solari (Italy) 16:20<br />
E. Palmisani, A. Consolaro, A. Pistorio, S. Lanni,<br />
S. Dalprà, B. Schiappapietra, G. Bracciolini,<br />
A. Frisina, A. Martini, A. Ravelli<br />
Abstract N° OP0004<br />
Predictors of achievement of inactive disease in children<br />
with juvenile idiopathic arthritis treated with Etanercept<br />
15:00 - 16:30 Hall 5.1<br />
Fellows in Training Session<br />
Beginning and succeeding as a clinical<br />
academic researcher<br />
Learning Objectives:<br />
• To identify the balance between work and private life<br />
• To identify the balance between different aspects of<br />
your work: patient care and research<br />
• To identify key elements on starting clinical research<br />
Chairperson(s):<br />
Sofia Ramiro (Portugal)<br />
Axel Hueber (Germany)<br />
Ronald van Vollenhoven (Sweden) 15:05<br />
The big balancing act: time management<br />
E. Roussou (United Kingdom) 15:35<br />
M. Thapper<br />
Abstract N° OP0005<br />
“Rheumaholidays”, “niche” speciality and “women’s<br />
preference” is how final years medical students view<br />
rheumatology as a speciality when asked if they would<br />
consider it as part of fountation years training<br />
Loreto Carmona (Spain) 15:45<br />
Tips for becoming a successful clinical researcher<br />
Sofia Ramiro (Portugal) 16:15<br />
Panel discussion<br />
15:00 - 16:30 Room Europa 2<br />
Basic and Translational Science Session<br />
Meet the ADAM's family: ADAM, MMP's,<br />
ADAMTS<br />
Learning Objectives:<br />
• To understand the role of TIMPs in inflammation<br />
• To understand the function of ADAM17 and its role<br />
in inflammation<br />
• To understand how MMPs contribute to OA<br />
Chairperson(s):<br />
Carl Blobel (USA)<br />
Francesco dell’Accio (United Kingdom)<br />
Kati E. Georgiadis (USA) 15:05<br />
Abstract N° SP0019<br />
An aggrecanase-selective inhibitor for the treatment of<br />
osteoarthritis<br />
Stefan Rose-John (Germany) 15:25<br />
Abstract N° SP0020<br />
ADAM17 orchestrates pro- and anti-inflammatory cytokine<br />
activities<br />
Carl Blobel (USA) 15:45<br />
Abstract N° SP0021<br />
ADAM17/TACE is a key molecule in immune-complex<br />
and complement induced<br />
Amanda Fosang (Australia) 16:05<br />
Abstract N° SP0022<br />
Knock-in mice reveal in vivo consequences of MMP<br />
activity for OA<br />
15:00 - 16:30 Room Berlin 2<br />
Basic and Translational Science Session<br />
Talking microparticles<br />
Chairperson(s):<br />
Carlo Chizzolini (Switzerland)<br />
Paul Bowness (United Kingdom)<br />
Jörg H. Distler (Germany) 15:05<br />
Abstract N° SP0023<br />
Role of microparticles in inflammation<br />
Nigel Mackman (USA) 15:30<br />
Abstract N° SP0024<br />
Microparticles in haemostasis and thrombosis<br />
Mauro Perretti (United Kingdom) 15:55<br />
Abstract N° SP0025<br />
Neutrophil microparticles - what do they do?<br />
3<br />
Wednesday, 6 June 2012<br />
21
Wednesday, 6 June 2012<br />
22<br />
<strong>Scientific</strong> <strong>Programme</strong><br />
15:00 - 16:30 Room Dublin<br />
Health Professionals Session<br />
How to run an osteoarthritis clinic in daily<br />
practice<br />
Learning Objectives:<br />
• Describe various organizational models for osteoarthritis<br />
clinics, in particular the health professionals’<br />
role<br />
• Describe the key elements of the initial assessment to<br />
be employed in an osteoarthritis clinic<br />
• Describe the key elements of interventions to be<br />
included in an osteoarthritis clinic<br />
• Describe measurement instruments to evaluate the<br />
effectiveness of an osteoarthritis clinic on the individual<br />
patient’s and group levels<br />
Chairperson(s):<br />
Joost Dekker (Netherlands)<br />
Anne Marie Norén (Sweden)<br />
Krysia Dziedzic (United Kingdom) 15:05<br />
Abstract N° SP0015<br />
An overview of best practices for OA care<br />
Susan M. Oliver (United Kingdom) 15:25<br />
Abstract N° SP0016<br />
A nurse-led osteoarthritis clinic in specialist care<br />
Sita Bierma-Zeinstra (Netherlands) 15:45<br />
Abstract N° SP0017<br />
A stepped care approach towards hip and knee osteoarthritis<br />
in primary care<br />
Linda Fernandes (Norway) 16:05<br />
Abstract N° SP0018<br />
EULAR recommendations on non-pharmacological<br />
management of hip and knee OA<br />
15:00 - 16:30 Room Paris 2<br />
Practical Skills Session<br />
Ultrasound basic 1<br />
Chairperson(s):<br />
Marcin Szkudlarek (Denmark)<br />
Maria-Antonietta d'Agostino (France) 15:05<br />
Grading of synovitis in small joints<br />
Wolfgang Hartung (Germany) 15:25<br />
Grading of synovitis in large joints<br />
George W. Bruyn (Netherlands) 15:45<br />
Defining the ultrasound appearance of tenosynovitis<br />
Marcin Szkudlarek (Denmark) 16:05<br />
The practical case<br />
15:00 - 16:30 Room New York 1<br />
EULAR Projects in Clinical Affairs<br />
EULAR criteria - work to improve<br />
rheumatologic care<br />
eular berlin 2012<br />
Chairperson(s):<br />
Daniel Aletaha (Austria)<br />
Maya H. Buch (United Kingdom)<br />
Daniel Aletaha (Austria) 15:05<br />
Introduction<br />
Laure Gossec (France) 15:20<br />
EULAR recommendations for management of psoriatic<br />
arthritis<br />
N. Duru (Netherlands) 15:30<br />
M. C. van der Goes, J. W. Jacobs, T. Andrews,<br />
M. Boers, F. Buttgereit, N. Caeyers, M. Cutolo,<br />
S. Halliday, J. A. Da Silva, J. R. Kirwan, D. Ray,<br />
J. Rovensky, G. Severijns, R. Westhovens,<br />
J. W. Bijlsma<br />
Abstract N° OP0006<br />
EULAR evidence-based recommendations on the<br />
management of medium to high dose systemic glucocorticoid<br />
therapy in rheumatic diseases<br />
M. H. Buch (United Kingdom) 15:40<br />
L. Carmona, L. Silva, M. Boers on behalf<br />
of EULAR Task Force<br />
Abstract N° OP0007<br />
Development of EULAR recommendations for the<br />
reporting of clinical trial extension studies<br />
Michael T. Nurmohamed (Netherlands) 15:50<br />
Challenges in implementing EULAR recommendations:<br />
the CV risk recommendations<br />
L. Barbosa (Portugal) 16:00<br />
S. Ramiro, S. Garcês, M. J. Santos, J. Canas da Silva<br />
on behalf of Portuguese Rheumatology Nurse<br />
Practitioners Working Group<br />
Abstract N° OP0008-HPR<br />
Challenges with the applicability of the EULAR recommendations<br />
for rheumatology nursing management in<br />
Portugal<br />
Maxime Dougados (France) 16:10<br />
Conclusion
eular berlin 2012<br />
<strong>Scientific</strong> <strong>Programme</strong><br />
15:00 - 16:30 Room New York 3<br />
PARE Session<br />
Political campaigning<br />
Learning Objectives:<br />
• How to influence policy makers at national and E.U.<br />
level by using relevant data and new forms of social<br />
media to maximise the impact of key messages<br />
Chairperson(s):<br />
Marios Kouloumas (Cyprus)<br />
Josef S. Smolen (Austria)<br />
Jona Hölderle (Germany) 15:05<br />
Using social media to foster community and mobilise<br />
supporters<br />
Till Uhlig (Norway) 15:25<br />
Abstract N° SP0026<br />
How to use the new data from EUMUSC.NET to<br />
support national political campaigning<br />
Dragan Chichikj (Macedonia, 15:45<br />
The former Yugoslav Republic of)<br />
Abstract N° SP0027<br />
How to use the EULAR Brussels declaration 2010 in<br />
support of national campaigning<br />
L. M. Thomsen (Denmark) 16:05<br />
Abstract N° OP0009-PARE<br />
Easy-to-open packaging - a practical tool developed by<br />
involving people with arthritis<br />
I. Põldemaa (Estonia) 16:15<br />
K. Mustkivi, E. Adler<br />
Abstract N° OP0010-PARE<br />
"Life with a secret" - successful campaign designed by<br />
young rheumatics<br />
16:30 – 17:00 Coffee break<br />
17:00 - 18:30 Hall 1.1<br />
Clinical Science Session<br />
Lupus in little and big folks<br />
Learning Objectives:<br />
• In recent years a number of important clinical trials<br />
have been conducted in lupus and EULAR has developed<br />
management recommendations<br />
• This session seeks to deepen their understanding and<br />
facilitate their implementation<br />
Chairperson(s):<br />
Dimitrios Boumpas (Greece)<br />
Alberto Martini (Italy)<br />
David Jayne (United Kingdom) 17:05<br />
Abstract N° SP0028<br />
Adult lupus nephritis<br />
Alberto Martini (Italy) 17:25<br />
Paediatric lupus nephritis<br />
Caroline Gordon (United Kingdom) 17:45<br />
Abstract N° SP0029<br />
Adult neuropsychiatric lupus<br />
Tadej Avcin (Slovenia) 18:05<br />
Abstract N° SP0030<br />
Paediatric neurochiatric lupus<br />
17:00 - 18:30 Hall 6.2 A<br />
Clinical Science Session<br />
"RADAR" - RAre Diseases Associated<br />
with Rheumatology<br />
Learning Objectives:<br />
• EULAR strategic objective #1: to strengthen activities<br />
in areas that are currently less prioritized, such as<br />
non-inflammatory and orphan diseases<br />
Chairperson(s):<br />
Rolando Cimaz (Italy)<br />
Bernhard Manger (Germany)<br />
Julien Haroche (France) 17:05<br />
Abstract N° SP0031<br />
Erdheim-Chester disease - a multisystem disease with<br />
rheumatologic manifestations<br />
Christina Lampe (Germany) 17:30<br />
Abstract N° SP0032<br />
Mucopolysaccharidoses - what should the rheumatologist<br />
know?<br />
Jochen Zwerina (Austria) 17:55<br />
Abstract N° SP0033<br />
Stickler´s syndrome and other hereditary collagen disorders<br />
17:00 - 18:30 Hall 5.2 A<br />
How to Manage/Treat (HOT)<br />
How to manage 2<br />
Loic Guillevin (France) 17:05<br />
Abstract N° SP0034<br />
Vasculitis<br />
Yannick Allanore (France) 17:45<br />
Abstract N° SP0035<br />
Raynaud's phenomenon and systemic sclerosis<br />
Wednesday, 6 June 2012<br />
23
Wednesday, 6 June 2012<br />
24<br />
<strong>Scientific</strong> <strong>Programme</strong><br />
17:00 - 18:30 Hall 5.2 B<br />
Outcomes Science Session<br />
Equitable or equal? To what or to whom?<br />
Equity issues in rheumatology<br />
Learning Objectives:<br />
• By attending this session, one will learn basic<br />
concepts of health equity in rheumatic diseases, such<br />
as disparities, inequalities and inequities<br />
• You will also learn how equity is studied and<br />
approached<br />
• Examples of inequities in rheumatology will be presented<br />
Chairperson(s):<br />
Annelies Boonen (Netherlands)<br />
Estibaliz Loza (Spain)<br />
Francis Guillemin (France) 17:05<br />
Some variability may be good; other may lead to inequities<br />
Cory Borkhoff (Canada) 17:30<br />
Abstract N° SP0036<br />
Disparities in access and in quality of care in rheumatology<br />
Sherine E. Gabriel (USA) 17:55<br />
How could we reduce inequities?<br />
P. Putrik (Netherlands) 18:20<br />
S. Ramiro, T. Kvien, T. Uhlig , A. Boonen on behalf<br />
of Working Group Equity in Clinical Eligibility<br />
Criteria for RA Treatment<br />
Abstract N° OP0011<br />
Inequalities across 46 European countries in clinical<br />
eligibility criteria for the start of a first (reimbursed)<br />
biologic in patients with rheumatoid arthritis<br />
17:00 - 18:30 Hall 6.2 B<br />
Challenges in Clinical Practice Session<br />
Two difficult SLE patient cases<br />
Learning Objectives:<br />
• To understand the differential diagnosis of kidney<br />
problems in patients with APS<br />
• To understand the differential diagnosis of thrombocytopenia<br />
in patients with SLE<br />
Chairperson(s):<br />
Johannes W.J. Bijlsma (Netherlands)<br />
Nurten Duzu (Netherlands)<br />
Ruth Fritsch-Stork (Netherlands) 17:05<br />
Abstract N° SP0037<br />
Case 1 presentation: Kidney problems in patients<br />
with APS<br />
Ronald Derksen (Netherlands) 17:15<br />
Abstract N° SP0037<br />
Case 1 discussion<br />
Remco Luijten (Netherlands) 17:45<br />
Abstract N° SP0037<br />
Case 2 presentation: Thrombocytopenia in patients<br />
with SLE<br />
Ronald Derksen (Netherlands) 17:55<br />
Abstract N° SP0037<br />
Case 2 discussion<br />
17:00 - 18:30 Hall 6.1<br />
PReS Session<br />
Aseptic bone inflammation<br />
Chairperson(s):<br />
Julien Wipff (France)<br />
Hermann Girschick (Germany)<br />
Hermann Girschick (Germany) 17:05<br />
Abstract N° SP0038<br />
Chronic osteomyelitis in children<br />
Gilles Hayem (France) 17:30<br />
SAPHO syndrome, the perspective from the adult rheumatologist<br />
Christian M. Hedrich (USA) 17:55<br />
Abstract N° SP0039<br />
Immunological and genetic basis of CRMO<br />
A. Z. Bech (Denmark) 18:20<br />
T. Herlin, O. R. Hansen, C. Heuck, B. Fiirgaard<br />
Abstract N° OP0012<br />
Chronic recurrent non-bacterial osteomyelitis in Danish<br />
children<br />
17:00 - 18:30 Hall 5.1<br />
eular berlin 2012<br />
Fellows in Training Session<br />
From bench to bedside and vice versa<br />
in paeditaric rheumatology<br />
Learning Objectives:<br />
• Show the new developments in translational<br />
research in pediatric rheumatology and stimulate interactions<br />
and exchanges between young researchers<br />
Chairperson(s):<br />
Lucy Wedderburn (United Kingdom)<br />
Klaus Tenbrock (Germany)<br />
Ellen Wehrens (Netherlands) 17:05<br />
T effector cells out of control in JIA<br />
Kiran Nistala (United Kingdom) 17:25<br />
Balancing TH17 cells in arthritis<br />
Dirk Holzinger (Germany) 17:45<br />
MRP's: immune modulators and biomarkers in autoinflammation<br />
Elisabetta Traggiai (Italy) 18:05<br />
Purinergic control of B cell response and relevance for<br />
autoimmunity
eular berlin 2012<br />
<strong>Scientific</strong> <strong>Programme</strong><br />
17:00 - 18:30 Room Europa 2<br />
Basic and Translational Science Session<br />
From joint development to osteoarthritis<br />
Learning Objectives:<br />
• To gain insight into novel models that are useful for<br />
the study of osteoarthritis<br />
• To understand the contribution of abnormal joint and<br />
skeletal development to OA<br />
Chairperson(s):<br />
Francis Berenbaum (France)<br />
Amanda Fosang (Australia)<br />
Stefan Schulte-Merker (Netherlands) 17:05<br />
Abstract N° SP0043<br />
Zebrafish: a remarkable model to study skeletal development<br />
and disease<br />
Petra Seemann (Germany) 17:25<br />
Abstract N° SP0044<br />
Joint development and disease: the chick limb mode<br />
Harrie Weinans (Netherlands) 17:45<br />
Abstract N° SP0045<br />
Joint shape modeling and osteoarthritis<br />
M. van den Bosch (Netherlands) 18:05<br />
A. Blom, P. van Lent, H. van Beuningen,<br />
F. van de Loo, E. Blaney Davidson,<br />
P. van der Kraan, W. van den Berg<br />
Abstract N° OP0013<br />
Synovial overexpression of WNTS and WISP1 induces<br />
cartilage damage by skewing of TGF-beta signaling and<br />
reduction of the anti-hypertrophic factor SOX9<br />
P. Van Lent (Netherlands) 18:15<br />
M. ter Huurne, A. Blom, L. Casteilla, R. Blattes,<br />
C. Jorgensen, W. van den Berg<br />
Abstract N° OP0014<br />
Intra-articular injection of adipose-derived stem cells<br />
(ADSCS) inhibits synovial activation and protects<br />
against cartilage damage and osteophyte formation in<br />
murine experimental osteoarthritis<br />
17:00 - 18:30 Room Berlin 2<br />
Basic and Translational Science Session<br />
Fibroblasts transforming rheumatology<br />
Chairperson(s):<br />
Steffen Gay (Switzerland)<br />
Andrew Filer (United Kingdom)<br />
Elena Neumann (Germany) 17:05<br />
Abstract N° SP0046<br />
Pluripotent fibroblasts in RA<br />
Christopher P. Denton (United Kingdom) 17:25<br />
Abstract N° SP0047<br />
Role of fibroblasts in scleroderma<br />
Rik Lories (Belgium) 17:45<br />
Abstract N° SP0048<br />
Spondylarthropathy - a fibroblast driven disease?<br />
C. Beyer (Germany) 18:05<br />
N. Reich, S. C. Schindler, A. Distler, C. Dees,<br />
M. Tomcik, C. Hirth-Dietrich, G. von Degenfeld,<br />
P. Sandner, O. Distler, G. Schett, J. H. Distler<br />
Abstract N° OP0015<br />
Stimulation of soluble guanylate cyclase reduces experimental<br />
dermal fibrosis<br />
M. Tomcik (Czech Republic) 18:15<br />
K. Palumbo-Zerr, J. Avouac, A. Horn,<br />
A. Khodzighorova, P. Zerr, C. Dees, A. Distler,<br />
C. Beyer, R. Becvar, L. Senolt, O. Distler, G. Schett,<br />
J. H. Distler<br />
Abstract N° OP0016<br />
Tribbles homolog 3 mediates the stimulatory effects of<br />
TGF-beta on fibroblast activation and dermal fibrosis in<br />
systemic sclerosis<br />
17:00 - 18:30 Room Dublin<br />
Health Professionals Session<br />
Crossing boundaries of primary<br />
to secondary care<br />
eular berlin 2012<br />
Learning Objectives:<br />
• How to meet the future demands for cooperation<br />
between specialised care and primary care?<br />
Chairperson(s):<br />
Mari Klokkerud (Norway)<br />
Alison Hammond (United Kingdom)<br />
Stefan Bergman (Sweden) 17:05<br />
Opportunities and challenges in a future primary health<br />
care for people with rheumatic diseases<br />
Nina Østerås (Norway) 17:25<br />
Abstract N° SP0040<br />
Collaboration across health service levels - an example<br />
of a Norwegian joint projection programme between<br />
primary care and specialist care<br />
Connie R. Ziegler (Denmark) 17:45<br />
Abstract N° SP0041<br />
Hopes and real life experiences of communication<br />
between specialist health care and primary health<br />
Birgit Prodinger (Canada) 18:05<br />
Abstract N° SP0042<br />
Future challenges for health professionals; communication<br />
across health care levels<br />
Wednesday, 6 June 2012<br />
25
Wednesday, 6 June 2012<br />
26<br />
<strong>Scientific</strong> <strong>Programme</strong><br />
17:00 - 18:30 Room Paris 2<br />
Practical Skills Session<br />
Crystals in synovial fluid 1<br />
Learning Objectives:<br />
• The most common obstacles encountered by those<br />
interested in starting the crystal analysis process are:<br />
– the idea that crystal analysis is not possible<br />
without a fully equipped compensated polarized<br />
microscope<br />
– that it is time consuming<br />
– that it is difficult to differentiate urate from<br />
pyrophosphate crystals and<br />
– that learning will be a difficult process<br />
• These will be discussed, and the keys for starting with<br />
the generally available instruments - the ordinary<br />
microscope - will be given<br />
Chairperson(s):<br />
Eliseo Pascual Gomez (Spain)<br />
Thomas Bardin (France)<br />
Tutors:<br />
Jose Pimentao (Portugal)<br />
Francesca Oliviero (Italy)<br />
Mariano Andrés (Spain)<br />
17:00 - 18:30 Room Berlin 1<br />
Practical Skills Session<br />
MRI Workshop basic 1<br />
Chairperson(s):<br />
Kay-Geert Hermann (Germany)<br />
Mikkel Østergaard (Denmark)<br />
Espen A. Haavardsholm (Norway) 17:05<br />
Basic MRI technical issues and how to interpret and use<br />
the different MR image types in peripheral arthritis<br />
Mikaël Boesen (Denmark) 17:20<br />
MRI in rheumatoid arthritis<br />
Mikkel Østergaard (Denmark) 17:35<br />
Abstract N° SP0049<br />
MRI in psoriatic arthritis - update on the current state<br />
Kay-Geert Hermann (Germany) 17:50<br />
MRI of gout update on the current state<br />
Espen A. Haavardsholm (Norway) 18:05<br />
Recognizing common MRI pathologies in arthritis.<br />
Interactive assessment of MR images on PC projector<br />
17:00 - 18:30 Room New York 3<br />
eular berlin 2012<br />
PARE Session<br />
Less well-known but just as important:<br />
some 'other' rare musculoskeletal diseases<br />
Learning Objectives:<br />
• To raise awareness of the issues faced by people living<br />
with less well known RMDs e.g. access to effective<br />
treatments, stigma and social participation<br />
Chairperson(s):<br />
Kim Fligelstone (United Kingdom)<br />
Nele Caeyers (Belgium)<br />
Alan Tyndall (Switzerland) 17:05<br />
Abstract N° SP0050<br />
Treating the lesser-known RMDs<br />
Kirsten Lerstroem (United Kingdom) 17:25<br />
Abstract N° SP0051<br />
Accessing spealist care for rare and complex RMDs<br />
Ann T. Kennedy (Ireland) 17:45<br />
Abstract N° SP0052<br />
Taking action against stigmatization<br />
Cor van Drogen (Netherlands) 18:05<br />
Abstract N° SP0053<br />
Working to participate equally<br />
18:45 - 20:00 Hall 1.2<br />
EULAR 2012 Opening Plenary Session
eular berlin 2012<br />
<strong>Scientific</strong> <strong>Programme</strong><br />
08:15 – 09:45 Hall 1.2<br />
Satellite Symposium: Roche<br />
08:15 – 09:45 Hall 1.1<br />
Satellite Symposium: Abbott<br />
08:15 – 09:45 Hall 6.1<br />
Satellite Symposium: AstraZeneca<br />
08:15 – 09:45 Hall 4.1<br />
Satellite Symposium: Lilly<br />
08:15 – 09:45 Room Dublin<br />
Satellite Symposium: Ibsa - Laboratoires Genèvrier<br />
08:15 – 09:45 Room Paris 2<br />
Satellite Symposium: medac<br />
08:15 – 09:45 Room New York 1<br />
Satellite Symposium: Savient Pharmaceuticals<br />
08:15 - 09:45 Room Europa 2<br />
Basic and Translational Science Session<br />
MicroRNA - macro effect<br />
Chairperson(s):<br />
Ingo Tarner (Germany)<br />
Astrid Jüngel (Switzerland) 08:20<br />
Abstract N° SP0054F<br />
MicroRNA in rheumatoid arthritis epigenetics<br />
Gabor Illei (USA) 08:40<br />
Abstract N° SP0055<br />
MicroRNA in connective tissue disease<br />
Hans-Martin Jäck (Germany) 09:00<br />
Abstract N° SP0056<br />
Potential therapeutic use of microRNAs in rheumatology<br />
M. Trenkmann (Switzerland) 09:20<br />
M. Brock, R. E. Gay, R. Speich, B. A. Michel,<br />
S. Gay, L. C. Huber<br />
Abstract N° OP0017<br />
The TNF-alpha-induced miR-18A activates rheumatoid<br />
arthritis synovial fibroblast through a positive feedback<br />
loop in NF-kappa B signalling<br />
S. Vettori (Italy) 09:30<br />
M. Brock, N. Iwamoto, B. Maurer, A. Jungel,<br />
R. E. Gay, M. Calcagni, G. Valentini, J. J. Distler,<br />
S. Gay, O. Distler<br />
Abstract N° OP0018<br />
MicroRNA-145 down-regulation in systemic sclerosis is<br />
limited to skin fibroblasts and influenced by epigenetic<br />
modifications and negative feedback loop by TGF-ß<br />
08:15 - 09:45 Room Berlin 2<br />
Basic and Translational Science Session<br />
New developments in the pre-clinical<br />
phases of rheumatoid arthritis<br />
Learning Objectives:<br />
• Learn about new autoantibodies other than ACPAs in<br />
very early RA<br />
• Update on how the joint stroma might be the key<br />
driver in early disease<br />
• Appreciate the emerging data relating to lymph<br />
nodes in early RA development<br />
Thursday, 7 June 2012<br />
27
Thursday, 7 June 2012<br />
28<br />
<strong>Scientific</strong> <strong>Programme</strong><br />
Chairperson(s):<br />
Diane van der Woude (Netherlands)<br />
Lars Klareskog (Sweden)<br />
Rene Toes (Netherlands) 08:20<br />
New antibodies in early RA<br />
Andrew Filer (United Kingdom) 08:40<br />
Abstract N° SP0057<br />
Leucocyte - stromal interactions in preclinical RA<br />
Lisa van Baarsen (Netherlands) 09:00<br />
Abstract N° SP0058<br />
Where does RA start - the joint or lymphoid tissues?<br />
U. Harre (Germany) 09:20<br />
D. Georgess, R. Axmann, H. Bang,<br />
R. Toes, H. U. Scherer, A. Catrina, L. Klareskog,<br />
P. Jurdic, G. Schett<br />
Abstract N° OP0019<br />
Anti-citrullinated protein antibodies directly induce<br />
bone loss in rheumatoid arthritis<br />
J. Lubbers (Netherlands) 09:30<br />
M. Brink, L. A. van de Stadt, S. Vosslamber,<br />
J. G. Wesseling, D. van Schaardenburg,<br />
S. M. Rantapaa-Dahlqvist, C. L. Verweij<br />
Abstract N° OP0020<br />
Validation of gene signatures to predict rheumatoid<br />
arthritis development<br />
10:15 - 11:45 Hall 1.2<br />
What is New (WIN)<br />
WIN Session 2<br />
Francis Berenbaum (France) 10:20<br />
Osteoarthritis<br />
Mikkel Østergaard (Denmark) 11:00<br />
Abstract N° SP0059<br />
Clinical implications of imaging advances<br />
10:15 - 11:45 Hall 1.1<br />
Abstract Session<br />
Abstract Session: Update on non anti-TNF<br />
biologics<br />
Chairperson(s):<br />
Maya H. Buch (United Kingdom)<br />
Stanley Cohen (USA)<br />
P.-Y. Berclaz (USA) 10:20<br />
M. Genovese, M. Greenwald, C.-S. Cho,<br />
A. Berman, L. Jin, G. Cameron, L. Wang,<br />
L. Xie, D. Braun, S. Banerjee<br />
Abstract N° OP0021<br />
A phase 2 study of multiple subcutaneous doses of<br />
LY2439821, an anti-IL-17 monoclonal antibody, in<br />
patients with rheumatoid arthritis in two populations:<br />
naïve to biologic therapy or inadequate responders to<br />
tumor necrosis factor alpha inhibitors<br />
eular berlin 2012<br />
M. Schiff (USA) 10:30<br />
R. Fleischmann, M. Weinblatt, R. Valente,<br />
D. van der Heijde, G. Citera, C. Zhao,<br />
M. Maldonado<br />
Abstract N° OP0022<br />
Abatacept SC versus Adalimumab on background<br />
Methotrexate in RA: one year results from the AMPLE<br />
study<br />
T. W. Huizinga (Netherlands) 10:40<br />
A. J. Kivitz, M. Rell-Bakalarska,<br />
R. M. Fleischmann, M. Jasson, A. R. Radin,<br />
M. C. Genovese<br />
Abstract N° OP0023<br />
Sarilumab for the treatment of moderate-to-severe<br />
rheumatoid arthritis: results of a phase 2, randomized,<br />
double-blind, placebo-controlled, international study<br />
N. Damjanov (Serbia) 10:50<br />
M. Tlustochowicz, J. Aelion, A. Dimic,<br />
M. Greenwald, A. Diehl, I. Bhattacharya,<br />
S. Menon, I. Gourley<br />
Abstract N° OP0024<br />
Safety and efficacy of SBI-087 in subjects with active<br />
rheumatoid arthritis in a phase 2 randomized, doubleblind,<br />
placebo-controlled study<br />
B. Hsu (USA) 11:00<br />
S. Sheng, M. E. Weinblatt, J. S. Smolen<br />
Abstract N° OP0025<br />
Results from a multicenter, international, randomized,<br />
double-blind, placebo-controlled, phase 2 study of<br />
sirukumab, a human anti-IL-6 monoclonal antibody, in<br />
patients with active rheumatoid arthritis despite Methotrexate<br />
therapy<br />
I. Ancuta (Romania) 11:10<br />
C. Codreanu, R. Ionescu, M. Parvu, M. Bojinca<br />
Abstract N° OP0026<br />
Sustained and cumulated response over time in RA<br />
patients treated with Rituximab after initial failure of<br />
anti-TNF agents<br />
S. Drynda (Germany) 11:20<br />
M. Gloetzner, D. Leesch, J. Kekow<br />
Abstract N° OP0027<br />
A single nucleotide polymorphism in the MED29 gene<br />
is associated with the clinical outcome of a TNF-blocker<br />
and B cell directed therapy in RA patients<br />
K. Chatzidionysiou (Sweden) 11:30<br />
E. Lie, E. Nasonov, G. Lukina, M. Hetland, U. Tarp,<br />
I. Ancuta, K. Pavelka, D. Nordström, C. Gabay,<br />
H. Canhao, M. Tomsic, P. van Riel, J. Gomez-Reino,<br />
T. Kvien, R. van Vollenhoven<br />
Abstract N° OP0028<br />
Efficacy of different doses of Rituximab for the treatment<br />
of RA: data from the CERERRA collaboration
eular berlin 2012<br />
<strong>Scientific</strong> <strong>Programme</strong><br />
10:15 - 11:45 Hall 6.2 A<br />
Abstract Session<br />
Abstract Session: Osteoarthritis<br />
Chairperson(s):<br />
Philip G. Conaghan (United Kingdom)<br />
Ali Guermazi (USA)<br />
A. Guermazi (USA) 10:20<br />
M. Jarraya, D. T. Felson, D. Hayashi, F. W. Roemer,<br />
Y. Zhang, J. Niu, M. Crema, M. Englund,<br />
J. A. Lynch, M. C. Nevitt, J. Torner, C. E. Lewis<br />
Abstract N° OP0029<br />
Medial meniscal root tears are associated with medial<br />
meniscal extrusion and medial tibiofemoral cartilage<br />
damage - the MOST study<br />
P. M. Welsing (Netherlands) 10:30<br />
M. B. Kinds, A. Marijnissen, M. Viergever,<br />
P. J. Emans, F. P. Lafeber<br />
Abstract N° OP0030<br />
Identifying radiographic phenotypes of early knee<br />
osteoarthritis using separate quantitative features might<br />
improve patient selection for more targeted treatment<br />
J. Wesseling (Netherlands) 10:40<br />
S. M. Bierma-Zeinstra, M. Kloppenburg,<br />
J. W. Bijlsma<br />
Abstract N° OP0031<br />
Comparison between CHECK study (Cohort Hip&<br />
Cohort Knee) and osteoartritis initiative; development<br />
of pain and function in 3 years of follow-up<br />
F. Birrell (United Kingdom) 10:50<br />
A. Abraham, K. D. Mann, M. S. Pearce, R. M. Francis<br />
Abstract N° OP0032<br />
Ultrasound features of osteophytes and cartilage thickness<br />
at the knee are associated with pain and functional<br />
impairment: the Newcastle thousand families study<br />
R. Wittoek (Belgium) 11:00<br />
D. Elewaut, G. Verbruggen<br />
Abstract N° OP0033<br />
Radiographical follow-up data of a one-year open-label<br />
extension study of treatment with Adalimumab in<br />
erosive osteoarthritis of the IP joints<br />
M. Englund (Sweden) 11:10<br />
I. K. Haugen, A. Guermazi, F. W. Roemer, J. Niu,<br />
T. Neogi, P. Aliabadi, M. Clancy, D. T. Felson<br />
Abstract N° OP0034<br />
The association between radiographic hand osteoarthritis<br />
and meniscal damage on MRI in the general<br />
population<br />
J.-D. Laredo (France) 11:20<br />
A. Wyler, C. Alvarez, M. Aout, M. Lequesne,<br />
E. Vicaut<br />
Abstract N° OP0035<br />
Value of bilateral standing oblique radiographs («faux<br />
profil de Lequesne») in the diagnosis of hip osteoarthritis<br />
S. Lee (Korea, Republic Of) 11:30<br />
T.-N. Kim, S.-H. Kim<br />
Abstract N° OP0036<br />
Sarcopenic obesity is more closely associated with<br />
radiographic knee osteoarthritis than non-sarcopenic<br />
obesity: a cross-sectional study using data from the fifth<br />
Korean national health and nutrition examination<br />
survey (KNHANES V-1)<br />
10:15 - 11:45 Hall 5.2 A<br />
How to Manage/Treat (HOT)<br />
How to manage 3<br />
Jürgen Braun (Germany) 10:20<br />
Abstract N° SP0060<br />
Spondyloarthritis/ankylosing spondylitis drug therapy<br />
Filip van den Bosch (Belgium) 11:00<br />
Abstract N° SP0061<br />
Psoriatic arthritis<br />
10:15 - 11:45 Hall 5.2 B<br />
Abstract Session<br />
Abstract Session: Osteoporosis<br />
Chairperson(s):<br />
Gyula Poor (Hungary)<br />
Kenneth Saag (USA)<br />
O. Törring (Sweden) 10:20<br />
J. Brown, J.-E. B. Jensen, N. Gilchrist, C. Recknor,<br />
C. Roux, M. Austin, A. Wang, A. Grauer, P.-R. Ho,<br />
R. Wagman<br />
Abstract N° OP0037<br />
Denosumab discontinuation and associated fracture<br />
incidence: analysis from the FREEDOM trial<br />
I. Ghozlani (Morocco) 10:30<br />
A. Rezqi, A. Mounach, L. Achemlal, A. Bezza,<br />
A. El Maghraoui<br />
Abstract N° OP0038<br />
Vertebral fractures prevalence and abdominal aortic<br />
calcification in men<br />
A. Dhainaut (Norway) 10:40<br />
M. Hoff, U. Syversen, G. Haugeberg<br />
Abstract N° OP0039<br />
Increased porosity in hand bones is strongly associated<br />
with distal radius fracture in elderly women<br />
J. Kikuta (Japan) 10:50<br />
M. Ishii<br />
Abstract N° OP0040<br />
Dynamic in vivo imaging of TH17-mediated control of<br />
osteoclast function in live bones by using intravital<br />
multiphoton microscopy<br />
Thursday, 7 June 2012<br />
29
Thursday, 7 June 2012<br />
30<br />
<strong>Scientific</strong> <strong>Programme</strong><br />
D. Umlauf (Germany) 11:00<br />
H. Hidding, L. O. Lindemann, S. Frank, B. Dankbar,<br />
C. Cromme, M. Rupp, R. Stange, R. P. Marshall,<br />
M. Amling, A. Dietrich, M. Steiner, U. Kornak,<br />
A. Schwab, T. Pap, J. Bertrand<br />
Abstract N° OP0041<br />
Essential role for TRPC1 channels in osteoclast fusion<br />
and in osteoporotic bone loss<br />
H. Z. Ke (USA) 11:10<br />
M. S. Ominsky, Q.-T. Niu<br />
Abstract N° OP0042<br />
Increased modeling-based bone formation and decreased<br />
bone resorption on endocortical surfaces in male<br />
cynomolgus monkeys treated with sclerostin antibody<br />
A. Sehgal (USA) 11:20<br />
A. Mannalithra, A. Mithal, G. Singh,<br />
G. Triadafilopoulos<br />
Abstract N° OP0043<br />
Hip fracture in the extreme elderly: the last frontier of a<br />
growing public health problem<br />
D. Padhi (USA) 11:30<br />
M. Allison, A. J. Kivitz, M. J. Gutierrez,<br />
B. Stouch, C. Wang, G. Jang<br />
Abstract N° OP0044<br />
The effects of multiple doses of sclerostin antibody<br />
AMG 785 in healthy men and postmenopausal women<br />
with low bone mass<br />
10:15 - 11:45 Hall 6.2 B<br />
Abstract Session<br />
Abstract Session: RA prognosis, predictors,<br />
outcomes<br />
Chairperson(s):<br />
Günter Steiner (Austria)<br />
Carlo Salvarini (Italy)<br />
N. Soroka (Belarus) 10:20<br />
V. Yagur, N. Dostanko<br />
Abstract N° OP0045<br />
Genetic markers of sulphasalazine adverse reactions in<br />
rheumatoid arthritis patients<br />
M. Lahiri (Singapore) 10:30<br />
C. Morgan, R. N. Luben, D. K. Bunn, M. Lunt,<br />
S. M. Verstappen, D. P. Symmons, K.-T. Khaw,<br />
N. J. Wareham, I. N. Bruce<br />
Abstract N° OP0046<br />
A risk score to identify individuals at higher risk of<br />
inflammatory polyarthritis: results from the European<br />
prospective investigation of cancer (NORFOLK) and<br />
the NORFOLK arthritis register (the EPIC-2-NOAR<br />
study)<br />
eular berlin 2012<br />
J. Listing (Germany) 10:40<br />
D. Pattloch, J. Kekow, J. Kaufmann,<br />
G.-R. Burmester, A. Zink, A. Strangfeld<br />
Abstract N° OP0047<br />
Successful control of disease activity and treatment with<br />
biologics increase the life expectancy in rheumatoid<br />
arthritis patients<br />
E. Nikiphorou (United Kingdom) 10:50<br />
L. Carpenter, D. James, P. Kiely, D. Walsh,<br />
R. Williams, A. Young on behalf of Early<br />
Rheumatoid Arthritis Study (ERAS), Early<br />
Rheumatoid Arthritis Network (ERAN)<br />
Abstract N° OP0048<br />
Orthopaedic interventions for RA have changed over<br />
the period 1986-2011. An evaluation of joint surgery<br />
rates and DMARD/anti-TNF treatment patterns in two<br />
UK inception cohorts<br />
L. Aguilar-Lozano (Mexico) 11:00<br />
J. Padilla-Ibarra, C. Sandoval-Castro,<br />
J. D. Castillo-Ortiz, J. Morales-Torres,<br />
C. Hernandez, R. Burgos-Vargas, C. Pacheco-Tena,<br />
C. Ramos-Remus<br />
Abstract N° OP0049<br />
The lenght of remission and rate of relapse after<br />
Tocilizumab withdrawal in rheumatoid arthritis patients<br />
A. Ruyssen-Witrand (France) 11:10<br />
P.-A. Gourraud, D. Nigon, C. Lukas,<br />
C. Miceli-Richard, B. Jamard, A. Cantagrel,<br />
A. Cambon-Thomsen, P. Dieudé, A. Constantin<br />
Abstract N° OP0050<br />
Evolution of the alternative classification of HLA-DRB1<br />
alleles in rheumatoid arthritis: impact on the production<br />
of the anti-citrullinated protein antibodies and structural<br />
progression, data from the ESPOIR cohort<br />
S. Lillegraven (USA) 11:20<br />
N. A. Shadick, Z. Jabbar-Lopez, A. Potapov,<br />
M. L. Frits, C. K. Iannaccone, E. A. Haavardsholm,<br />
T. K. Kvien, M. E. Weinblatt, D. H. Solomon<br />
Abstract N° OP0051<br />
Joint damage progression in established rheumatoid<br />
arthritis: common and strongly associated with seropositivity<br />
A. Filer (United Kingdom) 11:30<br />
M. Z. Cader, A. Abhishek, G. Allen, C. Buckley,<br />
P. de Pablo, K. Raza<br />
Abstract N° OP0052<br />
Use of ultrasound to predict persistence in patients with<br />
very early synovitis
eular berlin 2012<br />
<strong>Scientific</strong> <strong>Programme</strong><br />
10:15 - 11:45 Hall 6.1<br />
Abstract Session<br />
PReS Abstract Session: Basic Science<br />
in paediatric rheumatology<br />
Chairperson(s):<br />
Nico Wulffraat (Netherlands)<br />
Martina Prelog (Germany)<br />
Nico Wulffraat (Netherlands) 10:20<br />
Introduction<br />
K. Tenbrock (Germany) 10:30<br />
K. Ohl, T. Rauen<br />
Abstract N° OP0053<br />
CREMalpha destabilizes Foxp3 expression in regulatory<br />
T cells<br />
A. Avau (Belgium) 10:40<br />
T. Mitera, K. Put, S. Put, T. Tousseyn, A. D. Billiau,<br />
C. Wouters, P. Matthys<br />
Abstract N° OP0054<br />
Complete Freund’s adjuvant induces, in interferongamma-deficient<br />
mice, a chronic inflammatory disease<br />
reminiscent of systemic juvenile idiopathic arthritis<br />
W. De Jager (Netherlands) 10:50<br />
S. J. Vastert, B. J. Noordman, B. J. Prakken,<br />
N. M. Wulffraat<br />
Abstract N° OP0055<br />
IL-1 receptor antagonist restores IL-18 NK cell axis in<br />
systemic JIA<br />
Y. Fleischer (Germany) 11:00<br />
K. Barczyk, L. Klotz, H. Wiendl, J. Roth<br />
Abstract N° OP0056<br />
12/15-lipoxygenase mediates GC-induced anti-inflammatory<br />
mechanisms in monocytes<br />
L. Watson (United Kingdom) 11:10<br />
A. Midgley, L. Ballantine, C. A. Jones,<br />
R. C. Holt, S. D. Marks, C. Pilkington, K. Tullus,<br />
M. W. Beresford<br />
Abstract N° OP0057<br />
Monocyte chemoattractant protein 1 is expressed from<br />
kidney epithelial cells in response to activated macrophages<br />
in juvenile-onset systemic lupus erythematosus<br />
(JSLE)<br />
K. N. Sustal (Germany) 11:20<br />
G. Almanzar, R. Trippen, K. Höfner, M. Prelog<br />
Abstract N° OP0058<br />
CCR6+ T cells in children with juvenile idiopathic<br />
arthritis<br />
Martina Prelog (Germany) 11:30<br />
Conclusion<br />
10:15 - 11:45 Hall 5.1<br />
Abstract Session<br />
Abstract Session: Lupus and Sjögren's:<br />
basics - diagnosis - treatment<br />
Chairperson(s):<br />
Jane E. Salmon (USA)<br />
Athanasios G. Tzioufas (Greece)<br />
T. Kaneko (Japan) 10:20<br />
Y. Saito, T. Kotani, H. Ohnishi, Y. Murata,<br />
Y. Yonemoto, K. Okamura, T. Matozaki,<br />
K. Takagishi<br />
Abstract N° OP0059<br />
Importance of the protein tyrosine phosphatase shp1 in<br />
dendritic cells for prevention of TH1 cell differentiation<br />
and autoimmunity: a potential target for the therapy<br />
P. L. Meroni (Italy) 10:30<br />
E. Raschi, C. Chighizola, C. Grossi, N. Ronda,<br />
R. Gatti, M. O. Borghi<br />
Abstract N° OP0060<br />
Beta2GPI and TLR4 interaction on endothelial cells: a<br />
bridge between innate and adaptive immunity in APS<br />
J. G. Hanly (Canada) 10:40<br />
On behalf of the Systemic Lupus International<br />
Collaborating Clinics (SLICC)<br />
Abstract N° OP0061<br />
Seizures in systemic lupus erythematosus: a prospective<br />
study of predictors and outcomes in a large, international,<br />
disease inception cohort<br />
K. Rao (USA) 10:50<br />
F. Ferrario, T. Cook, I. Bajema, J. A. Bruijn,<br />
L.-H. Noel, R. Maciuca, P. Brunetta, S. Shahdad<br />
Abstract N° OP0062<br />
Lupus nephritis histopathology interobserver agreement<br />
between local pathologists and an expert panel of<br />
nephropathologists in belong<br />
M. O'Toole (USA) 11:00<br />
A. Seyhan, Y. Zhang, F. W. Immermann,<br />
A. Hill, P. Reddy, J. Masferrer, T. Zhou, W. Mounts,<br />
M. Whitley, T. Walker, S. Kamp, J. James,<br />
S. Sridharan, J. T. Merrill, M. Honczarenko<br />
Abstract N° OP0063<br />
Impact of baseline interferon pathway activation on<br />
widespread gene expression changes with disease flare<br />
in lupus patients: interim report from the BOLD (biomarkers<br />
of lupus disease) study<br />
G. Bertsias (Greece) 11:10<br />
M. Tektonidou, Z. Amoura, M. Aringer, I. Bajema,<br />
J. Berden, J. Boletis, R. Cervera, T. Dörner,<br />
A. Doria, F. Ferrario, J. Flöge, F. Houssiau,<br />
J. P. Ioannidis, D. Isenberg, C. G. Kallenberg,<br />
L. Lightstone, S. Marks, A. Martini, G. Moroni,<br />
I. Neumann, P. Niaudet, M. Praga, M. Schneider,<br />
V. Tesar, C. Vasconcelos, R. van Vollenhoven,<br />
E. Zakharova, M. Haubitz, C. Gordon, D. Jayne,<br />
D. Boumpas<br />
Abstract N° OP0064<br />
Joint EULAR/ERA-EDTA recommendations for the<br />
management of adult and paediatric lupus nephritis<br />
Thursday, 7 June 2012<br />
31
Thursday, 7 June 2012<br />
32<br />
<strong>Scientific</strong> <strong>Programme</strong><br />
V. Devauchelle-Pensec (France) 11:20<br />
X. Mariette, S. Jousse-Joulin, J.-M. Berthelot,<br />
A. Perdriger, E. Hachulla, X. Puéchal, V. Le Guern,<br />
J. Sibilia, J.-E. Gottenberg, L. Chiche, V. Goeb,<br />
G. Hayem, J. Morel, C. Zarnitsky, J.-J. Dubost,<br />
J.-O. Pers, E. Nowak, A. Saraux on behalf of the<br />
TEARS study group (Institutional grant support<br />
from the French Health ministry PHRC 2007)<br />
Abstract N° OP0065<br />
Tolerance and efficacy of Rituximab in primary Sjögren<br />
syndrome (tears): results of a randomized controlled trial<br />
G. Cinquetti (France) 11:30<br />
C. Larroche, B. Combe, E. Hachulla, O. Meyer,<br />
E. Pertuiset, G. Kaplanski, X. Mariette,<br />
J.-E. Gottenberg on behalf of Club Rhumatismes et<br />
Inflammations<br />
Abstract N° OP0066<br />
Efficacy of Rituximab in systemic manifestations of<br />
patients with primary Sjögren’s syndrome: results from<br />
the AIR registry<br />
10:15 - 11:45 Hall 4.1<br />
Abstract Session<br />
Abstract Session: Regional pain and<br />
fibromyalgia: understanding mechanisms<br />
and effective management<br />
Chairperson(s):<br />
Serge Perrot (France)<br />
Mark Porcheret (United Kingdom)<br />
E. Docampo (Spain) 10:20<br />
G. Escaramis, R. Rabionet, J. Carbonell, J. Rivera,<br />
J. Alegre, J. Vidal, X. Estivill, A. Collado<br />
Abstract N° OP0067<br />
Cluster analysis of clinical data identifies fibromyalgia<br />
subgroups<br />
D. Bohn (Germany) 10:30<br />
H. Kühn-Becker, G. Schmutzer, W. Häuser<br />
Abstract N° OP0068<br />
Mediation of childhood/adolescence maltreatment and<br />
adult fibromyalgia syndrome by depression - a case<br />
control study<br />
E. Bossema (Netherlands) 10:40<br />
H. Van Middendorp, J. W. Jacobs, J. W. Bijlsma,<br />
R. Geenen<br />
Abstract N° OP0069-HPR<br />
The influence of weather on daily pain and fatigue in<br />
female patients with fibromyalgia<br />
W. Häuser (Germany) 10:50<br />
I. Kopp<br />
Abstract N° OP0070<br />
Update of the German evidence-based guideline on the<br />
management of fibromyalgia syndrome<br />
eular berlin 2012<br />
H. G. Predel (Germany) 11:00<br />
B. Giannetti, I. Burnett, A. M. Hug<br />
Abstract N° OP0071<br />
Efficacy and safety of diclofenac diethylamine 1.16% gel<br />
in the treatment of acute neck pain: a randomized,<br />
double-blind, placebo-controlled study<br />
T. Krogh (Denmark) 11:10<br />
E. M. Bartels, T. Ellingsen, K. Stengaard-Pedersen,<br />
R. Buchbinder, U. Fredberg, H. Bliddal,<br />
R. Christensen<br />
Abstract N° OP0072<br />
Comparative effectiveness of injection therapies in<br />
lateral epicondylitis: a systematic review and network<br />
meta-analysis of randomized controlled trials<br />
L. Grøvle (Norway) 11:20<br />
J. I. Brox, A. J. Haugen, A. Keller, B. Natvig,<br />
M. Grotle<br />
Abstract N° OP0073<br />
Prognostic factors for return to work in patients with<br />
sciatica<br />
N. T. Baerlecken (Germany) 11:30<br />
M. Stoll, T. Witte, R. E. Schmidt, D. Meyer-Olson<br />
Abstract N° OP0074<br />
Clinical study: frequency and manifestations of joint<br />
disease in HIV-infected patients<br />
10:15 - 11:45 Room Europa 2<br />
Abstract Session<br />
Abstract Session: Early pathogenic<br />
mechanisms; clues for targeted therapies<br />
in arthritis<br />
Chairperson(s):<br />
Frances Humby (United Kingdom)<br />
Ruth Fritsch-Stork (Netherlands)<br />
L. Yeo (United Kingdom) 10:20<br />
A. D. Filer, C. D. Buckley, D. Scheel-Toellner,<br />
K. Raza<br />
Abstract N° OP0083<br />
Comparison of synovial tissue cytokine mRNA profiles<br />
in very early arthritis patients with divergent outcomes<br />
C. Turesson (Sweden) 10:30<br />
M. Hansson, U. Bergström, L. T. Jacobsson,<br />
L. Mathsson, L. Klareskog, P.-J. Jakobsson,<br />
R. Holmdahl, J. Rönnelid<br />
Abstract N° OP0084<br />
Patterns of circulating antibodies in the pre-clinical<br />
phase of rheumatoid arthritis suggest epitope spreading<br />
in the immune reaction against citrullinated peptides<br />
M. Brink (Sweden) 10:40<br />
M. Hansson, L. Mathsson, L. Nogueira, G. Serre,<br />
P.-J. Jakobsson, R. Holmdahl, J. Rönnelid,<br />
L. Klareskog, S. Rantapää Dahlqvist<br />
Abstract N° OP0085<br />
Multiplex analysis of antibodies against citrullinated<br />
peptides in individuals prior to development of rheumatoid<br />
arthritis
eular berlin 2012<br />
<strong>Scientific</strong> <strong>Programme</strong><br />
P. Hoff (Germany) 10:50<br />
C. M. Spies, T. Gaber, J. Mazuch, B. Maier, M. Hahne,<br />
C. Strehl, C. L. Tran, N. Soboleva, A. Stoehr,<br />
M. Wagegg, M. Fangradt, M. Jakstadt, D. Huscher,<br />
G.-R. Burmester, J. Detert, A. Kramer, F. Buttgereit<br />
Abstract N° OP0086<br />
Alterations of immune cellular circadian rhythms in<br />
rheumatoid arthritis<br />
N. Y. Lin (Germany) 11:00<br />
Abstract N° OP0087<br />
Autophagy contributes to TNFα-mediated joint destruction<br />
D. De Rooy (Netherlands) 11:10<br />
N. Yeremenko, R. Knevel, E. Brouwer, G. Wilson,<br />
E. Lindqvist, T. Saxne, A. Krabben, M. Leijsma,<br />
R. Tsonaka, N. Daha, S. Zhernakova, J. Houwing-<br />
Duistermaat, T. Huizinga, D. Baeten, R. Toes,<br />
A. Van der Helm-van Mil<br />
Abstract N° OP0089<br />
Genetic studies on Dickkopf-1, sclerostin and the severity<br />
of joint destruction in rheumatoid arthritis<br />
W. de Munter (Netherlands) 11:20<br />
B. Walgreen, M. M. Helsen, A. W. Sloetjes,<br />
W. B. van den Berg, P. L. van Lent<br />
Abstract N° OP0090<br />
LDL receptor deficiency results in osteophyte formation<br />
during experimental osteoarthritis which is increased<br />
under high cholesterol conditions<br />
10:15 - 11:45 Room Berlin 2<br />
Abstract Session<br />
Abstract Session: Spondyloarthritis -<br />
translational science<br />
Chairperson(s):<br />
Paul Bowness (United Kingdom)<br />
Peggy Jacques (Belgium)<br />
D. Poddubnyy (Germany) 10:20<br />
K. Conrad, G. Ruiz-Heiland, U. Syrbe, H. Haibel,<br />
H. Appel, M. Rudwaleit, G. Schett, J. Sieper<br />
Abstract N° OP0091<br />
Prediction of radiographic spinal progression using<br />
biomarkers in patients with ankylosing spondylitis who<br />
are at high risk for progression<br />
U. Syrbe (Germany) 10:30<br />
R. Scheer, P. Wu, J. Sieper<br />
Abstract N° OP0092<br />
Differential systemic and synovial TH1 cell reactivity<br />
towards escherichia coli antigens in patients with<br />
ankylosing spondylitis and rheumatoid arthritis<br />
L. M. Van Duivenvoorde (Netherlands) 10:40<br />
C. A. Ambarus, H. Masdar, T. K. van Melsen,<br />
M. N. van Tok, P. P. Tak, N. G. Yeremenko,<br />
D. L. Baeten<br />
Abstract N° OP0093<br />
Relative overexpression of transmembrane versus soluble<br />
TNF in human and experimental spondyloarthritis<br />
G. Nocturne (France) 10:50<br />
S. Pavy, P. Goupille, M. Dougados, C. Roux,<br />
X. Mariette, C. Miceli-Richard<br />
Abstract N° OP0094<br />
Dkk1 serum level is increased in recent spondyloarthritis<br />
and is associated with higher prevalence of<br />
syndesmophytes. Data from the DESIR cohort<br />
M. Uddin (Canada) 11:00<br />
D. D. O'Reilly, R. D. Inman, W. P. Maksymowych,<br />
D. D. Gladman, S. Hamilton, R. Yazdani,<br />
P. Rahman<br />
Abstract N° OP0095<br />
Customized CNV microarray identified UGT2B17 as a<br />
novel susceptibility gene associated with familial ankylosing<br />
spondylitis<br />
A. Finckh (Switzerland) 11:10<br />
A. Ciurea, A. Scherer, U. Weber, M. Nissen, P. Exer,<br />
J. Bernhard, G. Tamborrini, R. Mueller, B. Weiss,<br />
R. Kissling, B. A. Michel on behalf of the<br />
Rheumatologists of SCQM<br />
Abstract N° OP0096<br />
Tobacco smoking is associated with increased disease<br />
activity in HLA-B27 positive axial spondyloarthritis patients,<br />
but does not alter the course of disease activity<br />
D. Poddubnyy (Germany) 11:20<br />
H. Haibel, J. Listing, E. Märker-Hermann,<br />
H. Zeidler, J. Braun, M. Rudwaleit, J. Sieper<br />
Abstract N° OP0097<br />
Cigarette smoking predicts radiographic progression in<br />
the spine in patients with axial spondyloarthritis in a<br />
dose-dependent manner<br />
K. Mchugh (United Kingdom) 11:30<br />
J. Shaw, S. Kollnberger, L. Utriainen, D. Firmin,<br />
S. Milling, C. Renner, P. Bowness<br />
Abstract N° OP0098<br />
The detection of a potentially pathogenic subset of<br />
HLA-B27 conformers at the cell surface in a rat model<br />
of SpA<br />
Thursday, 7 June 2012<br />
33
Thursday, 7 June 2012<br />
34<br />
<strong>Scientific</strong> <strong>Programme</strong><br />
10:15 - 11:45 Room Dublin<br />
Abstract Session<br />
HPR Abstract Session: Progress in<br />
rehabilitation - the future is bright<br />
Chairperson(s):<br />
Linda Fernandes (Norway)<br />
Karin Niedermann (Switzerland)<br />
M. J. Stukstette (Netherlands) 10:20<br />
J. Dekker, A. A. den Broeder, W. Noort van der<br />
Laan, J. W. Bijlsma, C. H. van den Ende<br />
Abstract N° OP0075-HPR<br />
A multidisciplinary and multidimensional program for<br />
hand osteoarthritis is not effective: results of a randomised<br />
controlled study<br />
M. Hermann (Norway) 10:30<br />
T. Nilsen, C. Støyva Eriksen, I. Haugen,<br />
B. S. Christensen, I. Kjeken<br />
Abstract N° OP0076-HPR<br />
Effects of a soft thumb base splint in persons with carpometacarpal<br />
osteoarthritis: a randomised controlled<br />
trial<br />
W. F. Peter (Netherlands) 10:40<br />
P. H. van der Wees, J. Verhoef, Z. de Jong,<br />
L. van Bodegom-Vos, W. K. Hilberdink, M. Fiocco,<br />
T. P. VlietVlieland<br />
Abstract N° OP0077-HPR<br />
The effect of an interactive workshop on the adherence<br />
with the Dutch physical therapy practice guideline for<br />
hip and knee osteoarthritis: a randomised controlled<br />
trial<br />
I. Kjeken (Norway) 10:50<br />
I. Bø, A. Rønningen, C. Spada, P. Mowinckel,<br />
K. B. Hagen, H. Dagfinrud<br />
Abstract N° OP0078-HPR<br />
A three week rehabilitation program had positive long<br />
term effects in patients with ankylosing spondylitis:<br />
results from a randomised controlled trial<br />
B. Hamnes (Norway) 11:00<br />
I. Kjeken, P. Mowinckel, K. B. Hagen<br />
Abstract N° OP0079-HPR<br />
Effects of a one week multidisciplinary inpatient selfmanagement<br />
programme for patients with fibromyalgia:<br />
a randomised controlled trial<br />
F. Jennings (Brazil) 11:10<br />
M. Cardoso, V. G. Cruz, H. A. Oliveira, J. Natour<br />
Abstract N° OP0080<br />
Aerobic training in patients with ankylosing spondylitis:<br />
a randomized controlled trial<br />
J. Meesters (Netherlands) 11:20<br />
W. Pont, L. Beaart-van de Voorde, T. Stamm,<br />
T. Vliet Vlieland<br />
Abstract N° OP0081<br />
Concepts important to patients with rheumatoid arthritis<br />
in rehabilitation and their coverage by rehabilitation<br />
tools<br />
eular berlin 2012<br />
G. Haugeberg (Norway) 11:30<br />
S. G. Eppeland, A. Diamantopoulos, D. M. Soldal<br />
Abstract N° OP0082<br />
Short term effect of 2-weeks rehabilitation on disease<br />
activity and health status in patients with ankylosing<br />
spondylitis<br />
10:15 - 11:45 Room Paris 2<br />
Abstract Session<br />
Abstract Session: Don't forget<br />
the "orphans"<br />
Chairperson(s):<br />
Duncan Porter (United Kingdom)<br />
Maurizio Cutolo (Italy)<br />
Duncan Porter (United Kingdom) 10:20<br />
Introduction: Keep up the interest on orphan conditions<br />
H. J. Lachmann (United Kingdom) 10:30<br />
I. Touitou, L. Obici, P. Woo, A. Naselli, R. Berendes,<br />
J. Anton, C. Modesto, P. Quartier, R. Merino,<br />
S. Ozen, R. Cimaz, A. Meini, N. Ruperto,<br />
M. Gattorno on behalf of PRINTO, Eurotraps and<br />
Eurofever Projects<br />
Abstract N° OP0107<br />
Clinical features at presentation in a series of 86 patients<br />
with genetically confirmed TRAPS and 33 patients with<br />
inflammatory symptoms and the R92Q variant from the<br />
Eurofevers/Eurotraps registry<br />
S. Colafrancesco (Italy) 10:40<br />
G. Picarelli, A. Gattamelata, R. Priori, G. Valesini<br />
Abstract N° OP0108<br />
Clinical and laboratory findings in a cohort of Italian<br />
patients with Adult Onset Still’s disease<br />
S. Bilge (Turkey) 10:50<br />
T. Kasifoglu, E. Gonullu, F. Bekdemir, C. Korkmaz<br />
Abstract N° OP0109<br />
Evaluation of potential risk factors of amyloidosis in<br />
familial Mediterranean fever<br />
J. Danjo (Japan) 11:00<br />
H. Dobashi, T. Kameda, K. Susaki, Y. Yamamoto,<br />
S. Nakashima, H. Shimada, M. Izumikawa,<br />
Y. Nishiyama, T. Matsunaga<br />
Abstract N° OP0110<br />
The utility of fluorodeoxyglucose-positron emission<br />
tomography for IgG4-related disease diagnosed according<br />
to comprehensive diagnostic criteria<br />
C. M. Feced Olmos (Spain) 11:10<br />
M. Fernández Matilla, J. J. Alegre Sancho,<br />
D. Ybáñez García, M. A. Martínez Ferrer,<br />
E. Valls Pascual, M. Robustillo Villarino,<br />
I. de la Morena Barrio<br />
Abstract N° OP0111<br />
Arthritis secondary to Epstein-Barr virus: an infrequent<br />
reality
eular berlin 2012<br />
<strong>Scientific</strong> <strong>Programme</strong><br />
A. Jawad (United Kingdom) 11:20<br />
A. Pákozdi, D. Watson, L. Kuitert<br />
Abstract N° OP0112<br />
Cystic fibrosis related arthritis in adults in south east<br />
England<br />
I. J. W. Hansen (Norway) 11:30<br />
S. Noraas, T. Skarpaas, V. Kjelland, G. Haugeberg<br />
Abstract N° OP0113<br />
Lyme arthritis in southern Norway - an endemic area for<br />
Lyme Borreliosis<br />
10:15 - 11:45 Room Berlin 1<br />
Abstract Session<br />
Abstract Session: Metabolic and crystal<br />
diseases of joints and bone<br />
Chairperson(s):<br />
Thomas Bardin (France)<br />
Jochen Zwerina (Austria)<br />
D. Holzinger (Germany) 10:20<br />
N. Nippe, K. Marketon, N. Dalbeth, T. Merriman,<br />
D. Baeten, N. Busso, T. Vogl, D. Foell, C. Gabay,<br />
J. Roth<br />
Abstract N° OP0099<br />
Toll-like receptor 4 agonists MRP 8 and MRP 14 act as<br />
endogenous enhancers of MSU-crystal induced IL-1<br />
secretion in vitro and reflect disease activity in gout<br />
patients in vivo<br />
P. Primatesta (Switzerland) 10:30<br />
D. Rothenbacher, A. Kleiner, W. Koenig,<br />
L. P. Breitling, H. Brenner<br />
Abstract N° OP0100<br />
Gout in patients with stable coronary heart disease and<br />
the impact of serum uric acid levels on adverse cardiovascular<br />
outcomes: a long-term follow-up study<br />
M. Wolfson (USA) 10:40<br />
R. A. Yood, F. D. Ottery, W. Irish<br />
Abstract N° OP0101<br />
Effect of chronic kidney disease status on pegloticase<br />
treatment response<br />
F. Perez-Ruiz (Spain) 10:50<br />
L. Martinez-Indart, J. I. Pijoan, A. M. Herrero-<br />
Beites, E. Krisnan, L. Carmona<br />
Abstract N° OP0102<br />
Presence of tophi and high level hyperuricemia are<br />
associated with increased risk of mortality in patients<br />
with gout<br />
C.-F. Kuo (United Kingdom) 11:00<br />
K.-H. Yu, S.-F. Luo, L.-C. See<br />
Abstract N° OP0103<br />
Risk of end-stage renal disease associated with gout: a<br />
nationwide population study<br />
M. Andres (Spain) 11:10<br />
V. Pardo, J. M. Caturla, E. Pascual<br />
Abstract N° OP0104<br />
Hypouricemia due to high urate renal excretion in septic<br />
systemic inflammatory response syndrome<br />
P. Hoff (Germany) 11:20<br />
T. Gaber, M. Hahne, C. Strehl, M. Fangradt,<br />
K. Schmidt-Bleek, G. R. Burmester,<br />
G. Schmidmaier, G. N. Duda, C. Perka, F. Buttgereit<br />
Abstract N° OP0105<br />
Accumulation of CD34+ hematopoietic stem cells in the<br />
initial inflammatory human fracture hematoma is driven<br />
by RANTES and eotaxin<br />
S. Bantia (USA) 11:30<br />
C. Parker, L. Harman, D. Papac, A. Hollister<br />
Abstract N° OP0106<br />
Effect of BCX4208 add-on therapy to allopurinol 300 mg<br />
on plasma hypoxanthine and xanthine concentrations<br />
in gout patients<br />
10:15 - 11:45 Room New York 1<br />
Abstract Session<br />
Abstract Session: Epidemiololgy<br />
and health services<br />
Chairperson(s):<br />
Loreto Carmona (Spain)<br />
Deborah Symmons (United Kingdom)<br />
J. A. B. Van Nies (Netherlands) 10:20<br />
E. Brouwer, T. W. J. Huizinga, M. D. Posthumus,<br />
A. H. M. van der Helm-van Mil<br />
Abstract N° OP0114<br />
Improving early recognition of arthritis: evaluation of<br />
the first year results on two early arthritis recognition<br />
clinics<br />
J. Primdahl (Denmark) 10:30<br />
H. C. Horn, R. Petersen, K. Hørslev-Petersen<br />
Abstract N° OP0115<br />
Clinical and radiological outcome in outpatients with<br />
rheumatoid arthritis followed by medical, nursing or<br />
shared care - a two year randomised controlled trial<br />
W. Kievit (Netherlands) 10:40<br />
M. Vermeer, I. Kuper, A. Braakman-Jansen,<br />
H. Bernelot Moens, T. Zijlstra, A. den Broeder,<br />
P. van Riel, J. Fransen, M. van de Laar<br />
Abstract N° OP0116<br />
Cost-effectiveness and cost-utility analysis of treat-totarget<br />
versus usual care in early rheumatoid arthritis:<br />
results of the DREAM registry<br />
T. Gati (Hungary) 10:50<br />
C. Morgan, R. N. Luben, M. Lahiri, S. M.<br />
Verstappen, D. K. Bunn, M. Lunt, D. P. Symmons,<br />
N. J. Wareham, K.-T. Khaw, I. N. Bruce<br />
Abstract N° OP0117<br />
HDL-C and HbA1c predict the development of inflammatory<br />
polyarthritis: results from the European prospective<br />
investigation of cancer (NORFOLK) and the<br />
NORFOLK arthritis register (EPIC-2-NOAR study)<br />
3<br />
Thursday, 7 June 2012<br />
35
Thursday, 7 June 2012<br />
36<br />
<strong>Scientific</strong> <strong>Programme</strong><br />
A. Z. Alhusain (United Kingdom) 11:00<br />
S. M. Verstappen, M. Lunt, H. Mirjafari, D. Bunn,<br />
T. Marshall, V. Charlton-Menys, P. Durrington,<br />
D. Symmons, I. N. Bruce<br />
Abstract N° OP0118<br />
Predictors of overall/cardiovascular mortality in patients<br />
with early inflammatory polyarthritis; the lipid-paradox?<br />
G. Singh (USA) 11:10<br />
A. Mannalithara, A. Mithal, G. Triadafilopoulos<br />
Abstract N° OP0119<br />
Great progress but much more needed: hospitalizations<br />
due to complicated gastric and duodenal ulcers in the<br />
US (1990-2009)<br />
A. J. Svendsen (Denmark) 11:20<br />
J. V. Hjelmborg, A. Skytthe, G. Houen, K. Kyvik,<br />
P. Junker<br />
Abstract N° OP0120<br />
The incidence of rheumatoid arthritis and the impact of<br />
smoking<br />
J. Eriksson (Sweden) 11:30<br />
J. Askling, M. Neovius<br />
Abstract N° OP0121<br />
Combined and specific costs for hospitalisations, drugs,<br />
and lost work days in prevalent contemporary RA: a<br />
nationwide cohort study<br />
10:15 - 11:45 Room New York 3<br />
PARE Session<br />
How to get a job and how to keep it<br />
Learning Objectives:<br />
• How better two-way communication between<br />
employers and employees can create a positive and<br />
supportive work environment for people with RMD<br />
and also maximise productivity<br />
Chairperson(s):<br />
Maria Batziou (Greece)<br />
Frane Grubisic (Croatia)<br />
Christina Flourentzou-Kakouri (Cyprus) 10:20<br />
Abstract N° SP0062<br />
How legislative initiatives can support disabled people<br />
in securing employment and ensuring social inclusion<br />
Tim Trengenza (United Kingdom) 10:40<br />
Promoting healthy workplaces for people with rheumatic<br />
and musculoskeletal diseases<br />
Olaf Tscharnezki (Germany) 11:00<br />
The role of employers and employees in promoting<br />
communication to create a positive and supportive work<br />
environment<br />
L. Willumsen (Denmark) 11:20<br />
H. Jeppesen<br />
Abstract N° OP0122-PARE<br />
Pauseboogie - campaign to raise awareness of the<br />
Danish rheumatism association<br />
eular berlin 2012<br />
T. Jasinski (Estonia) 11:30<br />
H. Lemetti, I. Käppa<br />
Abstract N° OP0123-PARE<br />
Local government services for disabled people in Tartu<br />
and the role of Tartu rheumatism association in<br />
mediating the services<br />
11:45 – 13:30 Poster viewing and lunch<br />
12:00 - 13:15 Hall 4.1<br />
Primary Care Session<br />
Hot topics for primary care: What's new?<br />
Learning Objectives:<br />
• To learn about management objectives<br />
• To understand the role of primary care<br />
Chairperson(s):<br />
Tore K. Kvien (Norway)<br />
Ana Maria Nielsen Bentsen (Spain)<br />
Cyrus Cooper (United Kingdom) 12:05<br />
Abstract N° SP0063<br />
State of the Art Plenary Lecture: Osteoporosis implications<br />
for primary care<br />
Robert B.M. Landewé (Netherlands) 12:35<br />
Abstract N° SP0064<br />
Spondyloarthritis: what's new for primary care?<br />
Wolfgang L. Gross (Germany) 12:55<br />
Polymyalgia Rheumatica: key issues for primary care<br />
diagnosis and management<br />
12:15 - 13:15 Poster Area<br />
Guided Poster Tours<br />
Please note that you need to register to participate in a<br />
guided Poster Tour.The number of participants is limited<br />
to 20 per Poster Tour. Registrations can be made at the<br />
Posters & Workshops Desk, located at the Registration<br />
Area (Hall 2.1) based on a “First-Come-First-Served”<br />
basis.”<br />
Detailed information on the Poster Tours is provided on<br />
pages 47 to 51.<br />
Poster Tour T01: (Epi)-Genetics and<br />
genomics 1: where are we?<br />
Chairperson(s):<br />
Rene Toes (Netherlands)<br />
Marthe Maehlen (Netherlands)<br />
Poster Tour T02: Novel aspects of joint<br />
homeostasis and pathology<br />
Chairperson(s):<br />
Dennis McGonagle (United Kingdom)<br />
Shea Carter (Belgium)<br />
Poster Tour T03: B cells and beyond<br />
Chairperson(s):<br />
Paul Emery (United Kingdom)<br />
Maya H. Buch (United Kingdom)
eular berlin 2012<br />
<strong>Scientific</strong> <strong>Programme</strong><br />
Poster Tour T04: RA small molecules -<br />
old and new<br />
Chairperson(s):<br />
Daniel Aletaha (Austria)<br />
Pedro Machado (Portugal)<br />
Poster Tour T05: SLE, APS, Sjögren's<br />
Chairperson(s):<br />
Dimitrios Boumpas (Greece)<br />
Cristina Pamfil (Greece)<br />
Poster Tour T06: Clinical scleroderma 1<br />
and inflammatory myopathy<br />
Chairperson(s):<br />
Oliver Distler (Switzerland)<br />
Britta Maurer (Switzerland)<br />
Poster Tour T07: Spondyloarthritis<br />
treatment<br />
Chairperson(s):<br />
Rik Lories (Belgium)<br />
Barbara Neerinckx (Belgium)<br />
Poster Tour T08: PReS - basic research in<br />
paediatric rheumatology<br />
Chairperson(s):<br />
Berent J. Prakken (Netherlands)<br />
Dirk Holzinger (Germany)<br />
Poster Tour T09: Orphan diseases and<br />
infectious arthritis<br />
Chairperson(s):<br />
Maurizio Cutolo (Italy)<br />
Alberto Sulli (Italy)<br />
Poster Tour T10: Health Professionals:<br />
Clinical aspects of care<br />
Chairperson(s):<br />
Patricia Cornell (United Kingdom)<br />
Mwidimi Ndosi (United Kingdom)<br />
13:30 - 15:00 Hall 1.2<br />
What is New (WIN)<br />
WIN Session 3<br />
Paul Emery (United Kingdom) 13:35<br />
Clinical aspects of rheumatoid arthritis<br />
Josef S. Smolen (Austria) 14:15<br />
Biological therapy of rheumatoid arthritis<br />
13:30 - 15:00 Hall 1.1<br />
Clinical Science Session<br />
Vasculitis: new therapies changing<br />
outcomes<br />
Learning Objectives:<br />
• Update participants in current clinical developments<br />
in the classification, diagnosis and outcomes of<br />
systemic vasculitis<br />
Chairperson(s):<br />
Alfred Mahr (France)<br />
Julia Holle (Germany)<br />
Niels Rasmussen (Denmark) 13:35<br />
Abstract N° SP0065<br />
Vasculitis definition: the revised Chapel Hill definitions<br />
Raashid Luqmani (United Kingdom) 13:55<br />
Abstract N° SP0066<br />
Classification and diagnosis of vasculitis<br />
Kerstin Westman (Sweden) 14:15<br />
Abstract N° SP0067<br />
Long term outcomes in systemic vasculitis<br />
N. Basu (United Kingdom) 14:35<br />
A. McClean, R. Luqmani, L. Harper, O. Flossmann,<br />
D. Jayne, M. Little, E. N. Amft, N. Dhaun,<br />
J. McLaren, V. Kumar, L. Erwig, G. Jones, D. Reid,<br />
G. Macfarlane<br />
Abstract N° OP0124<br />
Contextualising quality of life in ANCA- Associated<br />
Vasculitis (AAV)<br />
A. Mahr (France) 14:45<br />
L. B. Luong Nguyen, N. G. Bonitsis, A. Altenburg,<br />
C. C. Zouboulis<br />
Abstract N° OP0125<br />
Gender-specific differences in Adamantiades-Behçet’s<br />
disease presentation: meta-analyses of combined data<br />
from the German registry for Adamantiades-Behçet’s<br />
disease and from a systematic literature review<br />
13:30 - 15:00 Hall 6.2 A<br />
Clinical Science Session<br />
Molecular targets for therapy in fibrotic<br />
diseases<br />
Learning Objectives:<br />
• To understand common and distinct pathways in<br />
different fibrotic disorders<br />
• To identify molecular targets for therapies in different<br />
fibrotic disorders<br />
• To appreciate the challenges of proof of concept<br />
studies in fibrotic diseases<br />
Chairperson(s):<br />
Oliver Distler (Switzerland)<br />
Serena Guiducci (Italy)<br />
Raghu Kalluri (USA) 13:35<br />
Origins of fibroblasts in fibrotic diseases<br />
David Brenner (USA) 13:55<br />
Abstract N° SP0068<br />
Molecular targets for therapy in liver fibrosis<br />
Jörg H. Distler (Germany) 14:15<br />
Abstract N° SP0069<br />
Molecular targets for therapy in systemic sclerosis<br />
Dinesh Khanna (USA) 14:35<br />
Challenges in study design for proof of concept trials in<br />
fibrosis<br />
Thursday, 7 June 2012<br />
37
Thursday, 7 June 2012<br />
38<br />
<strong>Scientific</strong> <strong>Programme</strong><br />
13:30 - 15:00 Hall 5.2 A<br />
How to Manage/Treat (HOT)<br />
How to manage 4<br />
Serge Perrot (France) 13:35<br />
Abstract N° SP0070<br />
Management of pain<br />
Ernest Choy (United Kingdom) 14:15<br />
Abstract N° SP0071<br />
Fibromyalgia<br />
13:30 - 15:00 Hall 5.2 B<br />
Outcomes Science Session<br />
Soft predictors of hard outcomes<br />
Chairperson(s):<br />
Patrick Verschueren (Belgium)<br />
Maarten Boers (Netherlands)<br />
Gareth T. Jones (United Kingdom) 13:35<br />
Abstract N° SP0072<br />
Markers of premature mortality: chronic symptoms<br />
Tuulikki Sokka (Finland) 14:00<br />
Abstract N° SP0073<br />
Markers of premature mortality: poor physical fitness<br />
and performance<br />
Maria Suarez-Almazor (USA) 14:25<br />
Abstract N° SP0074<br />
Changing health behaviours with social marketing<br />
C. A. Scire' (United Kingdom) 14:50<br />
M. Lunt, D. P. Symmons, S. M. Verstappen<br />
Abstract N° OP0126<br />
Early and sustained remission is associated with<br />
improved survival in patients with inflammatory<br />
polyarthritis: results from the NORFOLK arthritis<br />
register<br />
13:30 - 15:00 Hall 6.2 B<br />
Challenges in Clinical Practice Session<br />
Myositis<br />
Chairperson(s):<br />
Eugen Feist (Germany)<br />
Jiri Vencovsky (Czech Republic)<br />
Udo Schneider (Germany) 13:35<br />
Case 1 presentation: Myositis and Alveolitis<br />
Eugen Feist (Germany) 13:45<br />
Case 1 discussion: Myositis and Alveolitis- a challenging<br />
treatment constellation<br />
Hermann Mann (Czech Republic) 14:05<br />
Case 2 presentation: Phenotype defined by autoantibodies<br />
in inflammatory myopathies<br />
Jiri Vencovsky (Czech Republic) 14:15<br />
Case 2 discussion: Phenotype defined by autoantibodies<br />
in inflammatory myopathies<br />
13:30 - 15:00 Hall 6.1<br />
Joint PReS/EULAR Session<br />
Autoinflammation 1: Linking<br />
autoinflammation to autoimmunity<br />
eular berlin 2012<br />
Learning Objectives:<br />
• Understand the complex interactions between<br />
autoinflammation (innate immune driven disease)<br />
and autoimmunity<br />
• Insights that the autoinflammation concept brings to<br />
disease classification<br />
• How the innate immune system can drive inflammation<br />
against itself<br />
• How the innate immune system activates adaptive<br />
immunity at the molecular level<br />
Chairperson(s):<br />
Tilmann Kallinich (Germany)<br />
Florence Apparailly (France)<br />
Michael F. McDermott (United Kingdom) 13:35<br />
Abstract N° SP0075<br />
Autoimmunity and autoinflammation- oppositive sides<br />
of the same coin<br />
Polly Ferguson (USA) 13:55<br />
Abstract N° SP0076<br />
Emerging genetics and molecular aspects of autoinflammatory<br />
bone disease<br />
Johannes Roth (Germany) 14:15<br />
How danger associated molecular patterns (DAMPs)<br />
may initiate and sustain autoimmune disease<br />
Fabio Martinon (Switzerland) 14:35<br />
Abstract N° SP0077<br />
Inflammasomes - powerhouses of intracellular innate<br />
immune responses<br />
13:30 - 15:00 Hall 5.1<br />
Fellows in Training Session<br />
EULAR <strong>Scientific</strong> Training Bursaries -<br />
an opportunity to win<br />
Chairperson(s):<br />
Dimitrios Boumpas (Greece)<br />
Georg Schett (Germany)<br />
Mary Conolly (Ireland) 13:35<br />
Investigation of miR-323, a novel microRNA in Rheumatoid<br />
Arthritis on disease pathogenesis<br />
Penelope Palominos (Brazil) 13:45<br />
Impact of psoriatic arthritis: is the patient's perspective<br />
correctly captured by existing questionnaires?<br />
Domenico Capocotta (Italy) 13:55<br />
The experience of a young Italian physician, right after<br />
his graduation at the Viennese center of excellence in<br />
rheumatology
eular berlin 2012<br />
<strong>Scientific</strong> <strong>Programme</strong><br />
Maria Stoenoiu (Belgium) 14:05<br />
Tendon friction rubs in systemic sclerosis: a possible<br />
explanation. An ultrasound and magnetic resonance<br />
imaging study<br />
Tünde Minier (Hungary) 14:15<br />
Systemic autoimmune diseases<br />
Tamas Gati (Hungary) 14:25<br />
Various clinical experiences in infirmary<br />
Anna Moltó Revilla (Spain) 14:35<br />
Clinical differences in rheumatoid arthritis in black<br />
individuals and Caucasians<br />
13:30 - 15:00 Hall 4.1<br />
Primary Care Session<br />
Supporting self management in OA:<br />
the role of primary care<br />
Learning Objectives:<br />
• Awareness of evidence for self management in OA<br />
• Understanding the role of the primary care team<br />
Chairperson(s):<br />
Ingemar Petersson (Sweden)<br />
Jurgen Damen (Netherlands)<br />
Francis Berenbaum (France) 13:35<br />
Abstract N° SP0078<br />
Self management in OA: what is the evidence?<br />
Mark Porcheret (United Kingdom) 13:55<br />
Abstract N° SP0079<br />
Self management for OA: the role of the GP<br />
Krysia Dziedzic (United Kingdom) 14:15<br />
Abstract N° SP0080<br />
Self management in OA: evidence for the role of the<br />
multidisciplinary team<br />
Beryl Svanberg (Sweden) 14:35<br />
The patient’s perspective on self management<br />
13:30 - 15:00 Room Europa 2<br />
Basic and Translational Science Session<br />
EULAR-EFIS Session: B regulatory cells<br />
Learning Objectives:<br />
• Immunology for clinicians<br />
Chairperson(s):<br />
Catherine Sautes-Fridman (France)<br />
Claudia Mauri (United Kingdom)<br />
Thomas F. Tedder (USA) 13:35<br />
Abstract N° SP0085<br />
B10 cells and regulatory B cells during inflammation,<br />
autoimmunity and cancer<br />
Claudia Mauri (United Kingdom) 14:00<br />
Abstract N° SP0086<br />
Regulation of autoimmunity by B regulatory cells<br />
Simon Fillatreau (Germany) 14:25<br />
Function of B regulatory cells during bacterial infections<br />
13:30 - 15:00 Room Berlin 2<br />
Basic and Translational Science Session<br />
Collateral damage in muscles<br />
Learning Objectives:<br />
• To learn how various inflammatory states including<br />
severe systemic insults can lead to severe secondary<br />
muscle damage<br />
• To understand the genetic basis for statin myopathy<br />
and its implications<br />
• Recognise that emerging different immunopathologic<br />
patterns of necrotising myopathy<br />
Chairperson(s):<br />
Pedro Machado (Portugal)<br />
David Isenberg (United Kingdom)<br />
Russell Lane (United Kingdom) 13:35<br />
Abstract N° SP0087<br />
Immune driven muscle disease: from the thymus to<br />
myocytes<br />
Robert Cooper (United Kingdom) 13:55<br />
Abstract N° SP0088<br />
The genetics of myositis - recent insights from autoimmune<br />
diseases and statins<br />
Oliver Boyer (France) 14:15<br />
Abstract N° SP0089<br />
Necrotising myopathy - the new kid on the block that<br />
the old kids need to recognise<br />
Ingrid E. Lundberg (Sweden) 14:35<br />
Abstract N° SP0090<br />
Steroid myopathy - do molecular mechanism bring us<br />
closer to novel treatment strategies?<br />
13:30 - 15:00 Room Dublin<br />
Joint Clinical/HPR/PARE Session<br />
Patient involvement in research. Past,<br />
present and future<br />
Learning Objectives:<br />
• To get an overview of "best practices" on how to<br />
capture the patient perspective in MSD research<br />
Chairperson(s):<br />
Christina Opava (Sweden)<br />
Dieter Wiek (Germany)<br />
John R Kirwan (United Kingdom) 13:35<br />
Abstract N° SP0081<br />
Fifteen years of experience with patient involvement in<br />
research. What has been achieved?<br />
Thursday, 7 June 2012<br />
39
Thursday, 7 June 2012<br />
40<br />
<strong>Scientific</strong> <strong>Programme</strong><br />
Maarten de Wit (Netherlands) 13:55<br />
Abstract N° SP0082<br />
Ten golden rules for researchers - how to capture the<br />
patient perspective in your research project?<br />
Ingvild Kjeken (Norway) 14:15<br />
Abstract N° SP0083<br />
What does it mean to involve patients successfully in<br />
research? The health professionals perspective<br />
Laure Gossec (France) 14:35<br />
Abstract N° SP0084<br />
Patient involvement in research on the international<br />
arena<br />
13:30 - 15:00 Room Paris 2<br />
Practical Skills Session<br />
Crystals in synovial fluid 2<br />
Learning Objectives:<br />
• The most common obstacles encountered by those<br />
interested in starting the crystal analysis process are:<br />
– The idea that crystal analysis is not possible<br />
without a fully equipped compensated polarized<br />
microscope<br />
– That it is time consuming<br />
– That it is difficult to differentiate urate from pyrophosphate<br />
crystals<br />
– That learning will be a difficult process<br />
• These will be discussed, and the keys for starting with<br />
the generally available instruments - the ordinary<br />
microscope - will be given<br />
Chairperson(s):<br />
Thomas Bardin (France)<br />
Eliseo Pascual Gomez (Spain)<br />
Tutors:<br />
Jose Pimentao (Portugal)<br />
Francesca Oliviero (Italy)<br />
Mariano Andrés (Spain)<br />
13:30 - 15:00 Room Berlin 1<br />
Practical Skills Session<br />
MRI Workshop advanced 1<br />
Chairperson(s):<br />
Kay-Geert Hermann (Germany)<br />
Mikkel Østergaard (Denmark)<br />
Robert G. Lambert (Canada) 13:35<br />
Abstract N° SP0091<br />
MRI in spondyloarthritides - update on the current state<br />
Iris Eshed (Israel) 13:55<br />
Non-inflammatory findings in hand MRI<br />
Claudia Schueller-Weidekamm (Austria) 14:15<br />
MRI of the cervical spine with a focus on rheumatoid<br />
arthritis<br />
Kay-Geert Hermann (Germany) 14:35<br />
Interactive MRI case interpretations<br />
13:30 - 15:00 Room New York 1<br />
eular berlin 2012<br />
EULAR Projects in Paediatric Rheumatology<br />
Working Parties 2.0: vision on the future<br />
Learning Objectives:<br />
• Learn about activities and vision in different fields of<br />
paediatric rheumatology presented by working<br />
parties<br />
Chairperson(s):<br />
Joost F. Swart (Netherlands)<br />
Michael Beresford (United Kingdom)<br />
Annet van Royen (Netherlands) 13:35<br />
Update on the juvenile dernatomyositis working party<br />
Tadej Avcin (Slovenia) 14:00<br />
Update on the SLE working party<br />
Joost Frenkel (Netherlands) 14:25<br />
Update on the periodic fever working party<br />
13:30 - 15:00 Room New York 3<br />
PARE Session<br />
What's new: latest advances in treatment<br />
and management<br />
Learning Objectives:<br />
• Latest advances in the treatment and management of<br />
connective tissue disorders and inflammatory<br />
diseases<br />
Chairperson(s):<br />
Iain B. McInnes (United Kingdom)<br />
Ursula Faubel (Germany)<br />
Simon Bowman (United Kingdom) 13:35<br />
Abstract N° SP0092<br />
Latest advances in connective tissue disorders<br />
Loreto Carmona (Spain) 14:10<br />
Latest advances in inflammatory diseases<br />
13:30 - 15:00 Room New York 2<br />
PReS Session<br />
ENCA Session: Rheumatic diseases in<br />
childhood: making the transition to adult<br />
health care easier<br />
Chairperson(s):<br />
Claudia Grave (Germany)<br />
Helle Rasmussen (Denmark)<br />
Delila Singh (United Kingdom) 13:35<br />
Experiences in transition from the view of a young<br />
woman with rheumatism<br />
Deborah Hilderson (Belgium) 14:15<br />
Paediatric rheumatology: the bridge between paediatrics<br />
and adult medicine - the Leuven project
eular berlin 2012<br />
<strong>Scientific</strong> <strong>Programme</strong><br />
13:30 - 15:00 Room London 3<br />
PReS AHP Sesssion<br />
Thieves Market: sharing difficult cases and<br />
best practices in taking care of children<br />
with rheumatic diseases<br />
Learning Objectives:<br />
• Difficult cases and best practices will be presented by<br />
the participants and an expert panel and discussed in<br />
the plenary<br />
Tutors:<br />
Janjaap van der Net (Netherlands)<br />
Susan Maillard (United Kingdom)<br />
Angelo Ravelli (Italy)<br />
15:00 – 15:30 Coffee break<br />
15:30 - 17:00 Hall 1.2<br />
What is New (WIN)<br />
WIN Session 4<br />
Dimitrios Boumpas (Greece) 15:35<br />
SLE<br />
Xavier Mariette (France) 16:15<br />
Sjögren's syndrome<br />
15:30 - 17:00 Hall 1.1<br />
Clinical Science Session<br />
Personalised medicine<br />
Learning Objectives:<br />
• To understand the definition of a biomarker<br />
• To appreciate current challenges applying biomarkers<br />
for diagnostic and prognostic purposes in clinical<br />
practice<br />
Chairperson(s):<br />
Pierre Miossec (France)<br />
Deborah Symmons (United Kingdom)<br />
William Robinson (USA) 15:35<br />
Personalised diagnosis: are biomarkers helpful?<br />
Gerd Rüdiger Burmester (Germany) 15:55<br />
Predictors of treatment response: a critical view on<br />
biomarkers<br />
Josef S. Smolen (Austria) 16:15<br />
Tayloring patient management beyond drugs<br />
A. C. Bay-Jensen (Denmark) 16:35<br />
I. Byrjalsen, A. Kenwright, A. Platt, M. A. Karsdal<br />
Abstract N° OP0127<br />
Identification of serological biomarker profiles associated<br />
with early response to Tocilizumab in rheumatoid<br />
arthritis<br />
S. R. Kapoor (United Kingdom) 16:45<br />
A. Filer, M. Fitzpatrick, B. A. Fisher, P. C. Taylor,<br />
C. Buckley, I. McInnes, K. Raza, S. P. Young<br />
Abstract N° OP0128<br />
Metabolic profiling of urine samples predicts response<br />
to anti-TNF therapy in patients with rheumatoid<br />
arthritis<br />
15:30 - 17:00 Hall 6.2 A<br />
Clinical Science Session<br />
New insights in osteoarthritis<br />
Learning Objectives:<br />
• To precise the new insights in OA<br />
Chairperson(s):<br />
Tim McAlindon (USA)<br />
Pascal Richette (France)<br />
Philip G. Conaghan (United Kingdom) 15:35<br />
Abstract N° SP0093<br />
Role of imaging in osteoarthritis: biomarker, prognosis<br />
factor, outcome measure in RCT?<br />
David Walsh (United Kingdom) 15:55<br />
Abstract N° SP0094<br />
Links between angiogenesis, inflammation and pain in<br />
OA<br />
Stefan Lohmander (Sweden) 16:15<br />
Abstract N° SP0095<br />
Are we close to use biomarkers in daily practice in<br />
osteoarthritis?<br />
A. Abou-Raya (Egypt) 16:35<br />
S. Abou-Raya, M. Helmii, T. Khadrawi<br />
Abstract N° OP0129<br />
Effect of low dose oral prednisolone on symptoms and<br />
systemic inflammation in older adults with moderate to<br />
severe knee osteoarthritis: a randomized placebocontrolled<br />
trial<br />
H. J. Kerkhof (Netherlands) 16:45<br />
S. Bierma-Zeinstra, B. Hofman, F. Rivadeneira,<br />
A. Uitterlinden, C. Janssens, J. van Meurs<br />
Abstract N° OP0130<br />
Prediction model for knee osteoarthritis including<br />
clinical, genetic and biochemical risk factors<br />
15:30 - 17:00 Hall 5.2 A<br />
How to Manage/Treat (HOT)<br />
How to manage 5<br />
Michael Doherty (United Kingdom) 15:35<br />
Abstract N° SP0096<br />
Gout and other crystal diseases<br />
Tuulikki Sokka (Finland) 16:15<br />
Abstract N° SP0097<br />
Comorbidity in rheumatic diseases<br />
Thursday, 7 June 2012<br />
41
Thursday, 7 June 2012<br />
42<br />
<strong>Scientific</strong> <strong>Programme</strong><br />
15:30 - 17:00 Hall 5.2 B<br />
Outcomes Science Session<br />
Update on ACR/EULAR RA classification<br />
criteria: what have we learned?<br />
Learning Objectives:<br />
• Recently, ACR and EULAR proposed new classification<br />
criteria for rheumatoid arthritis<br />
• This session will give an overview of the validation of<br />
these criteria, of the changes these criteria have made<br />
already, and of what we can expect in the future<br />
Chairperson(s):<br />
Loreto Carmona (Spain)<br />
Alan J. Silman (United Kingdom)<br />
Daniel Aletaha (Austria) 15:35<br />
The new ACR/EULAR criteria: can they replace the 1987<br />
criteria? Validation 2 years later<br />
Désirée van der Heijde (Netherlands) 15:55<br />
Abstract N° SP0098<br />
What is erosive disease in the criteria?<br />
J. Humphreys (United Kingdom) 16:15<br />
S. Verstappen, M. Lunt, K. Hyrich, T. Marshall,<br />
D. Symmons<br />
Abstract N° OP0131<br />
Incidence of rheumatoid arthritis in the UK using the<br />
2010 ACR/EULAR classification criteria for RA; and<br />
comparison with estimates using the 1987 ACR criteria<br />
J. Nicolau (France) 16:25<br />
P. Boumier, A. Daragon, O. Mejjad, J.-F. Ménard,<br />
S. Pouplin, O. Vittecoq, P. Fardellone, X. Le Loët<br />
Abstract N° OP0132<br />
Validation of the 2010 ACR/EULAR classification criteria<br />
for rheumatoid arthritis in the very early arthritis<br />
community-based (VERA) cohort: slight improvement<br />
after excluding erosion criterion<br />
D. Nakagomi (Japan) 16:35<br />
K. Ikeda, A. Okubo, T. Iwamoto, Y. Sanayama,<br />
K. Takahashi, M. Yamagata, H. Takatori, K. Suzuki,<br />
K. Takabayashi, H. Nakajima<br />
Abstract N° OP0133<br />
Ultrasonographic assessment of synovitis improves the<br />
accuracy of 2010 American college of rheumatology/<br />
European league against rheumatism classification<br />
criteria for rheumatoid arthritis to predict development<br />
of a Methotrexate-requiring disease<br />
A. Krabben (Netherlands) 16:45<br />
A. Abhishek, K. Britsemmer, A. Filer,<br />
T. W. J. Huizinga, K. Raza, D. van Schaardenburg,<br />
A. H. M. van der Helm-van Mil<br />
Abstract N° OP0134<br />
Risk stratification in patients with undifferentiated<br />
arthritis according to the 2010 ACR/EULAR criteria<br />
15:30 - 17:00 Hall 6.2 B<br />
eular berlin 2012<br />
Challenges in Clinical Practice Session<br />
Underrecognized and challenging<br />
manifestations in systemic sclerosis<br />
Learning Objectives:<br />
• To understand the limitations in diagnosing, classifying<br />
and treating myopathies in connective tissue<br />
diseases such as systemic sclerosis<br />
• To be able to identify calcinosis cutis as a possible<br />
cause of ulcers in systemic sclerosis and to be updated<br />
on treatment options for calcinosis cutis<br />
Chairperson(s):<br />
Marco Matucci-Cerinic (Italy)<br />
Serena Vettori (Italy)<br />
Britta Maurer (Switzerland) 15:35<br />
Abstract N° SP0099<br />
Case 1 presentation: Myopathy in SSc<br />
Ulrich Walker (Switzerland) 15:45<br />
Abstract N° SP0100<br />
Case 1 discussion: Myopathy in SSc<br />
Niamh Quillinan (United Kingdom) 16:15<br />
Case 2 presentation: Calcinosis cutis<br />
Christopher P. Denton (United Kingdom) 16:25<br />
Abstract N° SP0101<br />
Case 2 discussion: Calcinosis cutis<br />
15:30 - 17:00 Hall 6.1<br />
PReS Session<br />
Macrophage activation syndrome<br />
Learning Objectives:<br />
• To understand MAS and HLH and their pathogenesis<br />
and treatment<br />
Chairperson(s):<br />
Pierre Quartier (France)<br />
Alberto Martini (Italy)<br />
Angelo Ravelli (Italy) 15:35<br />
Abstract N° SP0102<br />
Diagnostic criteria<br />
Jan-Inge Henter (Sweden) 15:55<br />
Abstract N° SP0103<br />
Treatment of hemophagocytic lymphohistiocytosis<br />
Alexei Grom (USA) 16:15<br />
The pathogenesis of MAS<br />
S. Davì (Italy) 16:35<br />
B. Lattanzi, E. Demirkaya, S. Rosina, A. Novelli ,<br />
N. Ruperto, A. Martini, R. Q. Cron, A. Ravelli on<br />
behalf of International Investigator Consortium<br />
for MAS Diagnostic Criteria
eular berlin 2012<br />
<strong>Scientific</strong> <strong>Programme</strong><br />
Abstract N° OP0135<br />
Clinical and therapeutic features of 270 patients with<br />
macrophage activation syndrome enrolled in a multinational<br />
survey<br />
Nicola Ruperto (Italy) 16:45<br />
Canakinumab in systemic juvenile idiopathic arthritis<br />
with active systemic features<br />
15:30 - 17:00 Hall 5.1<br />
Fellows in Training Session<br />
Dealing with journalists<br />
Chairperson(s):<br />
Leo van de Putte (Netherlands)<br />
Laure Gossec (France)<br />
Johannes W.J. Bijlsma (Netherlands) 15:35<br />
The value of media engagement - best practice and<br />
personal experience<br />
Jeff Smith (United Kingdom) 15:45<br />
The what and why of media activity<br />
Candice Debleu (United Kingdom) 16:00<br />
The audience - key messages - interview skills<br />
Leo van de Putte (Netherlands) 16:15<br />
Open floor Q&A<br />
15:30 - 17:00 Hall 4.1<br />
Primary Care Session<br />
Work and workability in rheumatic<br />
diseases: what does it mean for primary care<br />
Learning Objectives:<br />
• Awareness of importance of musculosketal problems<br />
in work absence<br />
• Awareness of how to recognise patients at risk of<br />
work absence presenting to GPs<br />
• Understanding the role of the primary care team in<br />
supporting people to stay at work<br />
Chairperson(s):<br />
Fernando León Vázquez (Spain)<br />
Elaine Hay (United Kingdom)<br />
Ingemar Petersson (Sweden) 15:35<br />
What we know about work absence in MSK disorders<br />
from disease registers<br />
Steven J. Linton (Sweden) 15:55<br />
Abstract N° SP0104<br />
How to spot those at risk of work absence NEW: how to<br />
identify those at risk of developing work disability<br />
Hendrik J. Bieleman (Netherlands) 16:15<br />
Keeping people in work: what works in primary care?<br />
F. Buttgereit (Germany) 16:35<br />
R. Tuominen<br />
Abstract N° OP0136<br />
Impact of morning stiffness on work performance in<br />
people with rheumatoid arthritis<br />
D. Pattloch (Germany) 16:45<br />
P. Herzer, S. Zinke, A. Gräßler, A. Zink,<br />
A. Strangfeld<br />
Abstract N° OP0137-PC<br />
Decreasing incidence of disability pensions in patients<br />
with rheumatoid arthritis in Germany<br />
15:30 - 17:00 Room Europa 2<br />
Basic and Translational Science Session<br />
Immunological memory<br />
Learning Objectives:<br />
• Immunological memory is pivotal to combat infection<br />
and thereby to the survival of the host. However,<br />
in case directed against the bodies own molecules, it<br />
is can cause chronic inflammation. The latest insights<br />
of this “pathological memory”will be discussed<br />
Chairperson(s):<br />
Hans-Ulrich Scherer (Netherlands)<br />
Andrew Cope (United Kingdom)<br />
Andreas Radbruch (Germany) 15:35<br />
Abstract N° SP0109<br />
Twisting pathogenic T cell memory<br />
Vivi Malström (Sweden) 15:55<br />
Abstract N° SP0110<br />
CD28null T cells in myositis<br />
Antonio Lanzavecchia (Switzerland) 16:15<br />
Immunological memory in humans<br />
A. Magnani (Italy) 16:35<br />
A. Meloni, M. Gattorno, A. Martini, E. Traggiai<br />
Abstract N° OP0138<br />
B cell subsets phenotype in autoimmunity with immunodeficiency:<br />
analysis of a large cohort of patients with<br />
APECED syndrome<br />
H. E. Mei (Germany) 16:45<br />
I. Wirries, C. Giesecke, D. Frölich, M. Brisslert,<br />
S. Schmidt, R. Engelmann, C. Perka, A. Radbruch,<br />
T. Dörner<br />
Abstract N° OP0139<br />
A distinct subset of CD19-negative plasma cells resides<br />
in the human bone marrow<br />
Thursday, 7 June 2012<br />
43
Thursday, 7 June 2012<br />
44<br />
<strong>Scientific</strong> <strong>Programme</strong><br />
15:30 - 17:00 Room Berlin 2<br />
Basic and Translational Science Session<br />
Innate lymphoid cells: straddling innate<br />
and adaptive immunity<br />
Learning Objectives:<br />
• Recent observations have shown a close developmental<br />
link between lymphoid cells involved in lymphoid<br />
tissue formation (LTi), their inflammatory<br />
counterparts (TH17) and NK cells<br />
• The implications of these findings will be discussed<br />
and in particular the therapeutic implications in a<br />
range of immune mediated inflammatory diseases<br />
Chairperson(s):<br />
Francesca Barone (United Kingdom)<br />
Caroline Ospelt (Switzerland)<br />
Tom Cupedo (Netherlands) 15:35<br />
Abstract N° SP0111<br />
What are innate lympoid cells and what do they do<br />
David Withers (United Kingdom) 15:55<br />
Abstract N° SP0112<br />
Role of innate lymphoid cells in immunological memory<br />
Mark Coles (United Kingdom) 16:15<br />
Abstract N° SP0113<br />
Innate lymphoid cells in the formation of lymphoid<br />
tissue<br />
Sanjiv A. Luther (Switzerland) 16:35<br />
Abstract N° SP0114<br />
Innate lympoid cells and their interaction with stroma in<br />
tertiary lymphoid tissue formation<br />
15:30 - 17:00 Room Dublin<br />
Health Professionals Session<br />
Promotion of physical activity in<br />
rheumatology targeting patients, providers<br />
and the public<br />
Learning Objectives:<br />
• Define motivational interviewing and self-regulation<br />
• Describe the use of motivational interviewing and<br />
self-regulation to increase physical activity in rheumatoid<br />
arthritis<br />
• Describe outcomes of interventions using motivational<br />
interviewing and self-regulation to promote<br />
physical activity in rheumatoid arthritis<br />
• Describe education, monitoring and outcome in<br />
providers to increase physical activity in rheumatoid<br />
arthritis<br />
• Describe the key elements and effects of a health<br />
communications campaign promoting physical<br />
activity in arthritis<br />
Chairperson(s):<br />
Patricia Cornell (United Kingdom)<br />
Christina Opava (Sweden)<br />
Linda Ehrlich-Jones (USA) 15:35<br />
Abstract N° SP0105<br />
Motivational interviewing from the patient’s perspective<br />
to increase physical activity in arthritis<br />
Emalie Hurkmans (Netherlands) 15:55<br />
Abstract N° SP0106<br />
Motivational interviewing and self-regulation to<br />
increase physical activity in patients with rheumatoid<br />
arthritis<br />
Ingrid Demmelmaier (Sweden) 16:15<br />
Abstract N° SP0107<br />
Education, monitoring and outcome in providers of a<br />
self-regulation program to increase physical activity in<br />
rheumatoid arthritis<br />
Teresa J. Brady (USA) 16:35<br />
Abstract N° SP0108<br />
Promoting physical activity through mass media: the US<br />
centers for disease control and prevention´s health<br />
communications campaign targeting physical activity<br />
among people with arthritis<br />
15:30 - 17:00 Room Paris 2<br />
Practical Skills Session<br />
Ultrasound advanced 1<br />
eular berlin 2012<br />
Chairperson(s):<br />
Nemanja Damjanov (Serbia)<br />
Wolfgang A. Schmidt (Germany)<br />
Stephanie Finzel (Germany) 15:35<br />
What does high-resolution CT tell us about the<br />
sonographic appearance of erosions?<br />
Wolfgang A. Schmidt (Germany) 15:55<br />
What does dual energy CT tell us for the sonographic<br />
diagnosis of gout?<br />
Emilio Filippucci (Italy) 16:15<br />
Fusion imaging - can we use it in clinical practice?<br />
Nemanja Damjanov (Serbia) 16:35<br />
The practical case
eular berlin 2012<br />
<strong>Scientific</strong> <strong>Programme</strong><br />
15:30 - 17:00 Room Berlin 1<br />
Practical Skills Session<br />
MRI Workshop basic 2<br />
Chairperson(s):<br />
Kay-Geert Hermann (Germany)<br />
Mikkel Østergaard (Denmark)<br />
Espen A. Haavardsholm (Norway) 15:35<br />
Basic MRI technical issues and how to interpret and use<br />
the different MR image types in peripheral arthritis<br />
Mikkel Østergaard (Denmark) 16:05<br />
MRI in psoriatic arthritis - update on the current state<br />
Kay-Geert Hermann (Germany) 16:20<br />
MRI in gout - update on the current state<br />
Espen A. Haavardsholm (Norway) 16:35<br />
Recognizing common MRI pathologies in arthritis.<br />
Interactive assessment of MR images on PC projector<br />
15:30 - 17:00 Room New York 3<br />
PARE Session<br />
Comorbidity<br />
Learning Objectives:<br />
• To highlight the impact and associated risks faced by<br />
people living with at least one other significant condition<br />
caused by, or linked to, their RMD<br />
Chairperson(s):<br />
Kirsten Lerstroem (United Kingdom)<br />
David Magnusson (Sweden)<br />
Chris Naylor (United Kingdom) 15:35<br />
Abstract N° SP0115<br />
The link between longterm conditions and mental<br />
health<br />
Borgi Winkler-Rohlfing (Germany) 16:00<br />
Abstract N° SP0116<br />
Improving the prevention of comorbidity of lupus<br />
patients - a project of the German lupus patient organisation<br />
Michael T. Nurmohamed (Netherlands) 16:25<br />
Abstract N° SP0117<br />
RMDs and cardiovascular risk factors<br />
J. Cumming (United Kingdom) 16:50<br />
R. G. Hull<br />
Abstract N° OP0140-PARE<br />
The complexity of living with rheumatic and musculoskeletal<br />
diseases and other health problems<br />
17:45 – 19:00 Hall 1.1<br />
Satellite Symposium: Abbott<br />
17:45 – 19:00 Hall 5.2 A<br />
Satellite Symposium: MSD<br />
17:45 – 19:00 Hall 5.2 B<br />
Satellite Symposium: Pfizer<br />
17:45 – 19:00 Hall 6.2 B<br />
Satellite Symposium: Grünenthal<br />
17:45 – 19:00 Hall 4.1<br />
Satellite Symposium: Bristol-Myers Squibb<br />
17:45 – 19:00 Room Dublin<br />
Satellite Symposium: UCB Pharma<br />
17:45 – 19:00 Room Paris 2<br />
Satellite Symposium: Fidia<br />
Thursday, 7 June 2012<br />
45
eular berlin 2012<br />
Guided Poster Tours<br />
Guided Poster Tours 12:15 - 13:15<br />
Please note that you need to register to participate in guided a Poster Tour. The number of participants is limited to 20<br />
per Poster Tour. Registrations can be made at the Poster & Workshop Desk, located in the Registration area Hall 2.1<br />
based on a “First-Come-First-Served”basis.<br />
Poster Tour T01: (Epi)-Genetics and genomics 1: where are we? Hall 2.2<br />
Chairperson(s): Rene Toes (Netherlands), Marthe Maehlen (Netherlands)<br />
THU0001 VARIATION IN GRANZYME-B IS ASSOCIATED WITH PROGRESSION OF JOINT DESTRUCTION IN RHEUMATOID<br />
ARTHRITIS / R. Knevel* - A. Krabben - G. Wilson - E. Brouwer - E. Lindqvist - D. de Rooy - N. Daha - M. van der Linden -<br />
R. Tsonaka - S. Zhernakova - H.-J. Westra - L. Franke - J. Houwing-Duistermaat - R. Toes - T. Huizinga - T. Saxne - A. van der<br />
Helm-van Mil<br />
THU0002 FINE MAPPING AND EXPRESSION STUDIES OF THE 12Q13-14 LOCUS ASSOCIATED WITH RHEUMATOID ARTHRITIS /<br />
A.Yarwood* - A. Barton - J. Bowes - P. Martin - J. Worthington - S. Eyre on behalf of RACI<br />
THU0003 FINE-MAPPING OF AUTOIMMUNE SUSCEPTIBILITY LOCI USING IMMUNOCHIP IDENTIFIES NOVEL SUSCEPTIBILITY<br />
LOCI FOR PSORIATIC ARTHRITIS / J. Bowes* - P. Ho - E. Korendowych - N. McHugh - J. Packham - I. N. Bruce - A. Barton<br />
THU0004 CAMP RESPONSIVE ELEMENT MODULATOR (CREM) ALPHA CONTRIBUTES TO DECREASED NOTCH-1 EXPRESSION IN<br />
T CELLS FROM PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) / T. Rauen* - A. Grammatikos - C. M. Hedrich -<br />
V. C. Kyttaris - K. Tenbrock - U. Raffetseder - J. Floege - G. C. Tsokos<br />
THU0005 AN IMMUNOCHIP BASED INTERROGATION OF SCLERODERMA SUSCEPTIBILITY VARIANTS / J. Charlesworth -<br />
J. Stankovich - P. Lewis - J. Byron - W. Stevens - J. Sahhar - S. Proudman - J. Roddy - P. Nash - K. Tymms - M. Brown - J. Zochling<br />
THU0006 COMBINATORIAL CONTROL OF TH1 AND TH17 CELL FUNCTIONS BY SINGLE-NUCLEOTIDE POLYMORPHISMS AT<br />
GENES ASSOCIATED WITH THE IL-23 SIGNALING PATHWAY IN SPONDYLOARTHRITIS / L. Rogge* - M. Coffre - M. Roumier<br />
- M. Rybczynska - E. Sechet - H. Law - L. Gossec - M. Dougados - E. Bianchi<br />
THU0007 ANALYSIS OF PROTEIN ACETYLATION AND HISTONE DEACETYLASE EXPRESSION IN THE SYNOVIAL TISSUE REVEALS<br />
COMPLEX RELATIONSHIPS BETWEEN EPIGENETIC REGULATORY MECHANISMS AND INFLAMMATION IN RHEUMA-<br />
TOID ARTHRITIS / A. M. Grabiec* - C. Ospelt - L. G. M. van Baarsen - I. E. van Es - S. Gay - P. P. Tak - K. A. Reedquist<br />
THU0008 META-ANALYSIS OF THE ASSOCIATION OF SMOKING AND PTPN22 R620W GENOTYPE ON AUTOANTIBODY STATUS<br />
AND RADIOLOGICAL EROSIONS IN RHEUMATOID ARTHRITIS / L. H.Taylor* - S.Twigg - J. J.Worthington - P. Emery - A.W. Morgan<br />
- A. G. Wilson - M. D. Teare on behalf of UKRAGG<br />
THU0009 DIFFERENTIAL EXPRESSION OF DKK1 IN SYNOVIAL FIBROBLASTS FROM RESOLVING AND EARLY RHEUMATOID<br />
ARTHRITIS / M. Juarez* - D. Scheel Toellner - L.Yeo - K. Howlett - R. Bayley - B. de Paz - R. Hardy - K. Raza - M. Cooper -<br />
C. Buckley - A. Filer<br />
Poster Tour T02: Novel aspects of joint homeostasis and pathology Hall 2.2<br />
Chairperson(s): Dennis McGonagle (United Kingdom), Shea Carter (Belgium)<br />
THU0020 SERUM PYRIDINOLINE LEVELS PREDICT THE SEVERITY OF FUTURE JOINT DESTRUCTION IN RHEUMATOID ARTHRITIS<br />
/ A. Krabben* - R. Knevel - T. W. J. Huizinga - G. Cavet - A. H. M. van der Helm-van Mil<br />
THU0021 CARTILAGE ZONE SPECIFIC PROTEINS: A QUANTITATIVE PROTEOMIC ANALYSIS / P. Fernández-Puente - L. Lourido -<br />
V. Calamia - J. Mateos - C. Ruiz-Romero - M. Lotz - F. J. Blanco*<br />
THU0022 ENHANCED EXPRESSION OF SUPPRESSOR OF CYTOKINE SIGNALING 3 IN ARTHRITIC CARTILAGE DYSREGULATES<br />
HUMAN CHONDROCYTE FUNCTION / F.Van De Loo* - B. van den Brand - S.Veenbergen - M. Bennink - E. Blaney-Davidson<br />
- H. van Beuningen - P. van der Kraan - W. van den Berg<br />
THU0023 A NOVEL ROLE FOR ELR+ CXC CHEMOKINE SIGNALING IN CARTILAGE HOMEOSTASIS / J. Sherwood* - G. Nalesso -<br />
J. Bertrand - P. Achan - L. Brandolini - T. Pap - C. Pitzalis - F. Dell'Accio<br />
THU0024 DIFFERENCES BETWEEN HEALTHY AND OSTEOARTHRITIS PROTEOMIC PROFILES OF BONE MARROW<br />
MESENCHYMAL STEM CELLS UNDERGOING CHONDROGENESIS / B. Rocha - V. Calamia - J. Mateos - P. Fernández-Puente<br />
- L. Lourido - C. Fernández-Costa - C. Fernández-López - N. Oreiro - C. Ruiz-Romero - F. J. Blanco*<br />
THU0025 EXPRESSION OF INTERLEUKIN-20 AND ITS RECEPTORS IN OSTEOBLASTS AND OSTEOCLASTS IN BONE TISSUE FROM<br />
PATIENTS WITH RHEUMATOID ARTHRITIS / J. Rømer* - P. A. Usher - M. N. Nielsen - J. Mandelbaum - M. Jackerott<br />
* Presenting author<br />
Thursday, 7 June 2012<br />
47
Thursday, 7 June 2012<br />
48<br />
Poster Tour T03: B cells and beyond Hall 2.2<br />
Chairperson(s): Paul Emery (United Kingdom), Maya H. Buch (United Kingdom)<br />
THU0086 SEROPOSITIVITY AND RESPONSE TO RTX: DATA FROM THE CERERRA COLLABORATION / K. Chatzidionysiou* - E. Lie -<br />
E. Nasonov - G. Lukina - M. Hetland - U. Tarp - I. Ancuta - K. Pavelka - D. Nordström - C. Gabay - H. Canhao - M. Tomsic -<br />
P. van Riel - J. Gomez-Reino - T. Kvien - R. van Vollenhoven<br />
THU0087 ONE SINGLE INFUSION OF RITUXIMAB 1G MIGHT BE SUFFICIENT IN THE LONG-TERM MANAGEMENT OF RHEUMA-<br />
TOID ARTHRITIS PATIENTS RESPONDING TO A FIRST CYCLE OF RITUXIMAB (2 X 1G): RESULTS OF A 2-YEAR MULTI-<br />
CENTER RANDOMIZED CONTROLLED TRIAL / M. Dougados* - B. Combe - X. Le Loët - J. Tebib - J. Sibilia - S. Rouanet -<br />
R. Jourdan - X. Mariette<br />
THU0088 ABNORMAL MEMORY B-CELL RECONSTITUTION FOLLOWING ANTI-CD20 THERAPY FOR AUTOIMMUNE DISEASES<br />
PREDICTS CLINICAL RELAPSE / G. Arumugakani* - A. Rawstron - R. Tooze - A. Cherukuri - A. Varghese - E. Vital - P. Emery -<br />
D. McGonagle<br />
THU0089 RESPONSE TO ABATACEPT AND TOCILIZUMAB IN PATIENTS WHO HAD FAILED RITUXIMAB- INITIAL SINGLE CENTRE<br />
EXPERIENCE / S. Das* - S. Horton - E.Vital - D. Bryer - P. Emery - M. Buch<br />
THU0090 SAFETY AND EFFICACY OF ATACICEPT IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RHEUMATOID<br />
ARTHRITIS: RESULTS FROM THE ATACICEPT FOR REDUCTION OF SIGNS AND SYMPTOMS IN RHEUMATOID ARTHRITIS<br />
TRIAL (III) / R. F. van Vollenhoven* - S. Wax - S. Copt - P. P. Tak<br />
THU0091 COMPARISON OF THE CLINICAL UTILITY OF ANTI-IL-6 RECEPTOR ANTIBODY THERAPY AND ANTI-TNF THERAPY IN<br />
AA AMYLOIDOSIS IN RHEUMATIC DISEASE / Y. Okuda* - M. Ohnishi - K. Takasugi<br />
THU0092 THE ADVANTAGE OF EARLY INTERVENTION BY TOCILIZUMAB FOR RHEUMATOID ARTHRITIS - FULL ANALYSIS OF<br />
ALL-CASE POSTMARKETING SURVEILLANCE IN 7,901 PATIENTS IN JAPAN / H. Yamanaka* - M. Harigai - S. Inokuma -<br />
N. Ishiguro - J. Ryu - S. Takei - T. Takeuchi - Y. Tanaka - Y. Sano - T. Koike<br />
THU0093 CLINICAL, RADIOGRAPHIC, AND IMMUNOGENIC EFFECTS AFTER 1 YEAR OF TOCILIZUMAB (TCZ)-BASED TREATMENT<br />
STRATEGY WITH AND WITHOUT METHOTREXATE (MTX) IN RA: THE ACT-RAY STUDY / M. Dougados* - K. Kissel - P. G.<br />
Conaghan - E. Martin-Mola - G. Schett - H. Amital - R. M. Xavier - O. Troum - C. Bernasconi - T. W. J. Huizinga<br />
THU0094 DIRECT COMPARISON OF FOUR BIOLOGICAL AGENTS IN BIO-NAÏVE RHEUMATOID ARTHRITIS PATIENTS / Y.Yonemoto*<br />
- K. Okamura - K. Takeuchi - M. Matsushita - T. Kaneko - T. Kobayashi - T. Aramaki - K. Takagishi<br />
THU0095 EARLY RESPONSE TO ABATACEPT PLUS MTX IN MTX-IR RA PATIENTS USING POWER DOPPLER ULTRASONOGRAPHY:<br />
AN OPEN-LABEL STUDY / M. D’Agostino* - R. Wakefield - H. Berner Hammer - O.Vittecoq - M. Galeazzi - P. Balint - E. Fillipucci<br />
- I. Moller - A. Iagnocco - E. Naredo - M. Ostergaard - C. Gaillez - W. Kerselaers - K. Van Holder - M. Le Bars on behalf of<br />
OMERACT-US Task Force<br />
THU0096 MAVRILIMUMAB IN RHEUMATOID ARTHRITIS: RESULTS OF A PHASE 2 DOUBLE-BLIND, PLACEBO CONTROLLED<br />
STUDY / G. Burmester* - M. Weinblatt - I. McInnes - O. Barbarash - E. Esfandieri - M. Sleeman - A. Godwood - F. Magrini on<br />
behalf of EARTH Study group<br />
THU0097 SYSTEMATIC REVIEW OF THE SAFETY OF PROTEIN KINASE INHIBITORS IN CLINICAL TRIALS IN RHEUMATOID<br />
ARTHRITIS / E. Salgado* - J. R. Maneiro - L. Carmona - J. J. Gomez-Reino<br />
Poster Tour T04: RA small molecules - old and new<br />
Chairperson(s): Daniel Aletaha (Austria), Pedro Machado (Portugal)<br />
eular berlin 2012<br />
Guided Poster Tours 12:15 - 13:15<br />
THU0127 FUNCTIONAL ACTIVITY OF MEMBRANE-BOUND GLUCOCORTICOID RECEPTORS / C. Strehl* - T. Gaber - M. Jakstadt -<br />
M. Hahne - P. Hoff - G.-R. Burmester - F. Buttgereit<br />
THU0128 THE EXTRA-LOW-DOSE METHOTREXATE TREATMENT FACILITATES THE INTRACELLULAR ACCUMULATION OF<br />
LONGER CHAIN SUBGROUPS OF METHOTREXATE POLYGLUTAMATES / Y. Koyama* - K. Hase - D. Hidaka - S. Nagano - T.<br />
Ota - A. Uchino - J. Nakagawa<br />
THU0129 SELECTIVE ELIMINATION OF PATHOGENIC TH17 CELLS FROM PERIPHERAL BLOOD OF RHEUMATOID ARTHRITIS<br />
PATIENTS BY A PURIFIED FUNGAL POLYSACCHARIDE / A. Alunno* - E. Pericolini - E. Gabrielli - O. Bistoni - S. Caterbi -<br />
E. Bartoloni - S.-K. Chow - A. Casadevall - A.Vecchiarelli - R. Gerli<br />
THU0130 ASSESSMENT OF TRANSAMINASITIS WITH DAILY METHOTREXATE THERAPY IN PATIENTS WITH INFLAMMATORY<br />
RHEUMATIC DISEASES. A LONG-TERM FOLLOW-UP COHORT STUDY / M. U. Martinez Martinez* - A. Sánchez-Arriaga - C.<br />
Abud-Mendoza<br />
THU0131 TOFACITINIB (CP-690,550), AN ORAL JANUS KINASE INHIBITOR: ANALYSIS OF MALIGNANCIES ACROSS THE RHEUMA-<br />
TOID ARTHRITIS CLINICAL PROGRAMME / X. Mariette* - J. R. Curtis - E. B. Lee - R. Riese - I. Kaplan - R. Chew - J. Geier -<br />
L. Wang - J. D. Bradley<br />
THU0132 COMPARISON OF DOSE ESCALATION OF INFLIXIMAB AND THE ADDITION OF TACROLIMUS IN RHEUMATOID<br />
ARTHRITIS PATIENTS WITH AN INADEQUATE RESPONSE TO INFLIXIMAB AND METHOTREXATE COMBINATION<br />
THERAPY / Y.Yonemoto* - K. Okamura - T. Kaneko - T. Kobayashi - K. Takagishi<br />
THU0133 INTRA-ARTICULAR METHOTREXATE: CLINICAL AND POWER DOPPLER ULTRASONOGRAPHY STUDY OF SYNOVITIS<br />
IN MEDIUM SEIZED JOINTS OF RHEUMATOID ARTHRITIS PATIENTS / M. Mortada* - A. SOLYMAN<br />
THU0134 BIOMARKERS OF METOTHREXATE ADVERSE REACTIONS IN RHEUMATOID ARTHRITIS PATIENTS / N. Dostanko* -<br />
V.Yagur - N. Soroka<br />
* Presenting author
eular berlin 2012<br />
Guided Poster Tours 12:15 - 13:15<br />
Poster Tour T05: SLE, APS, Sjögren's Hall 2.2<br />
Chairperson(s): Dimitrios Boumpas (Greece), Cristina Pamfil (Greece)<br />
THU0158 SIX YEAR FOLLOW-UP STUDY OF BONE MINERAL DENSITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS /<br />
J. Jacobs* - L.-A. Korswagen - A. Schilder - L. van Tuyl - B. Dijkmans - W. Lems - A.Voskuyl - I. Bultink<br />
THU0159 INCIDENCE AND PREVALENCE OF MAJOR CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT IN SYSTEMIC LUPUS<br />
ERYTHEMATOSUS (SLE): A 3 YEAR PROSPECTIVE EVALUATION AND CLINICAL CORRELATIONS IN 370<br />
PATIENTS / E. I. Kampylafka* - H. Alexopoulos - M. L. Kosmidis - D. B. Panagiotakos - P. G.Vlachoyiannopoulos - M. C. Dalakas<br />
- H. M. Moutsopoulos - A. G. Tzioufas<br />
THU0160 WHITE MATTER LESIONS ARE PREDOMINANTLY DEMYELINATING IN SYSTEMIC LUPUS ERYTHEMATOSUS. AN<br />
SUPPORT VECTOR MACHINES CLASSIFICATION OF TEXTURE PARAMETERS / A. T. Lapa - M. P. Bento - L. Rittner -<br />
H. H. Ruocco - G. Castellano - B. D. Damasceno - L. T. L. Costallat - S. Appenzeller* - R. Lotufo - F. Cendes<br />
THU0161 NEUROPSYCHIATRIC INVOLVEMENT AND SLE: PERFORMANCE OF A NEW ALGORITHM FOR ATTRIBUTION OF NP<br />
EVENTS TESTED ON AN ITALIAN MULTICENTER COHORT / A. Bortoluzzi* - S. Bombardieri - C. Casu - F. Conti - S. De Vita<br />
- A. Doria - I. Farina - G. Ferraccioli - E. Gremese - E. Mansutti - M. Mosca - M. Padovan - M. Piga - A. Tincani - P. Tomietto -<br />
C. Tani - G.Valesini - M. Zen - A. Mathieu - M. Govoni on behalf of on behalf of the Italian Study Group for the Neuropsychiatric<br />
Involvement in Systemic Lupus Erythematosus<br />
THU0162 THROMBOTIC MICROANGIOPATHY IN RENAL BIOPSIES FROM PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS /<br />
J. Gerhardsson - A. Zickert - B. Sundelin - E. Svenungsson - I. Gunnarsson*<br />
THU0163 PREDICTORS OF METABOLIC SYNDROME AT ENROLMENT INTO A MULTICENTRE INTERNATIONAL INCEPTION<br />
COHORT OF PATIENTS WITH SLE / B. Parker* - M. B. Urowitz - M. Lunt - I. N. Bruce on behalf of SLICC Registry for<br />
Atherosclerosis<br />
THU0164 RISK OF SERIOUS INFECTIONS IN RHEUMATOID ARTHRITIS AND OTHER CHRONIC INFLAMMATORY IMMUNE-<br />
MEDIATED DISEASES TREATED WITH TNF ANTAGONISTS OR RITUXIMAB / T. Cobo-Ibáñez* - M. A. Descalzo - S. Muñoz-<br />
Fernández - E. Loza - L. Carmona - J. J. Gómez-Reino on behalf of on behalf of the BIOBADASER 2.0 Study Group<br />
THU0165 HIGH RATE OF CARDIOVASCULAR EVENTS IN LUPUS PATIENTS AT 5 YEAR FOLLOW UP AND ASSOCIATION OF<br />
CLASSICAL AND LUPUS RELATED RISK FACTORS / S. Skeoch* - S. Haque - B. Parker - Y. Ahmad - L. S. Teh - I. Bruce<br />
THU0166 REBAMIPIDE IN THE TREATMENT OF XEROSTOMIA IN SJÖGREN’S SYNDROME: RANDOMIZED PLACEBO-<br />
CONTROLLED STUDY / A. Abou-Raya* - S. Abou-Raya - N. Sallam - M. Helmii<br />
Poster Tour T06: Clinical scleroderma 1 and inflammatory myopathy Hall 2.2<br />
Chairperson(s): Oliver Distler (Switzerland), Britta Maurer (Switzerland)<br />
THU0231 THE EFFICACY OF TACROLIMUS IN PATIENTS WITH INTERSTITIAL LUNG DISEASES COMPLICATED WITH<br />
POLYMYOSITIS OR DERMATOMYOSITIS / T. Kurita* - S.Yasuda - K. Oba - K. Otomo - H. Shida - T. Watanabe - Y. Kanetsuka -<br />
M. Kono - T. Odani - Y. Fujieda - Y. Kon - T. Horita - N. Sato - T. Atsumi<br />
THU0232 PREGNANCY OUTCOME IN IDIOPATHIC INFLAMMATORY MYOPATHY PATIENTS IN A MULTICENTER STUDY / M.Vincze*<br />
- A.Váncsa - K. Dankó - L. Plestilova - J.Vencovsky - K. Gheorghe - I. Lundberg - P. Charles - H. Balsam - E. Wegier-Szewczyk<br />
THU0233 MYOPATHY IS A POOR PROGNOSTIC FEATURE IN SYSTEMIC SCLEROSIS. RESULTS FROM THE CANADIAN SCLERO-<br />
DERMA RESEARCH GROUP (CSRG) COHORT / M. Jung* - M. Baron - M. Hudson - A. Bonner - J. E. Pope on behalf of Canadian<br />
Scleroderma Research Group<br />
THU0234 SYSTEMATIC LITERATURE REVIEW: EFICACY OF RAYNAUD PHENOMENON PHARMACOLOGYCAL TREATMENT IN<br />
SYSTEMIC SCLEROSIS PATIENTS / P. Garcia De La Peña Lefebvre* - M. B. Nishishinya - C. A. PEREDA - J. ROMAN IVORRA -<br />
P. CARREIRA - E. LOZA - I. Rúa-Figueroa - S. Muñoz-Fernández<br />
THU0235 IDENTIFYING AND QUANTIFYING PROGNOSTIC FACTORS IN SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG<br />
DISEASE USING A TIME-VARYING COVARIATE SURVIVAL MODEL / O. A. Moore* - N. Goh - T. Corte - H. Rouse -<br />
O. Hennessy - V. Thakkar - J. Byron - J. Sahhar - J. Roddy - P.Youssef - P. Nash - J. Zochling - S. M. Proudman - W. Stevens -<br />
M. Nikpour on behalf of Australian Scleroderma Interest Group<br />
THU0236 LOW GRADE EROSIVE ARTHRITIS IS A GENUINE AND FREQUENT DISEASE MANIFESTATION OF SYSTEMIC SCLEROSIS<br />
/ E. Akbayrak - I. H. Tarner - U. Müller-Ladner - R. Dinser*<br />
THU0237 IMPACT OF RECURRENT ISCHEMIC DIGITAL ULCERS ON HAND DISABILITY IN SYSTEMIC SCLEROSIS / L. Mouthon* -<br />
P. Carpentier - A. Khau Van Kien - P. Clerson - H. Maillard - E. Hachulla - C. Frances - E. Diot - C. Lok - E. Puzenat - A. Sparsa -<br />
A. Bérezné - V. Gressin - M.-A. Richard<br />
THU0238 LONG-TERM FOLLOW-UP OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE<br />
SYSTEMIC SCLEROSIS / H. Tsukamoto* - T. Horiuchi - T. Miyamoto - H. Niiro - Y. Arinobu - Y. Inoue - M. Ayano - A. Tanaka -<br />
N. Ueda - M. Harada - K. Akashi<br />
THU0239 CARDIOVASCULAR RISK FACTORS IN ADULTS WITH POLYMYOSITIS AND DERMATOMYOSITIS – A MULTICENTER<br />
STUDY / L. C. Diederichsen* - A. C. Diederichsen - J. A. Simonsen - P. Junker - K. Søndergaard - I. E. Lundberg - N. Tvede -<br />
A. F. Christensen - L. Dreyer - L. Ejstrup - S. Jacobsen<br />
THU0240 ROSUVASTATIN IMPROVES IMPAIRED ENDOTHELIAL FUNCTION AND LOWERS HIGH SENSITIVITY CRP IN PATIENTS<br />
WITH SYSTEMIC SCLEROSIS – A PROSPECTIVE CASE-SERIES STUDY / O. Timár - Z. Szekanecz - G. Kerekes - J. Végh -<br />
A. V. Oláh - Z. Csiki - K. Dankó - S. Szamosi - Á. Németh - P. Soltész - G. Szücs*<br />
* Presenting author<br />
Thursday, 7 June 2012<br />
49
Thursday, 7 June 2012<br />
50<br />
eular berlin 2012<br />
Guided Poster Tours 12:15 - 13:15<br />
Poster Tour T07: Spondyloarthritis treatment Hall 4.2<br />
Chairperson(s): Rik Lories (Belgium), Barbara Neerinckx (Belgium)<br />
THU0260 CIRCULATING LEVELS OF TNF-LIKE CYTOKINE 1A (TL1A) ARE INCREASED IN PATIENTS WITH ANKYLOSING<br />
SPONDYLITIS / M. Konsta* - M. Tektonidou - A. Iliopoulos - G. Bamias - P. P. Sfikakis<br />
THU0261 CONTINUOUS NSAID USE REVERTS THE EFFECTS OF INFLAMMATION ON RADIOGRAPHIC PROGRESSION IN<br />
PATIENTS WITH ANKYLOSING SPONDYLITIS / F. Kroon* - R. Landewé - M. Dougados - D. van der Heijde<br />
THU0262 SCLEROSTIN DOES NOT PREDICT RADIOGRAPHIC PROGRESSION IN PATIENTS ON ANTI-TNF THERAPY – NEW<br />
RESULTS FROM THE EUROPEAN ANKYLOSING SPONDYLITIS (AS) INFLIXIMAB COHORT (EASIC) / X. Baraliakos* -<br />
F. Heldmann - J. Listing - G. Schett - T. Appelboom - J. Brandt - F. van den Bosch - M. Breban - G. Burmester - M. Dougados -<br />
P. Emery - H. Gaston - M. Gruenke - I. van der Horst-Bruinsma - R. Landewé - M. Leirisalo-Repo - J. Sieper - K. de Vlam - J. Braun<br />
on behalf of EASIC<br />
THU0263 DEVELOPMENT OF CHRONIC INFLAMMATORY CHANGES ON WHOLE BODY MAGNETIC RESONANCE IMAGING IN<br />
PATIENTS WITH EARLY AXIAL SPONDYLOARTHRITIS AFTER TWO YEARS OF CONTINUOUS TREATMENT WITH ETANER-<br />
CEPT – 2 YEAR DATA OF THE ESTHER TRIAL / I.-H. Song* - K.-G. Hermann - H. Haibel - C. Althoff - D. Poddubnyy - J. Listing<br />
- A. Weiss - E. Lange - B. Freundlich - M. Rudwaleit - J. Sieper<br />
THU0264 ADALIMUMAB SIGNIFICANTLY REDUCES RECURRENCE RATE OF ANTERIOR UVEITIS IN PATIENTS WITH ANKYLOSING<br />
SPONDYLITIS / C. van Denderen* - I. M.Visman - M. T. Nurmohamed - M. S. Suttorp-Schulten - I. E. van der Horst-Bruinsma<br />
THU0265 EARLY CHANGE IN BONE RESORPTION PREDICTS DISCONTINUATION OF TUMOR NECROSIS FACTOR-ALPHA<br />
BLOCKING THERAPY IN PATIENTS WITH ANKYLOSING SPONDYLITIS / S. Arends* - A. Spoorenberg - P. M. Houtman -<br />
M. K. Leijsma - C. G. M. Kallenberg - E. Brouwer - E. van der Veer<br />
THU0266 SARCOPENIA REVERSAL IN ANKYLOSING SPONDYLITIS (AS) UNDER ANTI-TNF THERAPY: A 24-MONTH LONGITU-<br />
DINAL ANALYSIS / M. A. Barros* - C. S. Saad - L. Takayama - J. C. Moraes - A. C. Medeiros - E. Bonfa - R. M. Pereira<br />
Poster Tour T08: PReS - basic research in paediatric rheumatology Hall 4.2<br />
Chairperson(s): Berent J. Prakken (Netherlands), Dirk Holzinger (Germany)<br />
THU0287 GLYCOSYLATION OF VITAMIN D BINDING PROTEIN REDUCED IN JUVENILE IDIOPATHIC ARTHRITIS PATIENTS AT RISK<br />
OF DISEASE EXTENSION / D. S. Gibson* - S. Finnegan - G. Manning - M. Duncan - S. Pennington - T. Moore - M. Rooney<br />
THU0288 PROTEOMIC PROFILING OF THE SYNOVIAL MEMBRANE IN EARLY UNTREATED JUVENILE IDIOPATHIC ARTHRITIS /<br />
S. Finnegan* - D. S. Gibson - M. Rooney<br />
THU0289 MICRORNA SIGNATURE IN PEDIATRIC LUPUS NEPHRITIS: A PILOT STUDY / P. Costa Reis* - P. A. Russo - K. E. Sullivan<br />
THU0290 PERIPHERAL MONONUCLEAR CELLS OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS PATIENTS HAVE NO INTRINSIC<br />
DEFECT IN INTERFERON-GAMMA SIGNALING / K. Put* - A. Avau - T. Mitera - S. Put - B. Bader-Meunier - P. Quartier -<br />
C. Wouters - P. Matthys<br />
THU0291 NEUTROPHIL APOPTOSIS IS NOT AFFECTED BY GLUCOCORTICOID OR DMARD TREATMENT IN JUVENILE-ONSET<br />
SYSTEMIC LUPUS ERYTHEMATOSUS / F. Gohar* - L. Ballantine - M. W. Beresford<br />
THU0292 STIMULATION OF JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS BLOOD CELLS INDUCES IL-17 PRODUCTION /<br />
L. Ballantine* - A. Midgley - L. Watson - M. Beresford<br />
THU0293 JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS (JSLE) AND JUVENILE DERMATOMYOSITIS (JDM) PATIENTS HAVE A<br />
DISTINCT PROFILE OF SOLUBLE APOPTOSIS MOLECULES / B. L. Liphaus* - M. H. B. Kiss - S. Carrasco - C. A. Silva -<br />
C. Goldenstein-Schainberg<br />
THU0294 REGULATORY T CELLS/TH17 BALANCE IN THE PATHOGENESIS OF PEDIATRIC BEHÇET DISEASE / T.-A. Tran* - A. Hubert<br />
- A. Letierce - B. Terrier - G. Geri - D. Saadoun - I. Kone-Paut - M. Rosenzwajg<br />
THU0295 ISOTYPE CHARACTERIZATION OF ANTI-INFLIXIMAB ANTIBODIES IN PEDIATRIC PATIENTS WITH RHEUMATIC<br />
DISEASES TREATED WITH INFLIXIMAB / M. Kosmač* - N. Toplak - G. Simonini - R. Cimaz - V. Čurin Sˇerbec - T. Avčin<br />
THU0296 MATRIX INTERFERENCE OF IL-6, IL-17, IL-21 AND TNF-ALPHA MEASUREMENT IN JUVENILE-ONSET SYSTEMIC LUPUS<br />
ERYTHEMATOSUS SERUM AND PLASMA / J. Ong* - D. Harris - G. Jeffers - L. Watson - L. Ballantine - M. Beresford<br />
* Presenting author
eular berlin 2012<br />
Guided Poster Tours 12:15 - 13:15<br />
Poster Tour T09: Orphan diseases and infectious arthritis Hall 4.2<br />
Chairperson(s): Maurizio Cutolo (Italy), Alberto Sulli (Italy)<br />
THU0379 A 20 YEAR SINGLE CENTRE EXPERIENCE OF AA AMYLOIDOSIS DEMONSTRATING CHANGES IN ITS EPIDEMIOLOGY /<br />
H. J. Lachmann* - J. D. Gillmore - A. D. Wechalekar - S. D. Gibbs - J. H. Pinney - D. M. Rowczenio - H. Trojer - T. Lane - C. P.Venner<br />
- S. M. Banypersad - J. A. Gilbertson - F. T. Hunt - D. Gopaul - D. F. Hutt - N. Wassef - M. B. Pepys - P. N. Hawkins<br />
THU0378 INTERLEUKIN-6 BLOCKING THERAPY BY TOCILIZUMAB IN PATIENTS WITH MULTICENTRIC CASTLEMAN’S DISEASE<br />
RESULTS IN A SIGNIFICANT DECREASE IN SERUM LEVELS OF IGG4 AND IGE / M. Murakami* - T. Matsutani - C. Aoki -<br />
H.-M. Lee - Y. Li - N. Nishimoto<br />
THU0377 EFFICACY, SAFETY AND PHARMACOKINETICS OF THE ANTI-INTERLEUKIN-1 BETA ANTIBODY CANAKINUMAB IN<br />
PATIENTS WITH SCHNITZLER SYNDROME / H. D. De Koning* - J. Schalkwijk - J. van der Ven-Jongekrijg - M. Stoffels -<br />
J. W. van der Meer - A. Simon<br />
THU0376 SERUM LEPTIN, RESISTIN, VISFATIN AND ADIPONECTIN LEVELS IN TUMOR NECROSIS FACTOR RECEPTOR-ASSOCI-<br />
ATED PERIODIC SYNDROME (TRAPS) / L. Cantarini* - L. Obici - G. Simonini - R. Cimaz - M. R. Bacarelli - G. Merlini - A.Vitale<br />
- O. M. Lucherini - M. G. Brizi - M. Galeazzi - A. Fioravanti<br />
THU0375 MALONDIALDEHYDE SERUM LEVELS AND MYCOARDIAL GLOBAL STRAIN IN IDIOPATHIC INFLAMMATORY<br />
MYOPATHY. / K. Ramirez-Santillan* - M.Vazquez-Zaragoza - A. Camargo-Coronel - E. Gomez - B. Mendoza-Perez - L. Moreno-<br />
Ruiz - A. Chavez-Negrete - L. Barile-Fabris<br />
THU0374 ARTICULAR SYMPTOMS IN CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME : A RETROSPECTIVE FRENCH STUDY /<br />
L. Houx* - X. Guennoc - E. Hachulla - I. Koné-Paut - P. Quartier - G. Grateau - P. Pillet - M. Hamidou - I. Lemelle - A. Pagnier -<br />
B. Neven - C. Richez - V. Devauchelle-Pensec<br />
THU0373 CLINICAL PRESENTATION OF ERDHEIM-CHESTER DISEASE: DATA FROM A COHORT OF 10 PATIENTS AND REVIEW OF<br />
THE LITERATURE / G. Cavalli* - B. Guglielmi - C. Campochiaro - A. Berti - M. G. Sabbadini - L. Dagna<br />
THU0372 MRI QUANTIFICATION OF FAT INFILTRATION IN SKELETAL MUSCLE OF PATIENTS WITH CAMPTOCORMIA / S. Guis* -<br />
J. P. Mattei - Y. Le Fur - N. Cuge - E. Soulier - P. Cozzone - D. Bendahan<br />
THU0371 INCREASED EXPRESSION OF INFLAMMATORY CYTOKINES AND CHEMOKINES IN AN AUTOINFLAMMATORY<br />
DISORDER, NAKAJO-NISHIMURA SYNDROME. / K. Arima* - N. Kanazawa - F. Furukawa - H. Ida - K.Yoshiura<br />
THU0370 RISK INFECTION ASSESSMENT IN RHEUMATOID ARTHRITIS PATIENTS FROM THE PORTUGUESE BIOREPORTAR AND<br />
REGISTAR DATABASES / I. Silva* - F. Araújo - M. Mateus - J. C. Branco<br />
THU0369 SEPTIC ARTHRITIS: CHANGING TRENDS IN EPIDEMIOLOGY OVER TWO DECADES / R. Kalagate - A. Rivera - C. H. Pritchard<br />
- L. H. Brent*<br />
THU0368 RISK OF HERPES VIRUSES INFECTIONS (HSV,VZV) DURING ANTI-TNF THERAPY IN PATIENTS WITH INFLAMMATORY<br />
RHEUMATIC DISEASES. SYSTEMATIC REVIEW AND META-ANALYSIS / H. Che - J. Morel - B. Combe - C. Lukas*<br />
Poster Tour T10: Health Professionals Clinical aspects of care Hall 4.2<br />
Chairperson(s): Patricia Cornell (United Kingdom), Mwidimi Ndosi (United Kingdom)<br />
THU0466-HPR MAINTENANCE OF PHYSICAL ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS: A QUALITATIVE INTERVIEW<br />
STUDY / K. Loeppenthin* - B. A. Esbensen - T. Thomsen - J. Midtgaard<br />
THU0467-HPR A STANDARDIZED EDUCATIONAL PROGRAM DIRECTED TO PATIENTS FOR SELF-CARE PROMOTION CAN BE EQUALLY<br />
EFFECTIVE IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA), SYSTEMIC LUPUS ERYTHEMATOSUS (SLE),<br />
ANKYLOSING SPONDYLITIS (AS) / L. Cano-García* - R. Navas-Fernández - F. G. Jiménez-Nuñez - I. Ureña - S. Manrique -<br />
C. M. Romero-Barco - V. Rodríguez-García - L. Nieves-Martín - M. Á. Belmonte-López - V. Coret - M. C. Ordóñez - M.V. Irigoyen<br />
- A. Fernández-Nebro<br />
THU0468-HPR MENTAL FUNCTIONING IN PATIENTS WITH RHEUMATOID ARTHRITIS OVER AN ELEVEN YEARS FOLLOW-UP PERIOD:<br />
THE ROLE OF COMORBIDITY / J. Van Den Hoek* - L. D. Roorda - H. Boshuizen - G. A. van den Bos - J. van Hees - I. Rupp -<br />
G. Tijhuis - J. Dekker<br />
THU0469-HPR SEXUAL PERCEPTION AND SEXUAL PROBLEMS IN PATIENTS WITH ANKYLOSING SPONDYLITIS / K. Hansen Berg* -<br />
A. Prøven - E. Almås - E. E. P. Benestad - M. Østensen - G. Haugeberg<br />
THU0470-HPR WILL I WASTE YOUR TIME? DELAYS IN HELP-SEEKING FOR RA FLARES / C. A. Flurey* - M. Morris - J. Pollock - R. Hughes<br />
- P. Richards - S. Hewlett<br />
THU0471-HPR CRYING WITHOUT TEARS: DIMENSIONS OF CRYING AND RELATIONS WITH OCULAR DRYNESS IN PATIENTS WITH<br />
SJÖGREN’S SYNDROME / N.Van Leeuwen* - E. R. Bossema - R. R.Vermeer - A. A. Kruize - H. Bootsma - J. W. Bijlsma - R. Geen<br />
THU0472-HPR CALIBRATION OF A MULTIDIMENSIONAL ITEM BANK TO MEASURE FATIGUE IN RHEUMATOID ARTHRITIS PATIENTS /<br />
S. Nikolaus* - C. Bode - E. Taal - C. Glas - M. van de Laar<br />
THU0481-HPR LESSONS FROM PATIENT REPORTED OUTCOMES OF BIOLOGIC TREATMENT: IMPROVEMENTS IN QUALITY OF LIFE<br />
AND HEALTH STATUS ARE STABLE OVER TIME DESPITE DECLINING PHYSICAL FUNCTION / T. Harrison* - C. Barnabe -<br />
L. Martin - S. G. Barr<br />
THU0482-HPR COMPARISON OF AGREEMENT AND RESPONSIVENESS TO TREATMENT EFFECTS OF 100MM VISUAL ANALOG SCALE<br />
AND 11 POINT NUMERICAL RATING SCALE TO ASSESS WRIST PAIN IN PATIENTS WITH RHEUMATOID ARTHRITIS /<br />
E. Taal* - M. M.Veehof - M. A. van de Laar<br />
* Presenting author<br />
Thursday, 7 June 2012<br />
51
Thursday, 7 June 2012<br />
52<br />
Genomics, genetics and epigenetics of rheumatic diseases<br />
eular berlin 2012<br />
<strong>Scientific</strong> Poster Session 1 11:45 - 13:30<br />
<strong>Scientific</strong> Poster Session 1<br />
THU0001 VARIATION IN GRANZYME-B IS ASSOCIATED WITH PROGRESSION OF JOINT DESTRUCTION IN RHEUMATOID<br />
ARTHRITIS / R. Knevel* - A. Krabben - G. Wilson - E. Brouwer - E. Lindqvist - D. de Rooy - N. Daha - M. van der Linden -<br />
R. Tsonaka - S. Zhernakova - H.-J. Westra - L. Franke - J. Houwing-Duistermaat - R. Toes - T. Huizinga - T. Saxne - A. van der<br />
Helm-van Mil<br />
THU0002 FINE MAPPING AND EXPRESSION STUDIES OF THE 12Q13-14 LOCUS ASSOCIATED WITH RHEUMATOID ARTHRITIS /<br />
A.Yarwood* - A. Barton - J. Bowes - P. Martin - J. Worthington - S. Eyre on behalf of RACI<br />
THU0003 FINE-MAPPING OF AUTOIMMUNE SUSCEPTIBILITY LOCI USING IMMUNOCHIP IDENTIFIES NOVEL SUSCEPTIBILITY<br />
LOCI FOR PSORIATIC ARTHRITIS / J. Bowes* - P. Ho - E. Korendowych - N. McHugh - J. Packham - I. N. Bruce - A. Barton<br />
THU0004 CAMP RESPONSIVE ELEMENT MODULATOR (CREM) ALPHA CONTRIBUTES TO DECREASED NOTCH-1 EXPRESSION IN<br />
T CELLS FROM PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) / T. Rauen* - A. Grammatikos - C. M. Hedrich -<br />
V. C. Kyttaris - K. Tenbrock - U. Raffetseder - J. Floege - G. C. Tsokos<br />
THU0005 AN IMMUNOCHIP BASED INTERROGATION OF SCLERODERMA SUSCEPTIBILITY VARIANTS / J. Charlesworth -<br />
J. Stankovich - P. Lewis - J. Byron - W. Stevens - J. Sahhar - S. Proudman - J. Roddy - P. Nash - K. Tymms - M. Brown - J. Zochling*<br />
THU0006 COMBINATORIAL CONTROL OF TH1 AND TH17 CELL FUNCTIONS BY SINGLE-NUCLEOTIDE POLYMORPHISMS AT<br />
GENES ASSOCIATED WITH THE IL-23 SIGNALING PATHWAY IN SPONDYLOARTHRITIS / L. Rogge* - M. Coffre - M. Roumier<br />
- M. Rybczynska - E. Sechet - H. Law - L. Gossec - M. Dougados - E. Bianchi<br />
THU0007 ANALYSIS OF PROTEIN ACETYLATION AND HISTONE DEACETYLASE EXPRESSION IN THE SYNOVIAL TISSUE REVEALS<br />
COMPLEX RELATIONSHIPS BETWEEN EPIGENETIC REGULATORY MECHANISMS AND INFLAMMATION IN RHEUMA-<br />
TOID ARTHRITIS / A. M. Grabiec* - C. Ospelt - L. G. M. van Baarsen - I. E. van Es - S. Gay - P. P. Tak - K. A. Reedquist<br />
THU0008 META-ANALYSIS OF THE ASSOCIATION OF SMOKING AND PTPN22 R620W GENOTYPE ON AUTOANTIBODY STATUS<br />
AND RADIOLOGICAL EROSIONS IN RHEUMATOID ARTHRITIS / L. H.Taylor* - S.Twigg - J. J.Worthington - P. Emery - A.W. Morgan<br />
- A. G. Wilson - M. D. Teare on behalf of UKRAGG<br />
THU0009 DIFFERENTIAL EXPRESSION OF DKK1 IN SYNOVIAL FIBROBLASTS FROM RESOLVING AND EARLY RHEUMATOID<br />
ARTHRITIS / M. Juarez* - D. Scheel Toellner - L.Yeo - K. Howlett - R. Bayley - B. de Paz - R. Hardy - K. Raza - M. Cooper - C. Buckley<br />
- A. Filer<br />
THU0010 TRANSCRIPTIONAL PROFILING OF RHEUMATOID ARTHRITIS FIBROBLAST-LIKE SYNOVIOCYTES IDENTIFIES A SUBSET<br />
OF INFLAMMATORY GENES WITH AU-RICH 3’-UNTRANSLATED REGIONS WHICH ARE SUPPRESSED BY HISTONE<br />
DEACETYLASE INHIBITORS VIA REDUCTION OF MRNA STABILITY / A. M. Grabiec* - A. M. Willemsen - A. H. C. van Kampen<br />
- P. P. Tak - K. A. Reedquist<br />
THU0011 MIR-223 EXPRESSION IN SERUM AND CD3+ PERIPHERAL CELLS OF RHEUMATOID ARTHRITIS / I. Muscari - C. Giannitti*<br />
- S. Niccolini - I. Fineschi - G. D. Sebastiani - I. Prevete - A. Iuliano - E. Balistreri - I. Gennai - G. Minisola - A. Spreafico -<br />
M. Galeazzi<br />
THU0012 TGFµ RECEPTOR POLYMORPHISMS IN SYSTEMIC SCLEROSIS RELATED PULMONARY ARTERIAL HYPERTENSION:<br />
RESULTS FROM A MULTICENTER EUSTAR STUDY OF EUROPEAN CAUCASIAN PATIENTS / E. Koumakis* - J. Wipff - M.<br />
Matucci-Cerinic - G. Riemekasten - P. Airo - D. Cusi - H. E. Wichmann - U. Müller-Ladner - P.Vlachoyiannopoulos - G. Chiocchia<br />
-Y. Allanore on behalf of EUSTAR network<br />
THU0013 INTERACTION BETWEEN TWO COMMON HLA ANTIGENS DEFINES A SUBSET OF INDIVIDUALS AT A VERY HIGH RISK<br />
FOR ANKYLOSING SPONDYLITIS / F. van Gaalen* - W.Verduyn - D. Roelen - S. Böhringer - T. Huizinga - D. van der Heijde -<br />
R. Toes<br />
THU0014 ASSOCIATION BETWEEN A POLYMORPHISM IN THE FRACTALKINE RECEPTOR, CX3CR1, AND RHEUMATOID<br />
ARTHRITIS / J. Stack* - K. Hegarty - G. Murphy - M. O'Sullivan - L. Fanning - L. Healy - M. Daly - S. Harney - F. Shanahan -<br />
M. Molloy<br />
THU0015 ASSOCIATION OF ACID PHOSPHATASE LOCUS 1*C ALLELE WITH THE RISK OF CARDIOVASCULAR EVENTS IN<br />
RHEUMATOID ARTHRITIS PATIENTS / M. Teruel* - J.-E. Martin - C. González-Juanatey - R. López-Mejias - J. A. Miranda-Filloy<br />
- R. Blanco - A. Balsa - D. Pascual-Salcedo - L. Rodriguez-Rodriguez - B. Fernández-Gutierrez - A. M. Ortiz - I. González-Alvaro<br />
- C. Gómez-Vaquero - N. Bottini - J. Llorca - M. A. González-Gay - J. Martin<br />
THU0016 INVESTIGATION OF RA GENETIC SUSCEPTIBILITY LOCI CONTRIBUTION TO RESPONSE OUTCOMES FOLLOWING<br />
CONVENTIONAL DMARD TREATMENT IN EARLY RA / M. D. Morgan* - S. Twigg - E. M. A. Hensor - P. G. Conaghan -<br />
J. Worthington - P. Emery - J. H. Barrett - A. W. Morgan on behalf of YEAR Consortium<br />
THU0017 GENETIC MARKERS OF METOTHREXATE ADVERSE REACTIONS IN RHEUMATOID ARTHRITIS PATIENTS / N. Dostanko*<br />
- V.Yagur<br />
THU0018 SUMO SPECIFIC PROTEASES 5 AND 7 CONTRIBUTE TO THE INBALANCED SUMOYLATION LEVEL OF RHEUMATOID<br />
ATHRITIS SYNOVIAL FIBROBLASTS / S. Strietholt* - M. A. Peters - S. Frank - A. Hillmann - G. Kollias - T. Pap<br />
THU0019 GENOME-WIDE PATHWAY ANALYSIS OF GENOME-WIDE ASSOCIATION STUDIES ON PSORIASIS AND BEHCET’S<br />
DISEASE / Y. H. Lee*<br />
* Presenting author
eular berlin 2012<br />
<strong>Scientific</strong> Poster Session 1 11:45 - 13:30<br />
Cartilage, synovium and osteoimmunology<br />
THU0020 SERUM PYRIDINOLINE LEVELS PREDICT THE SEVERITY OF FUTURE JOINT DESTRUCTION IN RHEUMATOID ARTHRITIS<br />
/ A. Krabben* - R. Knevel - T. W. J. Huizinga - G. Cavet - A. H. M. van der Helm-van Mil<br />
THU0021 CARTILAGE ZONE SPECIFIC PROTEINS: A QUANTITATIVE PROTEOMIC ANALYSIS / P. Fernández-Puente - L. Lourido -<br />
V. Calamia - J. Mateos - C. Ruiz-Romero - M. Lotz - F. J. Blanco*<br />
THU0022 ENHANCED EXPRESSION OF SUPPRESSOR OF CYTOKINE SIGNALING 3 IN ARTHRITIC CARTILAGE DYSREGULATES<br />
HUMAN CHONDROCYTE FUNCTION / F.Van De Loo* - B. van den Brand - S.Veenbergen - M. Bennink - E. Blaney-Davidson<br />
- H. van Beuningen - P. van der Kraan - W. van den Berg<br />
THU0023 A NOVEL ROLE FOR ELR+ CXC CHEMOKINE SIGNALING IN CARTILAGE HOMEOSTASIS / J. Sherwood* - G. Nalesso -<br />
J. Bertrand - P. Achan - L. Brandolini - T. Pap - C. Pitzalis - F. Dell'Accio<br />
THU0024 DIFFERENCES BETWEEN HEALTHY AND OSTEOARTHRITIS PROTEOMIC PROFILES OF BONE MARROW MESEN-<br />
CHYMAL STEM CELLS UNDERGOING CHONDROGENESIS / B. Rocha - V. Calamia - J. Mateos - P. Fernández-Puente -<br />
L. Lourido - C. Fernández-Costa - C. Fernández-López - N. Oreiro - C. Ruiz-Romero - F. J. Blanco*<br />
THU0025 EXPRESSION OF INTERLEUKIN-20 AND ITS RECEPTORS IN OSTEOBLASTS AND OSTEOCLASTS IN BONE TISSUE FROM<br />
PATIENTS WITH RHEUMATOID ARTHRITIS / J. Rømer* - P. A. Usher - M. N. Nielsen - J. Mandelbaum - M. Jackerott<br />
THU0026 P62/SQSTM1 LINKS REACTIVE OXYGEN SPECIES FORMATION AND OBESITY TO INCREASED TNFALPHA-MEDIATED<br />
JOINT DESTRUCTION VIA ITS SIGNALLING DOMAINS / A. Korb-Pap* - A. Hillmann - M. Heitzmann - S. Bürgis - G. Kollias<br />
- S. Hermann - M. Schäfers - A. Gessner - T. Pap - T. Weide - H. Pavenstädt<br />
THU0027 TREM-1 STIMULATION INHIBITS HUMAN OSTEOCLASTOGENESIS VIA DOWN-REGULATION OF M-CSF RECEPTOR<br />
EXPRESSION / B. Lee* - T.-H. Kim - E. Kwon - S. J. Choi - Y. H. Lee - J. Sohn - G. G. Song - J. D. Ji<br />
THU0028 FIBROBLAST-LIKE SYNOVIOCYTES INHIBIT TNF- AND RANKL-INDUCED HUMAN OSTEOCLAST PRECURSOR DIFFER-<br />
ENTIATION FOLLOWING EXPOSURE TO IL-1BETA / B. P. Harvey* - F. Syed - Z. Kaymakcalan<br />
THU0029 ANATOMICAL VARIATION IN THE MORPHOLOGY OF THE POSTERIOR CRUCIATE LIGAMENT SYNOVIO-ENTHESEAL<br />
COMPLEX AND CORRELATION WITH DEGENERATIVE CHANGE / D. Binks* - D. Bergin - A. Hindley - D. McGonagle -<br />
A. Radjenovic<br />
THU0030 EVIDENCE FOR GOOD INTRINSIC MESENCHYMAL STEM CELL ACTIVITY IN GELATINOUS HEBERDEN’S NODES IN<br />
OSTEOARTHRITIS AT CLINICAL PRESENTATION / T. Baboolal - S. Boxall - C. Buckley - A. L. Tan - S. Churchman - S. Calder -<br />
D. Kouroupis - P. Giannoudis - R. Hodgson - E. Jones - D. McGonagle*<br />
THU0031 BLOCKING AVB3 INTEGRIN WITH CILENGITIDE AFFECTS OSTEOCLASTOGENESIS IN VITRO AND PREVENTS<br />
COLLAGEN INDUCED ARTHRITIS IN VIVO / D. Sykoutri* - G. Nisha - S. Hayer - P. Mandl - J. S. Smolen - G. Prager - K. Redlich<br />
THU0032 INVOLVEMENT OF ER STRESS SIGNALS, PERK, IRE1, GRP78 IN RANKL-INDUCED, C-FOS AND NFATC1-MEDIATED<br />
OSTEOCLASTOGENESIS / W.-H.Yoo - E.-G. Lee* - M.-S. Sung - M. J. Hong - Y. K. Hong - C.-H. Lee - M. S. Lee<br />
THU0033 SET7/9 AND SIRT1 INDUCE PROMOTER-DRIVEN COLLAGEN 2ALPHA1 EXPRESSION IN 3D CULTURED HUMAN<br />
CHODROCYTES / H. Oppenheimer* - H. Meir - A. Haze - L. Kandel - M. Leibergall - M. Dvir-Ginzberg<br />
THU0034 RHEUMATOID ARTHRITIS BONE FRAGILITY IS ASSOCIATED WITH INCREASED DKK1 EXPRESSION AND DISTUR-<br />
BANCES IN THE BONE TURNOVER REGULATING GENES / J. Caetano-Lopes* - A. Rodrigues - A. Lopes - A. C. Vale -<br />
J. Monteiro - M. F.Vaz - A. Nazarian - H. Canhão - J. E. Fonseca<br />
THU0035 THROMBIN AND PLASMIN INDUCED PROTEOGLYCAN RELEASE IN HUMAN CARTILAGE IS PAR-DEPENDENT /<br />
L. Nieuwenhuizen* - R. Schutgens - G. Roosendaal - S. Mastbergen - D. Biesma - F. Lafeber<br />
THU0036 PPAR GAMMA AGONIST ROSIGLITAZONE COULD INHIBIT RA-FLS INDUCED OSTEOCLASTOGENESIS BY DOWN-<br />
REGULATING RANKL EXPRESSION AND SUPPRESSION OF ERK PHOSPHORYLATION / X. N. Wei - L. Dai* - L. J. Zhu -<br />
Y. Q. Mo - D. H. Zheng - B.Y. Zhang<br />
THU0037 IMMUNE COMPLEX-INDUCED INHIBITION OF OSTEOCLASTOGENESIS IS MEDIATED VIA ACTIVATING, BUT NOT<br />
INHIBITORY FCGAMMA RECEPTORS ON MYELOID PRECURSOR CELLS / L. C. Grevers* - P. L. van Lent - T. J. de Vries -<br />
V. Everts - W. B. van den Berg<br />
THU0038 HISTOLOGIC FEATURES OF OSTEOCHONDRAL JUNCTION IN JOINT DISORDERS / O. Addimanda* - B. Pavloska - L. Pulsatelli<br />
- G. Lisignoli - A. Facchini - R. Meliconi<br />
THU0039 EVIDENCE OF HLA-B27 IN HEALTHY INDIVIDUALS AND PATIENTS WITH UVEITIS IS A RISK FACTOR FOR ALTERATIONS<br />
IN BONE METABOLISM / S. Schmidt* - S. Finzel - J. Rech - M. Englbrecht - R. Said-Nahal - M. Breban - G. Schett<br />
THU0040 HISTOLOGY OF NASAL TISSUE DESTRUCTION IN GPA PATIENTS IS REFLECTED IN HUMAN TISSUE TRANSPLANTS OF<br />
GPA PATIENTS IN IMMUNODEFICIENT MICE / S. Ullrich* - N. Kesel - U. Schumacher - W. L. Gross - M. Laudien - A. Müller<br />
- K. Holl-Ulrich<br />
THU0041 GROWTH FACTORS INFLUENCE ADHESIVE PROPERTIES OF FIBROBLASTS FROM PATIENTS WITH RHEUMATOID<br />
ARTHRITIS, OSTEOARTHRITIS AND SYSTEMIC SCLEROSIS / S. Lefevre* - A. Lehr - S. Rehart - M. Rickert - J. Steinmeyer -<br />
A. Günther - U. Müller-Ladner - E. Neumann<br />
THU0042 THE DEVELOPMENT AND CHARACTERISATION OF COMPETITION ELISA FOR MEASUREMENT OF ACTIVE ADAMTS-4<br />
IN SERUM AND SYNOVIAL FLUID / Y. He - Q. L. Zheng - M. A. Karsdal - A.-C. Bay-Jensen*<br />
* Presenting author<br />
Thursday, 7 June 2012<br />
53
Thursday, 7 June 2012<br />
54<br />
Rheumatoid arthritis - comorbidity and clinical aspects<br />
THU0043 PREVALENCE OF CEREBRAL AMYLOID ANGIOPATHY IN RHEUMATOID ARTHRITIS / Á. Apáthy* - M. Bély<br />
eular berlin 2012<br />
<strong>Scientific</strong> Poster Session 1 11:45 - 13:30<br />
THU0044 DIFFERENT TYPE OF CAROTID ARTERIAL WALL REMODELING IN RHEUMATOID ARTHRITIS AS COMPARED TO<br />
HEALTHY SUBJECTS / A. M. Van Sijl* - K. van den Hurk - M. J. Peters - V. P. van Halm - G. Nijpels - C. D. Stehouwer -<br />
Y. M. Smulders - A. E.Voskuyl - J. M. Dekker - M. T. Nurmohamed<br />
THU0045 SCORE AND FRAMINGHAM PREDICT CV DISEASE INCIDENCE IN RA PATIENTS BETTER THAN INTIMA-MEDIA THICK-<br />
NESS / A. M. Van Sijl* - I. A. van den Oever - H. G. Raterman - M. J. Peters - V. P. van Halm - M. Boers - Y. M. Smulders -<br />
A. E. Voskuyl - M. T. Nurmohamed<br />
THU0046 PREVALENCE OF VITAMIN D DEFICIENCY IN RHEUMATOID ARTHRITIS PATIENTS: ASSOCIATION WITH ANAEMIA OF<br />
INFLAMMATION AND EFFECT OF VITAMIN D SUPPLEMENTATION / A. Abou-Raya* - S. Abou-Raya - M. Helmii<br />
THU0047 CAROTID PLAQUE CHARACTERISTICS ARE ASSOCIATED WITH DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS / A. G. P. Semb*<br />
- S. Rollefstad - S. Provan - T. K. Kvien - E. Stranden - I. Olsen - J. Hisdal<br />
THU0048 RADIUS 1: CORRELATION BETWEEN SERIOUS INFECTION EVENTS (SIES) AND RHEUMATOID ARTHRITIS (RA) DISEASE<br />
ACTIVITY IN PATIENTS REQUIRING A CHANGE IN THERAPY / A. Weaver* - O. Troum - M. Hooper - A. Koenig - S. Chaudhari<br />
- J.-Y. Feng - D. Wenkert<br />
THU0049 A PROPOSED EFFECTIVE STRATEGY TO SCREENING LATENT TB INFECTION IN RA PATIENTS / B. Mehta* - E. Zapantis -<br />
O. Petryna - P. Efthimiou<br />
THU0050 CARDIOVASCULAR RISK IN KOREAN PATIENTS WITH RHEUMATOID ARTHRITIS / C.-B. Choi* - Y.-K. Sung - S.-K. Cho -<br />
S.-Y. Park - J. Shim - J. J. Kim - C. N. Son - S.-C. Bae on behalf of KORONA investigators<br />
THU0051 AUTOINMUNE THYROID DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITIS: CASE – CONTROL STUDY / R. Gomez<br />
- J. M. Gutierrez - D. G. Fernandez-Avila* - M. C. Diaz - P. Aschner on behalf of Javeriana Investigation Group in Rheumatic<br />
Diseases<br />
THU0052 DURATION AND SEVERITY OF THE DISEASE IS IMPORTANT RISK FACTOR FOR CARDIAC AUTONOMIC NEUROPATHY<br />
AND ARTERIAL STIFFNESS IN WOMEN WITH RHEUMATOID ARTHTRITIS / D. S. Novikova* - T. Popkova - E. Udachkina -<br />
T. Lisitsyna - A. Novikov - E. Alexandrova - A.Volkov - E. Nasonov<br />
THU0053 REDUCED ENDOTHELIUM-INDEPENDENT VASCULAR REACTIVITY IS INDICATIVE OF CAROTID ATHEROSCLEROSIS IN<br />
PATIENTS WITH RHEUMATOID ARTHRITIS WITHOUT OVERT CARDIOVASCULAR DISEASE / E. Myasoedova* - S. Myasoedova<br />
- S. Obzherina - N. Svyatova - N. Shostak<br />
THU0054 URINARY TRACT INFECTIONS IN PATIENT WITH RHEUMATIC DISEASE: A RETROSPECTIVE STUDY / E. Sahinbegovic* -<br />
J. Zwerina - B. Parschalk - G. Schett - M. Englbrecht<br />
THU0055 INTERSTITIAL PNEUMONITIS ASSOCIATED WITH RHEUMATOID ARTHRITIS IS MORE PREVALENT IN AGED MALE<br />
WITH A HIGHER RF LEVEL, AND FREQUENTLY COMBINED WITH EMPHYSEMA / E. Matsubara* - S. Okiyama - S. Inokuma<br />
- K. Onishi - S. Nakachi - H. Asashima - K. Wakabayashi - K. Hagiwara - S. Kobayashi<br />
THU0056 IMPAIRED BETA CELL SIGNALING IS PRESENT IN NON DIABETIC RHEUMATOID ARTHRITIS PATIENTS / I. Ferraz-Amaro<br />
- M. González-Gay -V. Hernández-Hernández - M. Arce-Franco - E. Delgado-Frías* - M. Gantes - J. Muñiz - M. Dominguez-Luis<br />
- A. Herrera-García - J. Garcia-Dopico - L. Medina-Vega - A. Rodríguez-Vargas - F. Diaz-Gonzalez<br />
THU0057 DIFFERENTIAL IMPACT OF TRADITIONAL CARDIAC RISK FACTORS ON CORONARY PLAQUE PREVALENCE IN<br />
CORONARY ARTERY DISEASE (CAD)-NAÏVE SUBJECTS WITH RHEUMATOID ARTHRITIS COMPARED TO CONTROLS /<br />
G. A. Karpouzas* - J. Malpeso - T.-Y. Choi - S. Munoz - M. Budoff<br />
THU0058 PERIODONTAL DISEASE IS ASSOCIATED WITH RHEUMATOID ARTHRITIS (RA) BUT ITS SEVERITY IS NOT CORRELATED<br />
WITH RA DISEASE ACTIVITY / I. A. Choi* - J.-H. Kim - Y. M. Kim - K. H. Kim - H. W. Kim - K. Shin - E.Y. Lee - E. B. Lee - Y.-M. Lee<br />
-Y. W. Song<br />
THU0059 REDUCTION OF INFLAMMATION WITH ABATACEPT AND TOCILIZUMAB RESULTS IN LOWER N-TERMINAL PRO BRAIN<br />
NATRIURETIC PEPTIDE LEVELS IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM TWO PROSPECTIVE<br />
COHORT STUDIES / I.V. D. Oever* - M. T. Nurmohamed<br />
THU0060 RISK FACTORS OF INTERSTITIAL LUNG DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITIS / J. Kur-Zalewska * -<br />
M. Tlustochowicz - W. Tlustochowicz<br />
THU0061 ANEMIA IN PATIENTS WITH RHEUMATOID ARTHRITIS: A CROSS-SECTIONAL STUDY / J. Back* - E. Baecklund - G. Birgegard<br />
THU0062 ANALYSIS OF PERIOPERATIVE CLINICAL FEATURES AND COMPLICATIONS IN PATIENTS WITH RHEUMATOID<br />
ARTHRITIS TREATED WITH BIOLOGIC AGENTS / K. Ishii* - Y. Mochida - K. Harigane - Y.Yamada - N. Mitsugi - T. Saito<br />
THU0063 DOES BIOLOGIC TREATMENT MODIFY THE RELATIONSHIP OF THE VARIABLES ASSOCIATED WITH FATIGUE IN<br />
PATIENTS WITH RHEUMATOID ARTHRITIS? THE PEPS STUDY OF TOCILIZUMAB IN REAL LIFE / L. Gossec* - S. Rouanet -<br />
G. Steinberg - B. Combe<br />
THU0064 COMPARISON OF ESTIMATED FRACTURE RISK USING THE FRAX INDEX CALCULATED WITH AND WITHOUT BONE<br />
DENSITOMETRY IN PATIENTS WITH EARLY ARTHRITIS / L. Del Olmo* - P. Aguado - J. Coya - L. Lojo - L. Nuño - S. Gil -<br />
E. Martín Mola - A. Balsa<br />
THU0065 ROLE OF RETINOL BINDING PROTEIN 4 IN INSULIN RESISTANCE OF RHEUMATOID ARTHRITIS PATIENTS / M. Flores-<br />
Rodríguez* - I. Ferraz-Amaro - V. Hernández-Hernández - J.Viotti - C. Rodríguez de la Rosa - M. González-Gay - M. Arce-Franco<br />
- E. Delgado-Frías - M. Gantes - J. Muñiz - M. Dominguez-Luis - A. Herrera-García - J. García-Dopico - L. Medina-Vega -<br />
A. Rodríguez-Vargas - F. Diaz-Gonzalez<br />
* Presenting author
eular berlin 2012<br />
<strong>Scientific</strong> Poster Session 1 11:45 - 13:30<br />
THU0066 SMOKING FUNCTIONS AS A NEGATIVE REGULATOR OF IGF-1 LEVELS AND ACTIVATES THE CASCADE OF ADIPOKINE<br />
SIGNALING MOLECULES IN PATIENTS WITH RHEUMATOID ARTHRITIS / R. Doria Medina - M. Erlandsson - S. Lindblad<br />
Silfverswärd - M. Bokarewa*<br />
THU0067 USE OF CARDIOVASCULAR DRUGS IN PATIENTS WITH RA, OVERALL AND IN PATIENTS WITH A HISTORY OF ACUTE<br />
ISCHEMIC CARDIAC EVENTS / M. Holmqvist* - J. Eriksson - J. Askling<br />
THU0068 PREVALENCE OF DYSLIPIDAEMIA IN AN EARLY ARTHRITIS RHEUMATOID COHORT (ESPOIR COHORT). LACK OF<br />
IMPROVEMENT AFTER 4 YEARS OF FOLLOW-UP / M. Margerit* - P. Nguyen - B. Pereira - Y. Allanore - X. Le Loët - A. C. Rat -<br />
M. Soubrier<br />
THU0069 INCREASED RATE OF DIASTOLIC HEART FAILURE IN RHEUMATOID ARTHRITIS CORRELATES WITH SYSTEMIC<br />
INFLAMMATION AND PERSISTENT DISEASE ACTIVITY, INDEPENDENT FROM TREATMENT STRATEGY / M. Gottwald* -<br />
T. Schau - M. Neuss - D. Ridjab - I. Fischer - C. Butter - M. Zaenker<br />
THU0070 RHEUMATOID ARTHRITIS WITH MULTIFOCAL MIGRATORY VASCULOGENIC PNEUMONIA REFRACTORY TO ANTIBI-<br />
OTICS / M. Bély* - Á. Apáthy<br />
THU0071 HOSPITALIZATION AND RISK OF HOSPITALIZED INFECTION IN PATIENTS WITH RHEUMATOID ARTHRITIS BASED ON<br />
IORRA COHORT / N. Sugimoto* - A. Nakajima - E. Inoue - A. Kobayashi - D. Hoshi - K. Shidara - E. Sato - Y. Seto - E. Tanaka -<br />
A. Taniguchi - S. Momohara - H.Yamanaka<br />
THU0072 FREQUENCY OF FALLS AND FALL-RELATED RISK FACTORS IN PATIENTS WITH RHEUMATOID ARTHRITIS / N.Toroptsova*<br />
- O. Nikitinskaya<br />
THU0073 A PROPOSED MECHANISM FOR AUTONOMIC DYSFUNCTION IN RHEUMATOID ARTHRITIS – REDUCED VAGAL<br />
ACTIVITY RELATED TO HIGH INTRATHECAL IL-1B LEVELS / R. Altawil* - D. ,. Kadetoff, - M. Westman - M. Jensen-Urstad -<br />
M. Andersson - E. Kosek - J. Lampa<br />
THU0074 DIFFERENT RISK FACTORS ARE ASSOCIATED WITH SERIOUS INFECTION IN RHEUMATOID ARTHRITIS PATIENTS WITH<br />
AND WITHOUT PULMONARY COMORBIDITIES; ANALYSES FROM THE REAL DATABASE / R. Sakai* - M. Tanaka - T. Nanki<br />
- H.Yamazaki - K. Watanabe - R. Koike - N. Miyasaka - M. Harigai on behalf of the REAL Study Group<br />
THU0075 THE RISK OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH RHEUMATOID ARTHRITIS COMPARED TO THE<br />
GENERAL POPULATION: A VERY LARGE COHORT STUDY / S. C. Kim* - S. Schneeweiss - J. Liu - D. H. Solomon<br />
THU0076 STRAIN ECHOCARDIOGRAPHY FOR THE EVALUATION OF MYOCARDIAL FUNCTION IN PATIENTS WITH RHEUMATOID<br />
ARTHRITIS / N. M. Fine - C. S. Crowson - G. Lin - J. K. Oh - H. R.Villarraga - S. E. Gabriel*<br />
THU0077 CONCOMITANT FIBROMYALGIA AND DEPRESSION MIGHT BE A CAUSE OF DISCREPANCY BETWEEN BOOLEAN<br />
REMISSION AND DAS28 REMISSION IN RHEUMATOID ARTHRITIS / S.Yimaz Öner* - M. Can - P. Atagündüz - H. Direskeneli<br />
- N. Inanç<br />
THU0078 POLYMORPHISMS OF THE GENES ENCODING CD40 AND GROWTH DIFFERENTIATION FACTOR 15 AND IN THE 9P21.3<br />
REGION IN PATIENTS WITH RHEUMATOID ARTHRITIS AND CARDIOVASCULAR DISEASE / S. Rantapää Dahlqvist* -<br />
L. Ärlestig<br />
THU0079 FATIGUE IN RHEUMATOID ARTHRITIS PATIENTS: THE IMPACT OF DISEASE ACTIVITY, PAIN, DISABILITY AND DEPRES-<br />
SIVE DISORDERS / T. A. Lisitsyna * - O. Seravina - O. Kovalevskaya - D. Veltishchev - A. Zeltyn - D. Novikova - T. Popkova -<br />
A. Novikov - E. Alexandrova - E. Nasonov<br />
THU0080 EFFICACY OF VACCINATION AGAINST PANDEMIC A H1N1 INFLUENZA IN JAPANESE PATIENTS WITH RHEUMATOID<br />
ARTHRITIS - ANALYSIS FROM THE IORRA COHORT - / T. Kobashigawa* - A. Nakajima - E. Tanaka - E. Inoue - A. Taniguchi -<br />
S. Momohara - H.Yamanaka<br />
THU0081 ASSESSING THE CARDIOVASCULAR RISK BURDEN IN PATIENTS WITH RHEUMATOID ARTHRITIS: ROLE OF ANNUAL<br />
REVIEW CLINIC / V. Patel* - U. Karjigi - R. Abernethy - J. Dawson - A. Clewes - J. Novak - A. Cox - J. Williams - T. O'Rourke<br />
THU0082 AN EVALUATION OF FLARE IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS USING THE OMERACT PRELIMINARY<br />
FLARE QUESTIONNAIRE / V. P. Bykerk* - S. J. Bartlett - E. Choy - G. Boire - C. Hitchon - J. Pope - C. Thorne - B. Haraoui -<br />
E. Keystone - C. O. Bingham III on behalf of CATCH<br />
THU0083 ABNORMAL VOLUMETRIC DENSITY AND MICROARCHITECTURE AT THE RADIUS IN CHINESE FEMALE PATIENTS WITH<br />
RHEUMATOID ARTHRITIS: A CASE-CONTROL STUDY / Y. Zhu* - E. K. Li - V. W. Hung - P.-C. Leung - A. W. Kwok - L. Qin -<br />
L.-S. Tam<br />
THU0084 THE RELATIONSHIP BETWEEN SERUM LEPTIN:ADIPONECTIN RATIO, INSULIN RESISTANCE, AND CAROTID ATHERO-<br />
SCLEROSIS IN PATIENTS WITH RHEUMATOID ARTHRITIS / Y. Kang* - M. I. Kang - H. J. Park - S. W. Lee - S. K. Lee - Y. B. Park<br />
THU0085 DEPRESSION AND ITS RELATIONSHIPS IN MOROCCAN PATIENTS WITH RHEUMATOID ARTHRITIS / Y. Ibn Yacoub* -<br />
B. Amine - S. El kabbaj - N. Hajjaj-Hassouni<br />
Rheumatoid arthritis - other biologic treatment<br />
THU0086 SEROPOSITIVITY AND RESPONSE TO RTX: DATA FROM THE CERERRA COLLABORATION / K. Chatzidionysiou* - E. Lie -<br />
E. Nasonov - G. Lukina - M. Hetland - U. Tarp - I. Ancuta - K. Pavelka - D. Nordström - C. Gabay - H. Canhao - M. Tomsic -<br />
P. van Riel - J. Gomez-Reino - T. Kvien - R. van Vollenhoven<br />
THU0087 ONE SINGLE INFUSION OF RITUXIMAB 1G MIGHT BE SUFFICIENT IN THE LONG-TERM MANAGEMENT OF RHEUMA-<br />
TOID ARTHRITIS PATIENTS RESPONDING TO A FIRST CYCLE OF RITUXIMAB (2 X 1G): RESULTS OF A 2-YEAR MULTI-<br />
CENTER RANDOMIZED CONTROLLED TRIAL / M. Dougados* - B. Combe - X. Le Loët - J. Tebib - J. Sibilia - S. Rouanet -<br />
R. Jourdan - X. Mariette<br />
* Presenting author<br />
Thursday, 7 June 2012<br />
55
Thursday, 7 June 2012<br />
56<br />
eular berlin 2012<br />
<strong>Scientific</strong> Poster Session 1 11:45 - 13:30<br />
THU0088 ABNORMAL MEMORY B-CELL RECONSTITUTION FOLLOWING ANTI-CD20 THERAPY FOR AUTOIMMUNE DISEASES<br />
PREDICTS CLINICAL RELAPSE / G. Arumugakani* - A. Rawstron - R. Tooze - A. Cherukuri - A. Varghese - E. Vital - P. Emery -<br />
D. McGonagle<br />
THU0089 RESPONSE TO ABATACEPT AND TOCILIZUMAB IN PATIENTS WHO HAD FAILED RITUXIMAB– INITIAL SINGLE CENTRE<br />
EXPERIENCE / S. Das* - S. Horton - E.Vital - D. Bryer - P. Emery - M. Buch<br />
THU0090 SAFETY AND EFFICACY OF ATACICEPT IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RHEUMATOID<br />
ARTHRITIS: RESULTS FROM THE ATACICEPT FOR REDUCTION OF SIGNS AND SYMPTOMS IN RHEUMATOID ARTHRITIS<br />
TRIAL (III) / R. F. van Vollenhoven* - S. Wax - S. Copt - P. P. Tak<br />
THU0091 COMPARISON OF THE CLINICAL UTILITY OF ANTI-IL-6 RECEPTOR ANTIBODY THERAPY AND ANTI-TNF THERAPY IN<br />
AA AMYLOIDOSIS IN RHEUMATIC DISEASE / Y. Okuda* - M. Ohnishi - K. Takasugi<br />
THU0092 THE ADVANTAGE OF EARLY INTERVENTION BY TOCILIZUMAB FOR RHEUMATOID ARTHRITIS - FULL ANALYSIS OF<br />
ALL-CASE POSTMARKETING SURVEILLANCE IN 7,901 PATIENTS IN JAPAN / H.Yamanaka* - M. Harigai - S. Inokuma - N. Ishiguro<br />
- J. Ryu - S. Takei - T. Takeuchi - Y. Tanaka - Y. Sano - T. Koike<br />
THU0093 CLINICAL, RADIOGRAPHIC, AND IMMUNOGENIC EFFECTS AFTER 1 YEAR OF TOCILIZUMAB (TCZ)-BASED TREATMENT<br />
STRATEGY WITH AND WITHOUT METHOTREXATE (MTX) IN RA: THE ACT-RAY STUDY / M. Dougados* - K. Kissel -<br />
P. G. Conaghan - E. Martin-Mola - G. Schett - H. Amital - R. M. Xavier - O. Troum - C. Bernasconi - T. W. J. Huizinga<br />
THU0094 DIRECT COMPARISON OF FOUR BIOLOGICAL AGENTS IN BIO-NAÏVE RHEUMATOID ARTHRITIS PATIENTS / Y.Yonemoto*<br />
- K. Okamura - K. Takeuchi - M. Matsushita - T. Kaneko - T. Kobayashi - T. Aramaki - K. Takagishi<br />
THU0095 EARLY RESPONSE TO ABATACEPT PLUS MTX IN MTX-IR RA PATIENTS USING POWER DOPPLER ULTRASONOGRAPHY:<br />
AN OPEN-LABEL STUDY / M. D’Agostino* - R. Wakefield - H. Berner Hammer - O.Vittecoq - M. Galeazzi - P. Balint - E. Fillipucci<br />
- I. Moller - A. Iagnocco - E. Naredo - M. Ostergaard - C. Gaillez - W. Kerselaers - K. Van Holder - M. Le Bars on behalf of<br />
OMERACT-US Task Force<br />
THU0096 MAVRILIMUMAB IN RHEUMATOID ARTHRITIS: RESULTS OF A PHASE 2 DOUBLE-BLIND, PLACEBO CONTROLLED<br />
STUDY / G. Burmester* - M. Weinblatt - I. McInnes - O. Barbarash - E. Esfandieri - M. Sleeman - A. Godwood - F. Magrini on<br />
behalf of EARTH Study group<br />
THU0097 SYSTEMATIC REVIEW OF THE SAFETY OF PROTEIN KINASE INHIBITORS IN CLINICAL TRIALS IN RHEUMATOID<br />
ARTHRITIS / E. Salgado* - J. R. Maneiro - L. Carmona - J. J. Gomez-Reino<br />
THU0098 LONG-TERM EFFECTS OF RITUXIMAB ON B-CELL COUNTS AND AUTOANTIBODY PRODUCTION IN RHEUMATOID<br />
ARTHRITIS: USE OF HIGH-SENSITIVITY FLOW-CYTOMETRY FOR MORE SENSITIVE ASSESSMENT OF B-CELL DEPLE-<br />
TION / A.Váncsa* - L. Gergely - Z. Szabó - S. Szilvia - N. Bodnár - E.Végh - G. Szücs - S. Szántó - Z. Szekanecz<br />
THU0099 MONITORING OF ABATACEPT IN RHEUMATOID ARTHRITIS PATIENTS WITH PREVIOUS FAILURE TO BIOTHERAPIES<br />
SUGGESTS THAT CTLA-4/CD3E AND/OR CD28/CTLA-4 MRNA RATIO MAY PREDICT RESPONSE TO TREATMENT AT 3<br />
MONTHS / A. Eljaafari* - M.-L. Tartelin - H. Aissaoui - P. Miossec<br />
THU0100 RESULTS FROM A 2-PART, PROOF-OF-CONCEPT, DOSE-RANGING, RANDOMIZED, DOUBLE-BLIND, PLACEBO-<br />
CONTROLLED, PHASE 2 STUDY OF SIRUKUMAB, A HUMAN ANTI-IL-6 MONOCLONAL ANTIBODY, IN PATIENTS WITH<br />
ACTIVE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE THERAPY / B. Hsu* - S. Sheng - J. S. Smolen - M. E. Weinblatt<br />
THU0101 SECONDARY LOSS OF EFFICACY OF RITUXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS: HOW OFTEN DOES IT<br />
OCCUR AND WHAT DOES IT MEAN? / C. Marin- Huertas* - E. Becerra - I. De la Torre - G. Cambridge - J. C. Edwards -<br />
M. J. Leandro<br />
THU0102 EULAR-DAS28 VERSUS RAPID3 FOR TREATMENT MONITORING IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED<br />
WITH RITUXIMAB / C. M. Ancuta* - C. Belibou - E. Ancuta - S. Miu - R. Chirieac<br />
THU0103 SYNOVIAL PLASMA CELLS PREDICT RELAPSE AFTER RITUXIMAB THERAPY IN RHEUMATOID ARTHRITIS / E.Vital* -<br />
Y. M. El-Sherbiny - K. Henshaw - S. Dass - S. Das - M. Buch - F. Ponchel - P. Emery<br />
THU0104 NO EXPRESSION OF AN ALTERNATIVE CD20 TRANSCRIPT VARIANT IN B CELLS FROM PATIENTS WITH RHEUMATOID<br />
ARTHRITIS / M. Deschamps - B. Gaugler - P. Saas - C. Ferrand - E. Toussirot* on behalf of CIC Biotherapy 506<br />
THU0105 EFFECT OF SIRUKUMAB ON HEPCIDIN LEVELS AND MARKERS OF ANEMIA: RESULTS OF A PHASE 2B TRIAL IN<br />
PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE THERAPY / G. Toedter* - S. Sague - X. Wu -<br />
M. Curran - B. Hsu<br />
THU0106 RITUXIMAB AFTER FIRST ANTI-TNF FAILURE IS MORE EFFICIENT WITH HIGH IMPACT IN REDUCING TIME AND COSTS<br />
TO ACHIEVE SUPERIOR RATES OF LOW DISEASE ACTIVITY AND REMISSION / I. Ancuta* - C. Codreanu - R. Ionescu -<br />
M. Parvu - M. Bojinca<br />
THU0107 CCL19, A CHEMOKINE INVOLVED IN B-CELL TRAFFICKING, IS RELATED TO THE DECREASE OF BLOOD MEMORY B-<br />
CELLS AND PREDICTS THE CLINICAL RESPONSE TO RITUXIMAB IN RHEUMATOID ARTHRITIS: RESULTS FROM THE<br />
SMART STUDY / J. Sellam* - S. Rouanet - H. Hendel-Chavez - K. Abbed - B. Combe - J. Sibilia - X. Le¨Loët - J. Tebib - R. Jourdan<br />
- M. Dougados - Y. Taoufik - X. Mariette<br />
THU0108 GLOBAL MOLECULAR EFFECTS OF TOCILIZUMAB THERAPY IN SYNOVIAL BIOPSIES OF EARLY RA PATIENTS / J. Ducreux*<br />
- A. Nzeusseu Toukap - F. A. Houssiau - P. Durez - B. Lauwerys<br />
THU0109 TREATING TO TARGET ULTRASOUND WITH CLINICAL REMISSION BETTER EFFECTS THAN CLINICAL REMISSION IN<br />
RRP / K. Kume* - K. Amano - K. Hatta - H. Ohta<br />
THU0110 AFFINITY AND POTENCY OF THE ANTI-NKG2A MAB NNC141-0100: IMPLICATIONS FOR MABEL AND DOSING IN THE<br />
FIRST-IN-MAN TRIAL IN RHEUMATOID ARTHRITIS / L. Alifrangis* - P. André - V. Pascal - E. Bonnet - L. Radzikowski -<br />
M. B. Petersen - M. Bléry<br />
THU0111 SECUKINUMAB TREATMENT IMPROVES ACR50, HAQ-DI AND EULAR REMISSION RATES IN PATIENTS WITH RHEUMA-<br />
TOID ARTHRITIS / M. Genovese* - H. Kellner - P. Durez - C. E. Codding - G. Ligozio - H. B. Richards - C. Escrig - S. Mpofu<br />
* Presenting author
eular berlin 2012<br />
<strong>Scientific</strong> Poster Session 1 11:45 - 13:30<br />
THU0112 EFFECTS OF INFLAMMATORY ACTIVITY AND THERAPEUTIC INTERLEUKIN-6 RECEPTOR (IL-6R) BLOCKADE ON IL-6R<br />
ALPHA EXPRESSION AND STAT3 PHOSPHORYLATION IN RHEUMATOID ARTHRITIS (RA) / M. Skwarek - B. Heschel - M.<br />
Winzer - M. Aringer*<br />
THU0113 PREDICTIVE FACTORS OF RESPONSE TO RITUXIMAB THERAPY MODIFY THE ACCELERATED ATHEROSCLEROSIS IN<br />
PATIENTS WITH RHEUMATOID ARTHRITIS / M. Benucci* - G. Saviola - M. Manfredi - F. Atzeni - P. Sarzi Puttini<br />
THU0114 ABATACEPT AS AN EFFECTIVE TREATMENT IN THE MANAGEMENT OF POOR PROGNOSIS ACPA NEGATIVE UNDIFFER-<br />
ENTIATED ARTHRITIS / M. H. Buch* - J. E. Freeston - C. Rakieh - E. Middleton - A. L. Tan - D. Pickles - J. Ward - S. Horton -<br />
S. Das - R. Wakefield - P. Emery<br />
THU0115 THE EFFECTS OF COSTIMULATION BLOCKADE PERFORMED BY ABATACEPT: DECREASED PRODUCTION OF G-IFN BY<br />
CD8+ T CELLS AND OF IL-17 BY CD4+ T CELLS AFTER IN VITRO STIMULATION IN GOOD CLINICAL RESPONDERS /<br />
M. Scarsi* - S. Piantoni - M. Chiarini - C. Zanotti - L. Imberti - A. Tincani - P. Airò<br />
THU0116 SAFETY AND EFFICACY OF COURSES OF RITUXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS - RITAM STUDY /<br />
N. S. Damjanov* - D. Stefanovic - A. Dimic - T. Ilic - M. Lazarevic<br />
THU0117 ABATACEPT CAN DEMONSTRATE MAXIMUM EFFICACY WITHOUT BACKGROUND METHOTREXATE TREATMENT IN<br />
RHEUMATOID ARTHRITIS / N.Takahashi* - T. Kojima - K. Funahashi - D. Kato - H. Matsubara - Y. Hattori - N. Ishiguro on behalf<br />
of TBCR study group<br />
THU0118 25 HYDROXYVITAMIN D INTERFERE WITH THE CLINICAL RESPONSE TO RITUXIMAB IN RHEUMATOID ARTHRITIS /<br />
R. M'Barek - T. Dupré - F. Tubach - P. Dieudé - E. Palazzo - G. Hayem - K. Dawidowicz - S. Ottaviani - T. Alfaiate - V. Leçon-Malais<br />
- A. Boutten - O. Meyer*<br />
THU0119 LACK OF EFFECT OF SECUKINUMAB TREATMENT ON THE LIPID PROFILE IN PATIENTS WITH RHEUMATOID<br />
ARTHRITIS: RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE II STUDY / P. Durez* -<br />
M. Genovese - H. Kellner - C. Codding - G. Ligozio - H. Richards - C. Escrig - S. Mpofu<br />
THU0120 LONG-TERM SAFETY OF RITUXIMAB: 10-YEAR FOLLOW-UP IN THE RHEUMATOID ARTHRITIS GLOBAL CLINICAL<br />
TRIAL PROGRAMME / R. F. van Vollenhoven* - P. Emery - C. O. Bingham - E. Keystone - R. Fleischmann - D. E. Furst - N. Tyson<br />
- A. Mehbob - P. B. Lehane<br />
THU0121 THE INTERFERON TYPE I SIGNATURE TOWARDS PREDICTION OF NON-RESPONSE TO RITUXIMAB IN RHEUMATOID<br />
ARTHRITIS PATIENTS / H. Raterman - S.Vosslamber* - S. de Ridder - M. Nurmohamed - W. Lems - M. Boers - M. van der Wiel<br />
- B. Dijkmans - C.Verweij - A.Voskuyl<br />
THU0122 SAFETY OF SURGERY IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED BY RITUXIMAB IN ROUTINE CARE: DATA<br />
FROM THE FRENCH AIR REGISTRY / S. Godot* - J. E. Gottenberg - S. Paternotte - I. Pane - B. Combe - J. Sibilia - R.-M. Flipo -<br />
T. Schaeverbeke - P. Ravaud - E. Toussirot - F. Berenbaum - X. Mariette - D. Wendling - J. Sellam<br />
THU0123 STATINS DO NOT INFLUENCE CLINICAL RESPONSE AND B CELL DEPLETION AFTER RITUXIMAB TREATMENT IN<br />
RHEUMATOID ARTHRITIS / S. Das* - M. Fernandez Matilla - S. Dass - E.Vital - P. Emery<br />
THU0124 IMPORTANCE OF MONITORING OF C-REACTIVE PROTEIN LEVEL TO PREDICT ACHIEVEMENT OF BETTER CLINICAL<br />
OUTCOME DURING TREATMENT WITH TOCILIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS / T. Kojima* -<br />
K. Funahashi - N. Takahashi - D. Kato - H. Matsubara - Y. Hattori - Y.Yabe - N. Ishiguro on behalf of TBCR study group<br />
THU0125 A MULTI-CENTER, DOUBLE-DUMMY, DOUBLE-BLIND STUDY OF SUBCUTANEOUS (SC) ABATACEPT (ABA) COMPARED<br />
WITH INTRAVENEOUS (IV) ABA IN JAPANESE RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO<br />
METHOTREXATE / T. Matsubara* - H. Inoue - M. Iwahashi - A.Yamazaki - T. Takeuchi on behalf of Japan Abatacept Study Group<br />
THU0126 MULTICENTER RETROSPECTIVE STUDY: RESPONSE TO TOCILIZUMAB IN CLINICAL PRACTICE IS NOT INFLUENCED BY<br />
THE NUMBER OF PREVIOUS BIOTHERAPY OR BY ASSOCIATION WITH A DMARD / Y.-M. Pers* - C. Fortunet - E. Constant<br />
- J. Lambert - A. Mazouyes - M.Valnet - H. Marotte - P. Gaudin - D. Wendling - J.-F. Maillefert - C. Jorgensen<br />
Rheumatoid arthritis - non biologic treatment and small molecules<br />
THU0127 FUNCTIONAL ACTIVITY OF MEMBRANE-BOUND GLUCOCORTICOID RECEPTORS / C. Strehl* - T. Gaber - M. Jakstadt -<br />
M. Hahne - P. Hoff - G.-R. Burmester - F. Buttgereit<br />
THU0128 THE EXTRA-LOW-DOSE METHOTREXATE TREATMENT FACILITATES THE INTRACELLULAR ACCUMULATION OF<br />
LONGER CHAIN SUBGROUPS OF METHOTREXATE POLYGLUTAMATES / Y. Koyama* - K. Hase - D. Hidaka - S. Nagano -<br />
T. Ota - A. Uchino - J. Nakagawa<br />
THU0129 SELECTIVE ELIMINATION OF PATHOGENIC TH17 CELLS FROM PERIPHERAL BLOOD OF RHEUMATOID ARTHRITIS<br />
PATIENTS BY A PURIFIED FUNGAL POLYSACCHARIDE / A. Alunno* - E. Pericolini - E. Gabrielli - O. Bistoni - S. Caterbi -<br />
E. Bartoloni - S.-K. Chow - A. Casadevall - A.Vecchiarelli - R. Gerli<br />
THU0130 ASSESSMENT OF TRANSAMINASITIS WITH DAILY METHOTREXATE THERAPY IN PATIENTS WITH INFLAMMATORY<br />
RHEUMATIC DISEASES. A LONG-TERM FOLLOW-UP COHORT STUDY / M. U. Martinez Martinez* - A. Sánchez-Arriaga -<br />
C. Abud-Mendoza<br />
THU0131 TOFACITINIB (CP-690,550), AN ORAL JANUS KINASE INHIBITOR: ANALYSIS OF MALIGNANCIES ACROSS THE RHEUMA-<br />
TOID ARTHRITIS CLINICAL PROGRAMME / X. Mariette* - J. R. Curtis - E. B. Lee - R. Riese - I. Kaplan - R. Chew - J. Geier -<br />
L. Wang - J. D. Bradley<br />
THU0132 COMPARISON OF DOSE ESCALATION OF INFLIXIMAB AND THE ADDITION OF TACROLIMUS IN RHEUMATOID<br />
ARTHRITIS PATIENTS WITH AN INADEQUATE RESPONSE TO INFLIXIMAB AND METHOTREXATE COMBINATION<br />
THERAPY / Y.Yonemoto* - K. Okamura - T. Kaneko - T. Kobayashi - K. Takagishi<br />
THU0133 INTRA-ARTICULAR METHOTREXATE: CLINICAL AND POWER DOPPLER ULTRASONOGRAPHY STUDY OF SYNOVITIS<br />
IN MEDIUM SEIZED JOINTS OF RHEUMATOID ARTHRITIS PATIENTS / M. Mortada* - A. Solyman<br />
* Presenting author<br />
Thursday, 7 June 2012<br />
57
Thursday, 7 June 2012<br />
58<br />
eular berlin 2012<br />
<strong>Scientific</strong> Poster Session 1 11:45 - 13:30<br />
THU0134 BIOMARKERS OF METOTHREXATE ADVERSE REACTIONS IN RHEUMATOID ARTHRITIS PATIENTS / N. Dostanko* -<br />
V. Yagur - N. Soroka<br />
THU0135 ‘INDISPENSABLE OR INTOLERABLE?’ A RETROSPECTIVE REVIEW OF METHOTREXATE DISCONTINUATION IN<br />
RHEUMATOID ARTHRITIS / A. J. Badcock* - A. P. Malaviya - A. J. Ostor<br />
THU0136 CARDIOVASCULAR SAFETY FINDINGS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TOFACITINIB<br />
(CP-690,550), A NOVEL, ORAL JAK INHIBITOR / C. Charles-Schoeman* - P. Wicker - U. Sechtem - M. A. Gonzalez-Gay -<br />
S. Wood - M. Boy - J. Geier - D. Gruben - K. Soma - R. Riese - J. Bradley<br />
THU0137 EFFECTIVENESS AND TOLERANCE INFILTRATION INTRAARTICULAR CORTICOSTEROID ACCORDING TO DOSE /<br />
D. F. Pereira* - R. N.V. Furtado - J. Natour - N. P. Machado on behalf of Discipline of Rheumatology of the Federal University of<br />
São Paulo (UNIFESP), São Paulo, Brazil<br />
THU0138 PHARMACOKINETICS OF FOSTAMATINIB IN PATIENTS WITH IMPAIRED RENAL FUNCTION: A PHASE I STUDY / P. Martin<br />
- S. Oliver - M. Gillen - T. Marbury - D. Millson*<br />
THU0139 PHARMACOKINETICS OF FOSTAMATINIB IN PATIENTS WITH IMPAIRED HEPATIC FUNCTION: A PHASE I STUDY /<br />
P. Martin - S. Oliver - M. Gillen - T. Marbury - D. Millson*<br />
THU0140 TOFACITINIB (CP-690,550), AN ORAL JANUS KINASE INHIBITOR: ANALYSIS OF GASTROINTESTINAL ADVERSE EVENTS<br />
ACROSS THE RHEUMATOID ARTHRITIS CLINICAL PROGRAMME / E. B. Lee * - J. R. Curtis - R. Riese - C. Connell - R. Chew<br />
- M. Boy - E. Maller - C. Su - L. Wang - J. Bradley<br />
THU0141 BIOMARKER ASSESSMENT OF VX-509, AN INVESTIGATIONAL SELECTIVE JAK3 INHIBITOR, IN HEALTHY VOLUNTEERS /<br />
I. M. Catlett* - X. Luo - M. S. Penney - M. E. Pray - G. Spencer-Green - M. Botfield - T. Hoock<br />
THU0142 FENOFIBRATE REDUCES INFLAMMATION BUT HAS NO EFFECT ON ENDOTHELIAL PROGENITOR CELLS IN PATIENTS<br />
WITH RHEUMATOID ARTHRITIS / I. Shirinsky* - N. Kalinovskaya - O. Polovnikova - V. Shirinsky<br />
THU0143 TOFACITINIB (CP-690,550), AN ORAL JANUS KINASE INHIBITOR: ANALYSES OF EFFICACY ENDPOINTS BY SUBGROUPS<br />
IN A POOLED PHASE 2 AND 3 RHEUMATOID ARTHRITIS STUDY POPULATION / J. Kremer* - C. Zerbini - E. B. Lee -<br />
D. Gruben - S. Krishnaswami - S. H. Zwillich - T. Koncz - J. Bradley - C. A. Mebus<br />
THU0144 INDUCTION OF REMISSION AND INHIBITION OF JOINT DAMAGE IN PATIENTS WITH RHEUMATOID ARTHRITIS<br />
TREATED WITH MONO- OR COMBINATION THERAPY USING NON-BIOLOGICAL DMARDS IN ROUTINE CLINICAL<br />
PRACTICE / K. Katayama* - T. Okubo - T. Sato<br />
THU0145 A MULTI-BIOMARKER DISEASE ACTIVITY (MBDA) SCORE MEASURES RHEUMATOID ARTHRITIS DISEASE ACTIVITY IN<br />
PATIENTS TREATED WITH THE JAK INHIBITOR TOFACITINIB / K.Yamaoka* - S. Kubo - K. Sonomoto - S. Hirata - A.Voinov -<br />
M. Rowe - G. Cavet - K. Saito - Y. Tanaka<br />
THU0146 CLINICAL ANALYSIS OF HEPATITIS B VIRUS REACTIVATION ASSOCIATED WITH NON-BIOLOGICAL DISEASE-<br />
MODIFYING ANTIRHEUMATIC DRUG(S) IN PATIENTS WITH RHEUMATOID ARTHRITIS / Y.-Q. Mo - L. Dai* - D.-H. Zheng<br />
- J.-D. Ma - Y.-H. Li - C.-J. Zou - L.-J. Zhu - B.-Y. Zhang<br />
THU0147 COMPARISON OF BIOLOGICAL HASARDS OF 166-HOLMIUM-PHYTATE AND 90-YTTRIUM USED FOR RADIOSYNOV-<br />
IORTHESIS / S. Kiss - R.Vig - Z. Nagy - P. Geher - M. Szentesi*<br />
THU0148 QUALITY OF LIFE AND KNEE FUNCTION OF THE PATIENTS WITH RHEUMATOID ARTHRITIS AFTER ARTHROSCOPIC<br />
SYNOVECTOMY / M. Lipina* - M. Makarov - V. Amirdjanova - S. Makarov - V. Pavlov - G.Vardicova - V. Kolomacky - A. Roskidaylo<br />
THU0149 TREAT TO TARGET EARLY RHEUMATOID ARTHRITIS CLINIC: HIGH RATES OF REMISSION AND LOW DISEASE ACTIVITY<br />
ON TREATMENT WITH CONVENTIONAL DISEASE MODIFYING DRUGS / O. Semenova* - H. Thompson - S. Kallankara -<br />
O. Olabambo - Y. Patel - E. Baguley<br />
THU0150 LARGE DIFFERENCES IN AFFORDABILITY AND AVAILABILITY OF SYNTHETIC DMARDS ACROSS 46 EUROPEAN<br />
COUNTRIES / P. Putrik* - S. Ramiro - M. Pavlova - T. Kvien - T. Uhlig - A. Boonen on behalf of Working Group Equity in Treatment<br />
for RA across the European region<br />
THU0151 EFFECTS OF TOFACITINIB (CP-690,550), AN ORAL JANUS KINASE INHIBITOR, OR ADALIMUMAB ON PATIENT<br />
REPORTED OUTCOMES IN A PHASE 3 STUDY OF ACTIVE RHEUMATOID ARTHRITIS / R. F. van Vollenhoven* -<br />
G. Wallenstein - E. B. Lee - R. Fleischmann - S. H. Zwillich - D. Gruben - T. Koncz - J. Bradley - B. Wilkinson - V. Strand<br />
THU0152 HOW SHOULD THE PRIMARY ENDPOINT BE ANALYSED IN RHEUMATOID ARTHRITIS TRIALS WHICH MANDATE<br />
RESCUE PRIOR TO THE CLINICAL ENDPOINT? – ANALYSIS OF THREE PHASE 3 TRIALS OF TOFACITINIB / R. Fleischmann*<br />
- D. Gruben - S. Krishnaswami - S. H. Zwillich - B. Benda - C. A. Mebus - J. Bradley<br />
THU0153 IMPROVEMENTS IN DISEASE ACTIVITY SCORE BY BASELINE STATUS: POOLED ANALYSIS OF FIVE PHASE 3 STUDIES<br />
WITH TOFACITINIB (CP-690,550) IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS / R. M. Fleischmann* -<br />
S. Krishnaswami - D. Gruben - S. H. Zwillich - C. Mebus - J. D. Bradley<br />
THU0154 ADVERSE EFFECTS OF GLUCOCORTICOID THERAPY IN RHEUMATOID ARTHRITIS (RA): A SYSTEMATIC REVIEW AND<br />
META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS / S. Tarp* - E. M. Bartels - J. R. Kirwan - D. E. Furst - M. Boers -<br />
T. Woodworth - H. Bliddal - B. Danneskiold-Samsøe - L. E. Kristensen - S. Thirstrup - M. Rasmussen - R. Christensen<br />
THU0155 THE ADDITION OF ANOTHER DISEASE-MODIFYING ANTI-RHEUMATIC DRUG TO METHOTREXATE IN PLACE OF<br />
INFLIXIMAB IMPROVES THE RATE OF INFLIXIMAB-FREE SUSTAINED REMISSION / T. Kurasawa* - H. Nagasawa - K. Amano<br />
- T. Takeuchi - H. Kameda<br />
THU0156 RESPONSE OF RA ON MRI-DETECTED SYNOVITIS TO DOUBLE FILTRATION PLASMAPHERESIS / X.Yu* - L. Wang - P. Xu<br />
THU0157 TRIPTERYGIUM WILFORDII MULTIGLYCOSIDE COMBINED REGIMEN AS LONG-TERM MAINTENANCE THERAPY IN<br />
CHINESE RHEUMATOID ARTHRITIS PATIENTS / F. Lian - Y. Wang* - H. Xu - D. Chen - Z. Zhan - L. Liang - Q. Qiu - Y.Ye -<br />
X.Yang<br />
* Presenting author
eular berlin 2012<br />
<strong>Scientific</strong> Poster Session 1 11:45 - 13:30<br />
SLE, Sjögren's and APS - clinical aspects (other than treatment)<br />
THU0158 SIX YEAR FOLLOW-UP STUDY OF BONE MINERAL DENSITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS /<br />
J. Jacobs* - L.-A. Korswagen - A. Schilder - L. van Tuyl - B. Dijkmans - W. Lems - A.Voskuyl - I. Bultink<br />
THU0159 INCIDENCE AND PREVALENCE OF MAJOR CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT IN SYSTEMIC LUPUS<br />
ERYTHEMATOSUS (SLE): A 3 YEAR PROSPECTIVE EVALUATION AND CLINICAL CORRELATIONS IN 370 PATIENTS / E. I.<br />
Kampylafka* - H. Alexopoulos - M. L. Kosmidis - D. B. Panagiotakos - P. G.Vlachoyiannopoulos - M. C. Dalakas - H. M. Moutsopoulos<br />
- A. G. Tzioufas<br />
THU0160 WHITE MATTER LESIONS ARE PREDOMINANTLY DEMYELINATING IN SYSTEMIC LUPUS ERYTHEMATOSUS. AN<br />
SUPPORT VECTOR MACHINES CLASSIFICATION OF TEXTURE PARAMETERS / A.T. Lapa - M. P. Bento - L. Rittner - H. H. Ruocco<br />
- G. Castellano - B. D. Damasceno - L. T. L. Costallat - S. Appenzeller* - R. Lotufo - F. Cendes<br />
THU0161 NEUROPSYCHIATRIC INVOLVEMENT AND SLE: PERFORMANCE OF A NEW ALGORITHM FOR ATTRIBUTION OF NP<br />
EVENTS TESTED ON AN ITALIAN MULTICENTER COHORT / A. Bortoluzzi* - S. Bombardieri - C. Casu - F. Conti - S. De Vita<br />
- A. Doria - I. Farina - G. Ferraccioli - E. Gremese - E. Mansutti - M. Mosca - M. Padovan - M. Piga - A. Tincani - P. Tomietto -<br />
C. Tani - G.Valesini - M. Zen - A. Mathieu - M. Govoni on behalf of the Italian Study Group for the Neuropsychiatric Involvement<br />
in Systemic Lupus Erythematosus<br />
THU0162 THROMBOTIC MICROANGIOPATHY IN RENAL BIOPSIES FROM PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS /<br />
J. Gerhardsson - A. Zickert - B. Sundelin - E. Svenungsson - I. Gunnarsson*<br />
THU0163 PREDICTORS OF METABOLIC SYNDROME AT ENROLMENT INTO A MULTICENTRE INTERNATIONAL INCEPTION<br />
COHORT OF PATIENTS WITH SLE / B. Parker* - M. B. Urowitz - M. Lunt - I. N. Bruce on behalf of SLICC Registry for<br />
Atherosclerosis<br />
THU0164 RISK OF SERIOUS INFECTIONS IN REUMATOID ARTHRITIS AND OTHER CHRONIC INFLAMMATORY IMMUNE-<br />
MEDIATED DISEASES TREATED WITH TNF ANTAGONISTS OR RITUXIMAB / T. Cobo-Ibáñez* - M. A. Descalzo - S. Muñoz-<br />
Fernández - E. Loza - L. Carmona - J. J. Gómez-Reino on behalf of the BIOBADASER 2.0 Study Group<br />
THU0165 HIGH RATE OF CARDIOVASCULAR EVENTS IN LUPUS PATIENTS AT 5 YEAR FOLLOW UP AND ASSOCIATION OF<br />
CLASSICAL AND LUPUS RELATED RISK FACTORS / S. Skeoch* - S. Haque - B. Parker - Y. Ahmad - L. S. Teh - I. Bruce<br />
THU0166 REBAMIPIDE IN THE TREATMENT OF XEROSTOMIA IN SJÖGREN’S SYNDROME: RANDOMIZED PLACEBO-<br />
CONTROLLED STUDY / A. Abou-Raya* - S. Abou-Raya - N. Sallam - M. Helmii<br />
THU0167 EVALUATION OF TWO ASSAYS FOR ANTIPHOSPHOLIPID ANTIBODIES IN 712 SLE PATIENTS; CLINICAL ASSOCIATIONS<br />
DEPEND ON ISOTYPES AND CUT-OFF LEVELS / A. Vikerfors* - A.-B. Johansson - J. Gustafsson - A. Jonsen - D. Leonard -<br />
A. Zickert - G. Nordmark - G. Sturfelt - A. Bengtsson - L. Rönnblom - I. Gunnarsson - K. Elvin - E. Svenungsson<br />
THU0168 SERUM PROGRANULIN LEVELS ARE ELEVATED IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS, REFLECTING<br />
DISEASE ACTIVITY / A. Tanaka* - H. Tsukamoto - H. Mitoma - N. Ueda - M. Ayano - S.-I. Ohta - Y. Inoue - Y. Arinobu - H. Niiro<br />
- T. Horiuchi - K. Akashi<br />
THU0169 TRAF3IP2 GENE POLYMORPHISMS ARE ASSOCIATED WITH SUSCEPTIBILITY TO SYSTEMIC LUPUS ERYTHEMATOSUS /<br />
C. Perricone* - D. Di Fusco - C. Ciccacci - F. Ceccarelli - E. Cipriano - F. R. Spinelli - P. Borgiani - G.Valesini - F. Conti<br />
THU0170 THE EFFECT OF THE ANTIPHOSPHOLIPID SYNDROME (APS) ON SURVIVAL IN 679 PATIENTS WITH SLE: A PROSPEC-<br />
TIVE STUDY / C. C. Mok* - L.Y. Ho - K. L.Yu - C. H. To<br />
THU0171 THERAPEUTIC RESPONSE OF LUPUS NEPHRITIS BASED ON PATHOLOGICAL FINDINGS IN YOKOHAMA CITY UNIVER-<br />
SITY HOSPITAL / D. Kishimoto* - A. Ihata - R. Watanabe - T. Watanabe - K. Terauchi - K. Kobayashi - T. Uehara - K. Takase -<br />
M. Hama - R.Yoshimi - A. Ueda - M. Takeno - Y. Ishigatsubo<br />
THU0172 THE ROLE OF T REGULATORY LYMPHOCYTES IN LUPUS NEPHRITIS / D. P. E. Margiotta* - K. Giannakakis - M. Vadacca -<br />
A. Gigante - R. Cianci - A. Onetti Muda - A. Afeltra<br />
THU0173 SUPERVISED PHYSICAL EXERCISE IMPROVES ENDOTHELIAL FUNCTION AND INCREASE ENDOTHELIAL PROGEN-<br />
ITOR CELLS NUMBER IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / E.T. Reis Neto* - A. E. Silva - L. M. Camargo<br />
- P. Semedo - M. M. Pinheiro - N. P. Silva - E. I. Sato<br />
THU0174 ENDOTHELIAL MICROPARTICLES AND CIRCULATING ENDOTHELIAL PROGENITOR CELLS IN PRIMARY SJÖGREN’S<br />
SYNDROME PATIENTS: A POTENTIAL MARKER OF ENDOTHELIAL DAMAGE? / E. Bartoloni* - A. Alunno - M. Pirro -<br />
O. Bistoni - G. Schillaci - F. Bagaglia - F. Luccioli - G. Santoboni - G. Mirabelli - F. Cannarile - E. Mannarino - R. Gerli<br />
THU0175 T CELL REACTIVITY TO B2 GLYCOPROTEIN I IN SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTI-PHOSPHOLIPID<br />
SYNDROME: CORRELATION WITH SUBCLINICAL ATHEROSCLEROSIS / F. R. Spinelli* - C. Alessandri - E. Marocchi -<br />
F. Ceccarelli - A. Capozzi - M. Sorice - M. Arca - M. Pacelli - B. Buttari - R. Riganò - E. Profumo - G.Valesini - F. Conti<br />
THU0176 SUBCLINICAL MYOCARDIAL DYSFUNCTION IN PRIMARY ANTIPHOSPHOLIPID SYNDROME ASSESSED BY SPECKLE<br />
TRACKING ECHOCARDIOGRAPHY / G. Medina* - E. Calderon-Aranda - E. Gomez-Bañuelos - O.Vera-Lastra - L. J. Jara<br />
THU0177 ESR AS A PREDICTOR OF SLE DISEASE ACTIVITY AND DAMAGE / G. Stojan* - H. Fang - L. Magder - M. Petri<br />
THU0178 CIRCULATING FREE PROTEIN S LEVELS MAY BE LINKED TO CARDIOVASCULAR EVENTS AND VENOUS THROMBOSIS<br />
IN SLE / G. J. Silverman* - J. Jung - E. Akhter - M. Petri - C. Gronwall<br />
THU0179 PREVALENCE, ETIOLOGY AND RISK FACTORS FOR PULMONARY ARTERIAL HYPERTENSION IN A COHORT OF<br />
PATIENTS WITH LUPUS / I. Rúa-Figueroa * - F. León - A. Gª Quintana - S. Ojeda - F. Francisco - M. Gª Bello - P. Cabrera -<br />
N. Ojeda - J. Pulido - A. Naranjo - J. Ortega - G. P-Peñate<br />
THU0180 PREVALENCE AND CLINICAL SIGNIFICANCE OF SEVERE INFECTION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHE-<br />
MATOSUS: PRELIMINARY DATA FROM RELESSER (REGISTRY OF LUPUS OF THE SPANISH SOCIETY OF RHEUMA-<br />
TOLOGY) / I. Rúa-Figueroa * - J. Pego-Reigosa - M. Galindo - J. López-Longo - J. Calvo-Alen - M. J. Gª Yebenes - E. Tomero -<br />
E. Uriarte - C. Fito - A. S-Atrio - A. Olivé on behalf of RELESSER investigators from EAS-SER Group<br />
* Presenting author<br />
Thursday, 7 June 2012<br />
59
Thursday, 7 June 2012<br />
60<br />
eular berlin 2012<br />
<strong>Scientific</strong> Poster Session 1 11:45 - 13:30<br />
THU0181 SERUM LEVEL OF SYNDECAN-1 IS ASSOCIATED WITH DISEASE ACTIVITY IN PATIENTS WITH SYSTEMIC LUPUS<br />
ERYTHEMATOSUS / K.-J. Kim - J.-Y. Kim* - S.-J. Park - I.-W. Baek - C.-H.Yoon - W.-U. Kim - C.-S. Cho<br />
THU0182 DYSLIPOPROTEINEMIA AND ITS RELATION WITH THE ACTIVITY OF THE DISEASE AND ITS TREATMENT IN A LARGE<br />
SPANISH MULTICENTRIC LUPUS COHORT / J. Pego-Reigosa* - I. Rúa - C. Mouriño - M. Galindo - F. López-Longo - J. Calvo<br />
- M. García-Yébenes - E. Tomero - E. Uriarte - C. Fito - A. Sánchez - A. Olivé - M. Freire - A. F-Nebro on behalf of the<br />
RELESSER Group<br />
THU0183 CIGARETTE SMOKING AND ANTIPHOSPHOLIPID ANTIBODIES IN SYSTEMIC LUPUS ERYTHEMATOSUS / J. Gustafsson*<br />
- I. Gunnarsson - S. Pettersson - A. Zickert - A.Vikerfors - E. Hellbacher - S. Möller - K. Elvin - J. F. Simard - E. Svenungsson<br />
THU0184 IDENTIFICATION OF BIOMARKERS IN SLE PREGNANCIES USING URINARY PROTEOMICS / K. Schreiber* - K. Bramham -<br />
H. Mistry - O. Barrutia-Ateka - S. Lynham - A. Weston - M. A. Ward - L. M. Bertolaccini - L. C. Chappell - M. A. Khamashta<br />
THU0185 INDEPENDENT RISK FACTORS OF ENDOTHELIAL DYSFUNCTION (ED) AND ATHEROSCLEROSIS (AS) DEVELOPMENT<br />
IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) / K. Amosova* - O. Iaremenko - I. Matiyashchuk<br />
THU0186 CARDIAC VALVE ABNORMALITIES IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS DETECTED BY TRANSTHO-<br />
RACIC AND TRANSESOPHAGEAL ECHOCARDIOGRAPHY (TTE AND TEE) / L. S. Kholopov* - O. I. Dyadyk - A. E. Bagriy -<br />
V. O. Gajdukov - O.V. Samojlova<br />
THU0187 COMPLEMENT C4 GENE POLYMORPHISMS, SERUM PROTEIN LEVELS AND PROTEIN FUNCTIONAL ACTIVITY IN<br />
RELATIONSHIP WITH CLINICAL MANIFESTATIONS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / L.-A.<br />
Korswagen* - J. Jacobs - D. Wouters - I. Bultink - A. Schilder - D. Hamann - A.Voskuyl<br />
THU0188 LYMPHOPROLIFERATIVE COMPLICATIONS IN THE COURSE OF PRIMARY SJÖGREN’S SYNDROME: PREVALENCE AND<br />
COMMON FEATURES IN A LARGE COHORT OF PATIENTS / L. Quartuccio* - C. Baldini - R. Priori - E. Bartoloni Bocci -<br />
F. Carubbi - M. Isola - M. Maset - S. Salvin - N. Luciano - G. Picarelli - A. Alunno - A. Marrelli - R. Gerli - G. Valesini -<br />
S. Bombardieri - S. De Vita<br />
THU0189 INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / M. U. Martinez Martinez* -<br />
D. A. Herrera Van Oostdam - M. Magaña Aquino - L. Baranda Cándido - C. Abud Mendoza<br />
THU0190 ULTRASONAGRAPHIC ASSESSMENT OF SUBMANDIBULAR GLANDS IN ANTI-CENTROMERE ANTIBODY POSITIVE AND<br />
NEGATIVE PRIMARY SJOGREN’S SYNDROME PATIENTS / N. Hashimoto* - S. Uchiyama - M. Kitano - T. Iwasaki - H. Sano -<br />
T. Hashimoto<br />
THU0191 VISFATIN IN PATIENTS WITH LUPUS NEPHRITIS.CORRELATION WITH DISEASE ACTIVITY / N. Fouda* - N. Abaza - R. El<br />
Hilaly - H. El Said - R. El Kabarity<br />
THU0192 MYOSITIS IN PRIMARY SJÖGREN SYNDROME: DATA FROM A MULTICENTER COHORT / S. Colafrancesco* - A. Gattamelata<br />
- M. Modesti - A. Minniti - G. D'Amati - C. Giordano - M. Maset - L. Quartuccio - E. Bartoloni - F. Carrubi - P. Cipriani - C. Baldini<br />
- N. Luciano - S. De Vita - R. Gerli - R. Giacomelli - S. Bombardieri - G.Valesini - R. Priori<br />
THU0193 COMPARATIVE EVALUATION OF CUMULATIVE DAMAGE IN ADULT AND CHILDHOOD ONSET SYSTEMIC LUPUS<br />
ERYTHEMATOSUS / K. D. O. Peliçari - M. Postal - N. A. Sinicato - L. T. L. Costallat - R. Marini - S. Appenzeller*<br />
THU0194 ASSOCIATION BETWEEN AUTOANTIBODIES AND SOLUBLE FACTORS IN CEREBROSPINAL FLUIDS FROM PATIENTS<br />
WITH NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS / T. Fujii* - T. Yokoyama - S. Kondo-Ishikawa -<br />
N. Yamakawa - M. Nakano - N.Yukawa - H.Yoshifuji - K. Ohmura - T. Mimori<br />
THU0195 IFNB AND ITS RESPONSE PROTEINS IP-10 AND SIGLEC-1 AS BIOMARKERS OF DISEASE ACTIVITY IN SYSTEMIC LUPUS<br />
ERYTHEMATOSUS / T. Rose* - A. Gruetzkau - C. Dähnrich - A. Dzionek - H. Hirseland - G. Riemekasten - W. Schlumberger -<br />
P. Enghard - A. Radbruch - G.-R. Burmester - F. Hiepe - R. Biesen<br />
THU0196 BONE MICROARCHITECTURE AND BIOMECHANICAL PROPERTIES IN CHINESE FEMALE PATIENTS WITH SYSTEMIC<br />
LUPUS ERYTHEMATOSUS DAMAGE / X. L. Tang* - T.Y. Zhu - L. Qin - L. S. Tam - E. K. Li<br />
THU0197 TIME TO RECOVERY FROM PROTEINURIA IN LUPUS NEPHRITIS PATIENTS RECEIVING STANDARD OF CARE TREAT-<br />
MENT / Z. Touma* - M. B. Urowitz - D. Ibañez - D. D. Gladman<br />
Vasculitis<br />
THU0198 SERUM ANGIOPOIETIN-2 LEVEL STRONGLY REFLECTS THE DISEASE ACTIVITY AND RENAL FUNCTION IN ANCA-<br />
ASSOCIATED VASCULITIS / Y. Wada* - Y. Nozawa - H. Sato - T. Nakatsue - S. Murakami - T. Kuroda - M. Nakano - I. Narita<br />
THU0199 SUCCESSFUL OUTCOMES OF PREGNANCY IN PATIENTS WITH ANCA VASCULITIS / A. Croft* - S. W. Smith - S. Carr -<br />
S.Youssouf - A. Salama - C. Pusey - L. Harper - M. Morgan<br />
THU0200 CLINICAL AND RADIOLOGICAL CHARACTERISTICS OF INTERSTITIAL LUNG DISEASE IN JAPANESE PATIENTS WITH<br />
MICROSCOPIC POLYANGIITIS / A. Maeda* - H.Yamada - Y.Yamasaki - T. Shibata - H. Nagafuchi - Y. Kurihara - S. Ozaki<br />
THU0201 COGNITIVE IMPAIRMENT IN BEHÇET’S DISEASE IS NOT ASSOCIATED TO SYSTEMIC DISEASE ACTIVITY, CUMULATIVE<br />
PREDNISONE DOSE OR WHITE-MATTER LESIONS / L. A. Dutra - A. W. S De Souza* - H. Alessi - P. Braga Neto - B. D. V. S.<br />
Guedes - C. R. Gonçalves - A. J. da Rocha - P. H. Bertolucci - O. G. P. Barsottini<br />
THU0202 PROSPECTIVE EVALUATION OF AORTIC STRUCTURAL DAMAGE (ANEURYSM/DILATATION) USING A PREDEFINED<br />
SCREENING PROTOCOL IN BIOPSY-PROVEN GIANT-CELL ARTERITIS PATIENTS DURING LONG-TERM FOLLOW-UP /<br />
A. García-Martínez* - P. Arguis - S. Prieto-González - J. Hernández-Rodríguez - G. Espígol - M. Corbera - M. Alba - I. Tavera -<br />
E. Planas - M. C. Cid<br />
THU0203 CROSS-SECTIONAL ASSESSMENT OF DAMAGE IN TAKAYASU ARTERITIS WITH A VALIDATED TOOL / A. Omma - B. Erer*<br />
- O. Karadag - N.Yilmaz - F. Alibaz Oner - F.Yildiz - S. Kiraz - H. Direskeneli - E. Erken - A. Gul - L. Ocal - M. Inanc - S. Kamali<br />
THU0204 LUMBAR INTERSPINOUS BURSITIS IN ACTIVE POLYMYALGIA RHEUMATICA / C. Salvarani* - L. Barozzi - M. G. Catanoso -<br />
L. Boiardi - N. Pipitone - P. Macchioni - G. Pazzola - G. Bajocchi - O. Addimanda - F. Muratore<br />
* Presenting author
eular berlin 2012<br />
<strong>Scientific</strong> Poster Session 1 11:45 - 13:30<br />
THU0205 THE TEMPORAL APPEARANCE OF SYMPTOMS AND SIGNS IN CHURG STRAUSS SYNDROME: FROM THE PRODROMAL<br />
PHASE TO DAMAGE / C. Baldini* - P. Pepe - M. Latorre - A. della Rossa - V. Seccia - P. Iannicelli - V. Giorgerini - S. Galimberti -<br />
A. Tavoni - P. L. Paggiaro - S. Bombardieri<br />
THU0206 POPULATION-BASED EPIDEMIOLOGY AND DESCRIPTION OF BEHCET’S DISEASE IN THE AFRICAN DESCENT POPULA-<br />
TION OF MARTINIQUE, FRENCH WEST INDIES / C. Deligny* - L. Antonio - H. Merle - P. Numéric - A. Signate - V. Dehlinger<br />
- G. Jean Baptiste - S. Arfi<br />
THU0207 ACUTE SERUM AMYLOID A AND TLR2 ACTIVATION INDUCES PRO-INFLAMMATORY MECHANISMS IN A NOVEL EX<br />
VIVO TEMPORAL ARTERY EXPLANT CULTURE/MODEL OF GIANT CELL ARTERITIS / D. Molloy* - M. Connolly -<br />
J. McCormick - M. Haroon - D. J.Veale - C. Murphy - E. Molloy - U. Fearon<br />
THU0208 FATIGUE IS AN IMPORTANT PROBLEM IN PATIENTS WITH BEHCET’S SYNDROME / D. Buyuktas* - G. Hatemi - S. Yuksel<br />
Findikoglu - K. Tascilar - S. Ugurlu - S.Yurdakul<br />
THU0209 EFFICACY OF ANTI-TNF THERAPY IN 15 PATIENTS WITH REFRACTORY TAKAYASU’S ARTERITIS: LONG TERM UNICEN-<br />
TRIC FOLLOW-UP / E. Tombetti* - E. Baldissera - S. Franchini - F. Motta - P. Aiello - G. Cavalli - M. G. Sabbadini<br />
THU0210 THE COMPARISON OF CHILDHOOD POLYARTERITIS NODOSA AND CUTANEOUS POLYARTERITIS NODOSA /<br />
E. Demirkaya* - T. Turker - N. Ruperto - R. Cuttica - P. Brogan - P. Quartier - J. Anton - N. Ayaz - S. Garay - G. Espada -<br />
R. Khubchandani - F. Zulian - A. Bagga - A. Belot - C. A. Silva - S. M. Al-Mayouf - A. I. Estrella - S. Oliveira - C. S. Magalhães -<br />
A. Martini - S. Ozen<br />
THU0211 GASTROINTESTINAL MANIFESTATIONS OF BEHÇET’S DISEASE IN JAPAN: A STUDY OF 43 PATIENTS / H. Ideguchi* -<br />
A. Suda - M. Takeno - S. Ohno - Y. Ishigatsubo<br />
THU0212 INFLIXIMAB THERAPY FOR CHRONIC PROGRESSIVE NEURO-BEHÇET’S DISEASE: A 6-YEAR FOLLOW-UP STUDY /<br />
H. Kikuchi* - Y. Kimura - K. Asako - M. Takayama - H. Kono - Y. Ono - S. Hirohata<br />
THU0213 CYCLOPHOSPHAMIDE HAS NO EFFICACY IN JAPANESE PATIENTS WITH RENAL VASCULITIS ASSOCIATED WITH ANTI-<br />
NEUTROPHIL CYTOPLASMIC ANTIBODY-POSITIVE MICROSCOPIC POLYANGIITIS / I. Nakaya* - M. Iwabuchi - Y. Tsuchiya<br />
-Y. Shibagaki - T.Yamaguchi - S. Fukuhara - Y. Oe - M.Yahata - J. Soma - T. Sato - Y. Taguma<br />
THU0214 TREATMENT OF REFRACTORY GIANT CELL ARTERITIS WITH CYCLOPHOSPHAMIDE. A RETROSPECTIVE ANALYSIS OF<br />
35 PATIENTS FROM THREE TERTIARY CARE CENTERS / J. Loock* - J. C. Henes - I. Kötter - T. Witte - P. Lamprecht - M. Schirmer<br />
- W. L. Gross<br />
THU0215 INCIDENCE OF WEGENER’S GRANULOMATOSIS IN FINLAND IN 1981-2000 — DIFFERENT AGE GROUP PROPORTIONS<br />
IN FOUR 5-YEAR PERIODS / J. H. Takala* - H. Kautiainen - M. Leirisalo-Repo<br />
THU0216 SUBGLOTTIC STENOSIS AND TRACHEOBRONCHITIS IN GRANULOMATOSIS WITH POLYANGIITIS (GPA, WEGENER`S)<br />
ARE ASSOCIATED WITH A HIGH BURDEN OF DISEASE AND DAMAGE / J. Holle* - C. Röhl - M. Laudien - M. Both - K. Holl-<br />
Ulrich - W. Gross<br />
THU0217 NAILFOLD VIDEOCAPILLAROSCOPY IN PATIENTS WITH GRANULOMATOSIS WITH POLYANGIITIS (WEGENER´S): AN<br />
OBSERVATIONAL STUDY. / J. Uceda - R. Martinez - M. L.Velloso - J. L. Marenco*<br />
THU0218 HEMATOLOGICAL MALIGNANCIES (OTHER THAN LYMPHOMA) IN PATIENTS WITH GRANULOMATOUS POLYANGI-<br />
ITIS (WEGENER) / E. Baecklund - K. Hjorton* - J. Askling - A. Knight<br />
THU0219 ANTI-SACCHAROMYCES CEREVISAE ANTIBODIES (ASCA) IN ACTIVE BEHÇET’S DISEASE: A MARKER OF INTESTINAL<br />
INVOLVEMENT? / L. L. Prado* - K. L. Augusto - P. F. Magalhães - V. T.Viana - C. G. S. Saad - C. R. Gonçalves<br />
THU0220 RITUXIMAB FOR ANCA ASSOCIATED VASCULITIS: A SYSTEMATIC REVIEW / L. Silva* - R. Blanco - V. Martínez-Taboada -<br />
E. Loza - S. Muñoz-Fernández - J. M. Pego - I. Rúa-Figueroa on behalf of The Group for the Study of Systemic Autoimmune<br />
Diseases of the Spanish Society of Rheumatology<br />
THU0221 LUNG PHYSIOLOGY IMPAIRMENT IN ANCA-ASSOCIATED VASCULITIS (AASV) / L. F. Flores-Suarez* - S. Cardenas -<br />
L. Torre-Bouscoulet - S. Toral<br />
THU0222 DIFFERENCES IN CLINICAL PRESENTATION AND OUTCOME IN PATIENTS WITH EARLY VERSUS LATE ONSET GIANT-<br />
CELL ARTERITIS (GCA): ANALYSIS OF 94 PATIENTS / M. A. C. Alba * - A. García-Martínez - G. Espigol-Frigole - I. Tavera-<br />
Bahillo - S. Prieto-González - J. Hernández-Rodríguez - M. C. Cid<br />
THU0223 GENETICS OF BEHÇET’S DISEASE IN SARDINIA: TWO DISTINCT EXTENDED HLA HAPLOTYPES HARBOR THE B*51<br />
ALLELE IN NORMAL POPULATION AND IN PATIENTS / M. Piga* - F. Paladini - S. Lai - G. Passiu - C. Carcassi - R. Sorrentino<br />
- A. Mathieu<br />
THU0224 PREVALENCE OF ANTIBODIES AGAINST FERRITIN PEPTIDES: EPITOPE MAPPING OF HUMAN FERRITIN HEAVY CHAIN<br />
IN GCA AND PMR / N. T. Baerlecken* - K. Große - R. E. Schmidt - T. Witte<br />
THU0225 PREVALENCE OF TAKAYASU’S ARTERITIS IN IZMIR, TURKEY: A MULTICENTER STUDY / Y. Kucukyavas - K. Aksu - D. Solmaz<br />
- G. Can - A. Taylan - S. Akar - I. Sari* - M. Birlik - F. Onen - N. Akkoc<br />
THU0226 CLINICAL FEATURES AND MORTALITY CAUSES IN A LARGE COHORT OF SPANISH PATIENTS WITH ANCA ASSOCIATED<br />
VASCULITIDES / R. Solans-Laqué* - L. Caminal - L. Saez - J. J. Rios - M. Zamora - X. Solanich - M. Rodriguez - M. Lopez-Dupla<br />
- M. J. Castillo - E. Fonseca - J. L. Calleja - P. Fanlo - M. Abdilla on behalf of the Registro Español de Vasculitis Sistémicas (REVAS)<br />
from the Internal Medicine Society<br />
THU0227 ANCA-ASSOCIATED VASCULITIS: A RETROSPECTIVE STUDY FROM WESTERN INDIA / S. Nagaraj* - P. Joshi - V. Sharma -<br />
A. Buche - G. Mangat - R. Samant - C. Balakrishnan<br />
THU0228 SERUM IL-33 LEVEL IN BEHÇET’S DISEASE AND RHEUMATOID ARTHRITIS / S. S. Koca* - E. Donder - F. Deniz - M. Ozgen<br />
- N. Ilhan - A. Isik<br />
THU0229 DUAL EFFECTS OF TESTOSTERONE IN BEHCET’S DISEASE : IMPLICATIONS FOR A ROLE IN DISEASE PATHOGENESIS /<br />
T. Akdeniz* - G.Y. Demirel - M. Karakas - M. Bicakcigil - H. Direskeneli - O. Deyneli - S.Yavuz<br />
* Presenting author<br />
Thursday, 7 June 2012<br />
61
Thursday, 7 June 2012<br />
62<br />
eular berlin 2012<br />
<strong>Scientific</strong> Poster Session 1 11:45 - 13:30<br />
THU0230 RESPONSE TO TREATMENT WITH AZATHIOPRINE IN BEHCET'S SYNDROME PATIENTS WITH DIFFERENT ORGAN<br />
INVOLVEMENT AND DOCUMENTATION OF IMPROVEMENT USING PATIENT REPORTED OUTCOMES IN ROUTINE<br />
CLINICAL CARE / Y.Yazici* - A. L. Regens - C. J. Swearingen<br />
Scleroderma, myositis and related syndromes - clinical aspects and treatment<br />
THU0231 THE EFFICACY OF TACROLIMUS IN PATIENTS WITH INTERSTITIAL LUNG DISEASES COMPLICATED WITH<br />
POLYMYOSITIS OR DERMATOMYOSITIS / T. Kurita* - S.Yasuda - K. Oba - K. Otomo - H. Shida - T. Watanabe - Y. Kanetsuka -<br />
M. Kono - T. Odani - Y. Fujieda - Y. Kon - T. Horita - N. Sato - T. Atsumi<br />
THU0232 PREGNANCY OUTCOME IN IDIOPATHIC INFLAMMATORY MYOPATHY PATIENTS IN A MULTICENTER STUDY / M.Vincze*<br />
- A.Váncsa - K. Dankó - L. Plestilova - J.Vencovsky - K. Gheorghe - I. Lundberg - P. Charles - H. Balsam - E. Wegier-Szewczyk<br />
THU0233 MYOPATHY IS A POOR PROGNOSTIC FEATURE IN SYSTEMIC SCLEROSIS. RESULTS FROM THE CANADIAN SCLERO-<br />
DERMA RESEARCH GROUP (CSRG) COHORT / M. Jung* - M. Baron - M. Hudson - A. Bonner - J. E. Pope on behalf of Canadian<br />
Scleroderma Research Group<br />
THU0234 SYSTEMATIC LITERATURE REVIEW: EFICACY OF RAYNAUD PHENOMENON PHARMACOLOGYCAL TREATMENT IN<br />
SYSTEMIC SCLEROSIS PATIENTS / P. Garcia De La Peña Lefebvre* - M. B. Nishishinya - C. A. Pereda - J. Roman Ivorra -<br />
P. Carreira - E. Loza - I. Rúa-Figueroa - S. Muñoz-Fernández<br />
THU0235 IDENTIFYING AND QUANTIFYING PROGNOSTIC FACTORS IN SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG<br />
DISEASE USING A TIME-VARYING COVARIATE SURVIVAL MODEL / O. A. Moore* - N. Goh - T. Corte - H. Rouse -<br />
O. Hennessy - V. Thakkar - J. Byron - J. Sahhar - J. Roddy - P.Youssef - P. Nash - J. Zochling - S. M. Proudman - W. Stevens -<br />
M. Nikpour on behalf of Australian Scleroderma Interest Group<br />
THU0236 LOW GRADE EROSIVE ARTHRITIS IS A GENUINE AND FREQUENT DISEASE MANIFESTATION OF SYSTEMIC SCLEROSIS<br />
/ E. Akbayrak - I. H. Tarner - U. Müller-Ladner - R. Dinser*<br />
THU0237 IMPACT OF RECURRENT ISCHEMIC DIGITAL ULCERS ON HAND DISABILITY IN SYSTEMIC SCLEROSIS / L. Mouthon* -<br />
P. Carpentier - A. Khau Van Kien - P. Clerson - H. Maillard - E. Hachulla - C. Frances - E. Diot - C. Lok - E. Puzenat - A. Sparsa -<br />
A. Bérezné - V. Gressin - M.-A. Richard<br />
THU0238 LONG-TERM FOLLOW-UP OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE<br />
SYSTEMIC SCLEROSIS / H. Tsukamoto* - T. Horiuchi - T. Miyamoto - H. Niiro - Y. Arinobu - Y. Inoue - M. Ayano - A. Tanaka -<br />
N. Ueda - M. Harada - K. Akashi<br />
THU0239 CARDIOVASCULAR RISK FACTORS IN ADULTS WITH POLYMYOSITIS AND DERMATOMYOSITIS – A MULTICENTER<br />
STUDY / L. C. Diederichsen* - A. C. Diederichsen - J. A. Simonsen - P. Junker - K. Søndergaard - I. E. Lundberg - N. Tvede - A. F.<br />
Christensen - L. Dreyer - L. Ejstrup - S. Jacobsen<br />
THU0240 ROSUVASTATIN IMPROVES IMPAIRED ENDOTHELIAL FUNCTION AND LOWERS HIGH SENSITIVITY CRP IN PATIENTS<br />
WITH SYSTEMIC SCLEROSIS – A PROSPECTIVE CASE-SERIES STUDY / O. Timár - Z. Szekanecz - G. Kerekes - J. Végh -<br />
A. V. Oláh - Z. Csiki - K. Dankó - S. Szamosi - Á. Németh - P. Soltész - G. Szücs*<br />
THU0241 ETHNIC BUT NOT GENDER DIFFERENCES IN DISEASE MANIFESTATIONS IN DERMATOMYOSITIS PATIENTS /<br />
A. Tjärnlund* - L. Rider - F. Miller - V. P. Werth - I. E. Lundberg on behalf of the International Myositis Classification Criteria Project<br />
(IMCCP) consortium<br />
THU0242 INCIDENCE AND RISK FACTORS FOR LOW BONE MINERAL DENSITY IN PATIENTS WITH SYSTEMIC SCLEROSIS (SSC):<br />
A CASE-CONTROL STUDY / C. C. Mok* - P. T. Chan - K. M. Ma<br />
THU0243 STANDARDIZED MORTALITY RATIOS AND PREDICTORS OF SURVIVAL IN 215 SOUTHERN CHINESE PATIENTS WITH<br />
INFLAMMATORY MYOPATHIES / C. H. To* - C. C. Mok - H. So - M. L.Yip - K.Y. S.Ying<br />
THU0244 ADDITIVE VALUE OF SCLERODERMA HEALTH ASSESSMENT QUESTIONNAIRE (SHAQ) SCORES OVER HAQ DISABILITY<br />
INDEX VALUES FOR MEASURING DISABILITY AND QUALITY OF LIFE IN PATIENTS WITH SYSTEMIC SCLEROSIS /<br />
C. Becker* - D. Huscher - M. O. Becker - N. Hunzelmann - G. Riemekasten<br />
THU0245 RITUXIMAB HAS A BENEFICIAL EFFECT ON LUNG FUNCTION AND SKIN FIBROSIS IN PATIENTS WITH SYSTEMIC<br />
SCLEROSIS. AN OPEN LABEL STUDY / D. Daoussis* - S.-N. C. Liossis - I. Antonopoulos - T. Markatseli - G.Yiannopoulos -<br />
A. A. Drosos - A. P. Andonopoulos<br />
THU0246 PSYCHIATRIC DISORDERS IN RHEUMATOLOGY: EVALUATION OF A SCREENING PROTOCOL IN 100 HOSPITALIZED<br />
PATIENTS / F. Lumetti* - D. Giuggioli - A. Manfredi - D. Ferrari - E. Tedeschini - E. Simoni - M. Rigatelli - C. Ferri<br />
THU0247 HOME: THE EFFECT OF SYSTEMIC SCLEROSIS ON THE BLOOD FLOW IN THE HANDS / H. Knaapen* - A. E. Voskuyl -<br />
P. L. van Daele - J. P. J. Bloemsaat-Minekus - M. C.Vonk - A. J. M. Schuerwegh<br />
THU0248 EFFICACY OF IMATINIB MESYLATE ON SCLERODERMA ASSOCIATED PULMONARY ARTERIAL HYPERTENSION.<br />
H. Maki* - M. Hatano - A.Yao - T. Imamura - T. Inaba - T. Shiga - K. Kinugawa - R. Nagai<br />
THU0249 C - REACTIVE PROTEIN (CRP) IS ASSOCIATED WITH HIGH DISEASE ACTIVITY IN SSC AND ILD. RESULTS FROM THE<br />
CANADIAN SCLERODERMA RESEARCH GROUP (CSRG) / C. Muangchan - S. Harding - S. Khimdas - A. Bonner - M. Baron -<br />
J. E. Pope* on behalf of Canadian Scleroderma Research Group<br />
THU0250 CARDIOVASCULAR RISK ASSESSMENT IN SYSTEMIC SCLEROSIS USING THE SCORE CHART AND RECLASSIFICATION<br />
BY PRESENCE OF PLAQUES ON ULTRASONOGRAPHY / J. L. Rosales Alexander* - B. Joven - C. Magro Checa - E. Raya Alvarez<br />
- P. E. Carreira<br />
THU0251 ASSOCIATIONS OF SYSTEMIC SCLEROSIS AND OTHER AUTOIMMUNE DISEASES (ANALYSIS OF 153 PATIENTS FROM A<br />
SINGLE EUSTAR CENTRE) / K. Simic Pasalic* - N. Damjanov - G. Marinkovic<br />
THU0252 IMMUNOPROTEASOME SUBUNITS ARE UP-REGULATED IN INFLAMMATORY MYOPATHIES / K. M. Ghannam* -<br />
L. Martinez Gamboa1 - L. Naumann - S. Krause - M. Fettke - G. R. Burmester - E. Feist<br />
* Presenting author
eular berlin 2012<br />
<strong>Scientific</strong> Poster Session 1 11:45 - 13:30<br />
THU0253 ANTI-PM-SCL AUTOANTIBODIES IN POLYMYOSITIS AND DERMATOMYOSITIS / L. Plestilova* - K. Gheorghe - I. E.<br />
Lundberg - M.Vincze - K. Dankó - P. Charles - Z. Betteridge - N. McHugh - J.Vencovsk˘<br />
THU0254 CORRELATION BETWEEN MUSCLE PATHOLOGY FINDINGS AND CLINICAL VARIABLES IN PATIENTS WITH INFLAM-<br />
MATORY MYOSITIS / S. Wangkaew - S. Suwansirikul - K. Aroonrungwichian - N. Kasitanon* - W. Louthrenoo<br />
THU0255 MARKED INCREASE IN SERUM KL-6 AND SP-D LEVELS DURING 1ST 4 WEEKS AFTER TRATMENT PREDICTS POOR<br />
PROGNOSIS IN PATIENTS WITH ACTIVE INTERSTITIAL PNEUMONIA ASSOCIATED WITH POLYMYOSITIS/DERMATO-<br />
MYOSITIS / S. Arai* - K. Kurasawa - R. Maezawa - H. Okada - T. Owada - T. Fukuda<br />
THU0256 EFFECTIVENESS OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR INTERSTITIAL LUNG<br />
DISEASES IN PATIENTS WITH SYSTEMIC SCLEROSIS / T. Odani* - S.Yasuda - M. Kono - T. Kurita - Y. Fujieda - K. Otomo -<br />
Y. Kon - T. Horita - T. Atsumi<br />
THU0257 INVESTIGATION OF PARAMETERS OF ORAL APERTURE IN 131 PATIENTS WITH SYSTEMIC SCLEROSIS IN A THREE-YEAR<br />
SINGLE-CENTRE PROSPECTIVE STUDY / Z. Bálint - H. Farkas - K. Horváth - C.Varjú - G. Kumánovics - L. Czirják - T. Minier*<br />
THU0258 N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE IN A NOVEL SCREENING ALGORITHM FOR PULMONARY ARTERIAL<br />
HYPERTENSION IN SYSTEMIC SCLEROSIS / V. Thakkar* - W. Stevens - D. Prior - O. Moore - J. Byron - K. Patterson - P. Hissaria<br />
- J. Roddy - J. Zochling - J. Sahhar - P. Nash - K. Tymms - D. Celermajer - E. Gabbay - P.Youssef - S. Proudman - M. Nikpour on<br />
behalf of Australian Scleroderma Interest Group<br />
THU0259 THE LEVELS OF ADIPONECTIN ARE DECREASED IN THE SKIN AND SERA OF DIFFUSE CUTANEOUS SYSTEMIC<br />
SCLEROSIS PATIENTS / Y. Kubo* - S. Fukushima - M. Jinnin - T. Makino - I. Kajihara - A. Ichihara - K. Makino - H. Ihn<br />
Spondyloarthritis - treatment<br />
THU0260 CIRCULATING LEVELS OF TNF-LIKE CYTOKINE 1A (TL1A) ARE INCREASED IN PATIENTS WITH ANKYLOSING<br />
SPONDYLITIS / M. Konsta* - M. Tektonidou - A. Iliopoulos - G. Bamias - P. P. Sfikakis<br />
THU0261 CONTINUOUS NSAID USE REVERTS THE EFFECTS OF INFLAMMATION ON RADIOGRAPHIC PROGRESSION IN<br />
PATIENTS WITH ANKYLOSING SPONDYLITIS / F. Kroon* - R. Landewé - M. Dougados - D. van der Heijde<br />
THU0262 SCLEROSTIN DOES NOT PREDICT RADIOGRAPHIC PROGRESSION IN PATIENTS ON ANTI-TNF THERAPY – NEW<br />
RESULTS FROM THE EUROPEAN ANKYLOSING SPONDYLITIS (AS) INFLIXIMAB COHORT (EASIC) / X. Baraliakos* -<br />
F. Heldmann - J. Listing - G. Schett - T. Appelboom - J. Brandt - F. van den Bosch - M. Breban - G. Burmester - M. Dougados<br />
- P. Emery - H. Gaston - M. Gruenke - I. van der Horst-Bruinsma - R. Landewé - M. Leirisalo-Repo - J. Sieper - K. de Vlam -<br />
J. Braun on behalf of EASIC<br />
THU0263 DEVELOPMENT OF CHRONIC INFLAMMATORY CHANGES ON WHOLE BODY MAGNETIC RESONANCE IMAGING IN<br />
PATIENTS WITH EARLY AXIAL SPONDYLOARTHRITIS AFTER TWOYEARS OF CONTINUOUS TREATMENT WITH ETANER-<br />
CEPT – 2 YEAR DATA OF THE ESTHER TRIAL / I.-H. Song* - K.-G. Hermann - H. Haibel - C. Althoff - D. Poddubnyy - J. Listing<br />
- A. Weiss - E. Lange - B. Freundlich - M. Rudwaleit - J. Sieper<br />
THU0264 ADALIMUMAB SIGNIFICANTLY REDUCES RECURRENCE RATE OF ANTERIOR UVEITIS IN PATIENTS WITH ANKYLOSING<br />
SPONDYLITIS / C. van Denderen* - I. M.Visman - M. T. Nurmohamed - M. S. Suttorp-Schulten - I. E. van der Horst-Bruinsma<br />
THU0265 EARLY CHANGE IN BONE RESORPTION PREDICTS DISCONTINUATION OF TUMOR NECROSIS FACTOR-ALPHA<br />
BLOCKING THERAPY IN PATIENTS WITH ANKYLOSING SPONDYLITIS / S. Arends* - A. Spoorenberg - P. M. Houtman -<br />
M. K. Leijsma - C. G. M. Kallenberg - E. Brouwer - E. van der Veer<br />
THU0266 SARCOPENIA REVERSAL IN ANKYLOSING SPONDYLITIS (AS) UNDER ANTI-TNF THERAPY: A 24-MONTH LONGITU-<br />
DINAL ANALYSIS / M. A. Barros* - C. S. Saad - L. Takayama - J. C. Moraes - A. C. Medeiros - E. Bonfa - R. M. Pereira<br />
THU0267 A RANDOMIZED CONTROLLED TRIAL OF THE EFFICACY OF INCENTIVE SPIROMETER EXERCISE ON PULMONARY<br />
FUNCTIONS OF PATIENTS WITH ANKYLOSING SPONDYLITIS STABILIZED BY TUMOR NECROSIS FACTOR INHIBITOR<br />
THERAPY / B. S. Koo* - M. W. So - W. J. Seo - Y.-G. Kim - C.-K. Lee - B.Yoo<br />
THU0268 LOCAL INFLIXIMAB INJECTION OF SACROILIAC JOINTS IN EARLY AXIAL SPONDYLOARTHROPATHIES: IMPACT ON<br />
PARAMETERS OF DISEASE ACTIVITY / E. Soliman* - G. El-tantawy - K. Matrawy - A. Aldawoudy - A. Naguib<br />
THU0269 SPINAL AND SACROILIAC INFLAMMATION AS DETECTED BY MAGNETIC RESONANCE IMAGING IN PATIENTS WITH<br />
ANKYLOSING SPONDYLITIS, BEFORE AND AFTER 12 WEEKS THERAPY WITH NON-STEROIDAL ANTI-INFLAMMATORY<br />
DRUGS / E. Tyukhova - A. Smirnof - O. Rumyanceva - A. Bochkova*<br />
THU0270 EUROPEAN ANKYLOSING SPONDYLITIS (AS) INFLIXIMAB COHORT (EASIC) LONG-TERM EXTENSION: EFFICACY AND<br />
SAFETY OF INFLIXIMAB OVER A TIME PERIOD OF MORE THAN 7 YEARS IN PATIENTS WITH AS / F. Heldmann* -<br />
X. Baraliakos - J. Brandt - I. van der Horst-Bruinsma - R. Landewé - J. Sieper - G. R. Burmester - F. van den Bosch - K. de Vlam -<br />
H. Gaston - M. Grünke - T. Appelboom - P. Emery - M. Dougados - M. Leirisalo-Repo - M. Breban - J. Braun<br />
THU0271 INCREASE IN BONE MINERAL DENSITY AND DECREASE IN WNT3A, OPG, CTX-I AND OSTEOCALCIN IN PATIENTS<br />
WITH ANKYLOSING SPONDYLITIS TREATED WITH ALENDRONATE / H. Forsblad-d'Elia* - M. Nurkkala - K. Zetterberg -<br />
E. Klingberg - H. Carlsten on behalf of Center for Bone and Arthritis Research<br />
THU0272 EFFICACY OF ORAL PREDNISOLONE IN ACTIVE ANKYLOSING SPONDYLITIS – RESULTS OF A DOUBLE BLIND<br />
PLACEBO CONTROLLED TRIAL / H. Haibel* - C. Fendler - J. Listing - J. Callhoff - J. Braun - J. Sieper<br />
THU0273 SIMILAR RESPONSE RATES IN PATIENTS WITH ANKYLOSING SPONDYLITIS AND NON-RADIOGRAPHIC AXIAL<br />
SPONDYLOARTHRITIS AFTER ONE YEAR OF TREATMENT WITH ETANERCEPT - RESULTS OF THE ESTHER TRIAL /<br />
I.-H. Song* - K.-G. Hermann - H. Haibel - C. Althoff - D. Poddubnyy - J. Listing - A. Weiß - E. Lange - B. Freundlich - M. Rudwaleit<br />
- J. Sieper<br />
* Presenting author<br />
Thursday, 7 June 2012<br />
63
Thursday, 7 June 2012<br />
64<br />
eular berlin 2012<br />
<strong>Scientific</strong> Poster Session 1 11:45 - 13:30<br />
THU0274 DOUBLE-BLIND, PLACEBO-CONTROLLED, 28-WEEK TRIAL OF EFFICACY AND SAFETY OF INFLIXIMAB PLUS<br />
NAPROXEN VS NAPROXEN ALONE IN PATIENTS WITH EARLY, ACTIVE AXIAL SPONDYLOARTHRITIS TREATED WITH A<br />
SUBMAXIMAL DOSE OF NSAIDS: PRELIMINARY RESULTS OF INFAST PART I / J. Sieper* - J. Lenaerts - J. Wollenhaupt -<br />
V. I. Mazurov - L. Myasoutova - S.-H. Park - Y.-W. Song - R.Yao - D. Chitkara - N.Vastesaeger<br />
THU0275 SUSTAINED EFFICACY OF ADALIMUMAB IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS:<br />
WEEK 68 RESULTS FROM ABILITY 1 / J. Sieper* - D. van der Heijde - M. Dougados - F.Van den Bosch - P. Goupille - S. Sarkar -<br />
A. L. Pangan<br />
THU0276 A RANDOMIZED, OPEN-LABEL STUDY TO EXPLORE WHETHER PARTIAL REMISSION CAN BE MAINTAINED WITH<br />
NAPROXEN OR NO TREATMENT IN PATIENTS WITH EARLY, ACTIVE AXIAL SPONDYLOARTHRITIS: PRELIMINARY<br />
RESULTS OF INFAST PART II / J. Sieper* - J. Lenaerts - J. Wollenhaupt - V. I. Mazurov - L. Myasoutova - S.-H. Park - Y.-W. Song<br />
- R.Yao - D. Chitkara - N.Vastesaeger<br />
THU0277 ABSENCE OF RADIOGRAPHIC PROGRESSION AT TWO YEARS IN A COHORT OF PATIENTS WITH NON- RADIOGRAPHIC<br />
AXIAL SPONDYLOARTHRITIS TREATED WITH TNFA BLOCKERS / J. G. Lopez Velandia* - M. Almirall - J. Perez Ruiz - J. Maymó<br />
Guarch - M. P. Lisbona - A. Pàmies - I. Silvia - J. Carbonell<br />
THU0278 THE EFFECT OF ANTI-TUMOR NECROSIS FACTOR THERAPY WITH GOLIMUMAB ON RADIOGRAPHIC PROGRESSION<br />
IN DEFINITE ANKYLOSING SPONDYLITIS: 4-YEAR RESULTS / J. Braun* - D. van der Heijde - K.-G. Hermann - X. Baraliakos<br />
- A. Deodhar - A. Beutler - M. Mack - W. Xu - B. Hsu - R. Inman<br />
THU0279 ABSENCE OF RADIOGRAPHIC PROGRESSION OF HIP ARTHRITIS IN PATIENTS WITH ANKYLOSING SPONDYLITIS<br />
TREATED WITH INFLIXIMAB FOR 6 YEARS / M. Konsta* - V. K. Bournia - P. P. Sfikakis - D. Karras - A. Iliopoulos<br />
THU0280 EFFICACY AND SAFETY OF ADALIMUMAB IN PATIENTS WITH PERIPHERAL SPONDYLOARTHRITIS: RESULTS FROM A<br />
PHASE 3 STUDY / P. Mease* - J. Sieper - F.Van den Bosch - P. Rahman - K. Obermeyer - A. L. Pangan<br />
THU0281 EFFICACY OF ETANERCEPT THERAPY WITH AN EVERY OTHER WEEK REGIMEN IN PATIENTS WITH ANKYLOSING<br />
SPONDYLITIS / R. De Stefano* - E. Frati - L. Menza - M. Galeazzi<br />
THU0282 CLINICAL EFFICACY TO A SECOND ANTI-TNF THERAPY IS ASSOCIATED WITH THE DEVELOPMENT OF ANTIBODIES<br />
AGAINST THE FIRST ANTI-TNF THERAPY IN PATIENTS WITH SPONDYLOARTRHITIS / S. García Carazo* - C. Plasencia<br />
- D. Pascual Salcedo - G. Bonilla Hernan - L. Lojo - A. Villalba - L. Nuño - L. Del Olmo - S. Gil Barato - P. Alcocer Amores -<br />
F. Arribas - E. Perez - E. Martin Mola - A. Balsa<br />
THU0283 PREDICTIVE FACTORS OF RESPONSE AT 12 WEEKS IN PATIENTS WITH ANKYLOSING SPONDYLITIS STARTING<br />
BIOLOGICAL THERAPIES - RESULTS FROM THE PORTUGUESE REGISTER - REUMA.PT / S. Ramiro* - P. Machado - R. Roque<br />
- H. Santos - J. Polido-Pereira - D. Peixoto - C. Duarte - F. Pimentel-Santos - C. Silva - J. E. Fonseca - F. Teixeira - A. Marques -<br />
F. Araújo - J. Branco - J. A. P. da Silva - J. Costa - J. Pereira da Silva - L. Miranda - J. Canas da Silva - H. Canhão - A. van Tubergen<br />
- D. van der Heijde - R. Landewé - M. J. Santos<br />
THU0284 METALLOPROTEINASE-3 (MMP-3) IS A PREDICTOR FOR ANTI-TNFA RESPONSE IN PATIENTS WITH ANKYLOSING<br />
SPONDYLITIS (AS) / V. Navarro-Compán* - R. Mondéjar-García - R. Ariza-Ariza - V. Moreira-Navarrete - C. Leyva-Prado -<br />
C. González-Rodríguez - F. Navarro-Sarabia<br />
THU0285 NO EVIDENCE FOR A ROLE OF THE HYPOTHESIZED SEQUENCE INFLAMMATION - FATTY DEGENERATION – NEW<br />
BONE FORMATION IN PATIENTS WITH ANKYLOSING SPONDYLITIS TREATED WITH INFLIXIMAB OR OTHER ANTI-TNF<br />
AGENTS OVER 5 YEARS / X. Baraliakos* - F. Heldmann - J. Callhoff - J. Listing - D. Pappas - J. Braun<br />
THU0286 CLINICAL EFFICACY AND SAFETY OF INFLIXIMAB – FIRST RESULTS AFTER A DECADE OF CONTINUOUS TREATMENT<br />
IN ANKYLOSING SPONDYLITIS / X. Baraliakos* - J. Listing - C. Fritz - H. Haibel - R. Alten - G. Burmester - A. Krause - S. Schewe<br />
- M. Schneider - H. Sörensen - R. Schmidt - J. Sieper - J. Braun<br />
Basic science in paediatric rheumatology<br />
THU0287 GLYCOSYLATION OF VITAMIN D BINDING PROTEIN REDUCED IN JUVENILE IDIOPATHIC ARTHRITIS PATIENTS AT RISK<br />
OF DISEASE EXTENSION / D. S. Gibson* - S. Finnegan - G. Manning - M. Duncan - S. Pennington - T. Moore - M. Rooney<br />
THU0288 PROTEOMIC PROFILING OF THE SYNOVIAL MEMBRANE IN EARLY UNTREATED JUVENILE IDIOPATHIC ARTHRITIS /<br />
S. Finnegan* - D. S. Gibson - M. Rooney<br />
THU0289 MICRORNA SIGNATURE IN PEDIATRIC LUPUS NEPHRITIS: A PILOT STUDY / P. Costa Reis* - P. A. Russo - K. E. Sullivan<br />
THU0290 PERIPHERAL MONONUCLEAR CELLS OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS PATIENTS HAVE NO INTRINSIC<br />
DEFECT IN INTERFERON-GAMMA SIGNALING / K. Put* - A. Avau - T. Mitera - S. Put - B. Bader-Meunier - P. Quartier -<br />
C. Wouters - P. Matthys<br />
THU0291 NEUTROPHIL APOPTOSIS IS NOT AFFECTED BY GLUCOCORTICOID OR DMARD TREATMENT IN JUVENILE-ONSET<br />
SYSTEMIC LUPUS ERYTHEMATOSUS / F. Gohar* - L. Ballantine - M. W. Beresford<br />
THU0292 STIMULATION OF JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS BLOOD CELLS INDUCES IL-17 PRODUCTION /<br />
L. Ballantine* - A. Midgley - L. Watson - M. Beresford<br />
THU0293 JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS (JSLE) AND JUVENILE DERMATOMYOSITIS (JDM) PATIENTS HAVE A<br />
DISTINCT PROFILE OF SOLUBLE APOPTOSIS MOLECULES / B. L. Liphaus* - M. H. B. Kiss - S. Carrasco - C. A. Silva -<br />
C. Goldenstein-Schainberg<br />
THU0294 REGULATORY T CELLS/TH17 BALANCE IN THE PATHOGENESIS OF PEDIATRIC BEHÇET DISEASE / T.-A. Tran* - A. Hubert<br />
- A. Letierce - B. Terrier - G. Geri - D. Saadoun - I. Kone-Paut - M. Rosenzwajg<br />
THU0295 ISOTYPE CHARACTERIZATION OF ANTI-INFLIXIMAB ANTIBODIES IN PEDIATRIC PATIENTS WITH RHEUMATIC<br />
DISEASES TREATED WITH INFLIXIMAB / M. Kosmač* - N. Toplak - G. Simonini - R. Cimaz - V. Čurin Sˇerbec - T. Avčin<br />
THU0296 MATRIX INTERFERENCE OF IL-6, IL-17, IL-21 AND TNF-ALPHA MEASUREMENT IN JUVENILE-ONSET SYSTEMIC LUPUS<br />
ERYTHEMATOSUS SERUM AND PLASMA / J. Ong* - D. Harris - G. Jeffers - L. Watson - L. Ballantine - M. Beresford<br />
* Presenting author
eular berlin 2012<br />
<strong>Scientific</strong> Poster Session 1 11:45 - 13:30<br />
Paediatric rheumatology<br />
THU0297 HIGH PREVALENCE OF HAND AND WRIST IMPAIRMENTS IN JUVENILE IDIOPATHIC ARTHRITIS (JIA) / A. F. Hoeksma* -<br />
W. G. Zinger - M. A. van Rossum - K. M. Dolman - J. Dekker - L. D. Roorda<br />
THU0298 DISEASE SELF-MANAGEMENT IN ADOLESCENTS WITH CHRONIC MUSCULOSKELETAL AND RHEUMATIC DISEASES /<br />
A. Abou-Raya* - S. Abou-Raya<br />
THU0299 IL-1 INHIBITION IN A PATIENT WITH POLYMORPHISM IN THE INTERLEUKIN 1-RECEPTOR TYPE 1 GENE AND CLINICAL<br />
PHENOTYPE OF CRMO/DIRA / C. Zimmer* - M. Moll - N. Rieber - R. Goldbach-Mansky - I. Aksentijevich - J. Kuemmerle-<br />
Deschner<br />
THU0300 REDUCED ARTICULAR CARTILAGE THICKNESS IN JOINTS WITHOUT A HISTORY OF ACTIVE ARTHRITIS IN CHILDREN<br />
WITH JUVENILE IDIOPATHIC ARTHRITIS / D. Pradsgaard* - A. Spannow - C. W. Heuck - T. Herlin<br />
THU0301 NEOPTERIN (NPT) AND SOLUBLE INTERLEUKIN 2 RECEPTOR (SIL-2R) AS USEFUL MARKERS OF DISEASE ACTIVITY IN<br />
JUVENILE IDIOPATHIC ARTHRITIS (JIA) / E. Olesinska* - J. Postepski - J. Tabarkiewicz - B. Wilczynska - E. Tuszkiewicz-Misztal<br />
THU0302 SAFETY AND EFFICACY OF TOCILIZUMAB THERAPY IN CHILDREN WITH SYSTEMIC ONSET OF JUVENILE IDIOPATHIC<br />
ARTHRITIS / E. Alexeeva* - R. Denisova - S.Valiyeva - T. Bzarova - K. Isayeva - T. Sleptsova - E. Mitenko<br />
THU0303 THE EFFICACY AND SAFETY OF IBANDRONIC ACID FOR INTRAVENOUS ADMINISTRATION FOR TREATMENT OF<br />
SEVERE SYSTEMIC OSTEOPOROSIS IN PATIENTS WITH JUVENILE ARTHRITIS / S. Valiyeva - E. Alexeeva* - T. Bzarova -<br />
R. Denisova - K. Isayeva - T. Sleptsova - E. Mitenko<br />
THU0304 EFFICACY OF BIOLOGIC THERAPIES FOR PEDIATRIC RHEUMATIC DISEASES ASSOCIATED UVEITIS / E. Denisova* -<br />
L. Katargina - A. Starikova - N. Lubimova<br />
THU0305 COST-UTILITY OF TOCILIZUMAB IN THE TREATMENT OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS IN FINLAND /<br />
T. Hallinen - E. J. Soini* - A. Diamantopoulos - F. Dejonckheere - V.Vihervaara - A. Hautala - K. Aalto<br />
THU0306 PREDICTORS OF OUTCOME IN A COHORT OF ITALIAN CHILDREN/ADOLESCENTS WITH PRIMARY RAYNAUD’S<br />
PHENOMENON: A MULTICENTER STUDY / F. Falcini* - V. Denaro - F. Cuoco - G. Martini - S. Cappelli - A. Petaccia - F. Corona<br />
- G. Carnesecchi - F. La Torre - M. Matucci Cerinic - D. Rigante<br />
THU0307 VALIDATION OF JADAS IN INTERNATIONAL LEAGUE AGAINST RHEUMATISM (ILAR) SUBTYPES OF JUVENILE<br />
IDIOPATHIC ARTHRITIS (JIA) / F. Mcerlane* - M. W. Beresford - E. M. Baildam - S. E. Chieng - J. Davidson - H. E. Foster -<br />
J. Gardner-Medwin - M. Lunt - L. R. Wedderburn - K. L. Hyrich - W. Thomson<br />
THU0308 INDIRECT COMPARISON OF ACR RESPONSE OF BIOLOGIC TREATMENTS IN ACTIVE SJIA / A. Diamantopoulos - C. LeReun<br />
- R. Westhovens - F. Dejonckheere*<br />
THU0309 MEASLES, MUMPS AND RUBELLA VACCINATION SAFETY IN PATIENTS WITH JUVENILE RHEUMATIC DISEASES TAKING<br />
IMMUNOSUPPRESSIVE DRUGS / G. S. Pileggi* - M. T. R. A. Terreri - C. P. Barbosa - V. P. L. Ferriani<br />
THU0310 PERFORMANCE OF THE JUVENILE ARTHRITIS DISEASE ACTIVITY SCORE JADAS COMPARED TO THE ACR PEDIATRIC<br />
MEASURES OF RESPONSE IN 1470 JUVENILE IDIOPATHIC ARTHRITIS PATIENTS / G. Horneff* - K. Minden - I. Foeldvari on<br />
behalf of BIKER cooperative working group<br />
THU0311 WHAT HAPPENS WHEN ETANERCEPT IS DISCONTINUED IN “REMISSION” IN PATIENTS WITH JUVENILE IDIOPATHIC<br />
ARTHRITIS? / G. Horneff* - H. I. Hupppertz - I. Foeldvari - K. Minden<br />
THU0312 REDUCTION OF CONCOMITANT TREATMENT UPON THERAPY WITH ETANERCEPT IN JUVENILE IDIOPATHIC<br />
ARTHRITIS / G. Horneff* - K. Minden on behalf of German BIKER registry collaborative working group<br />
THU0313 IS MRI A RELIABLE TOOL FOR MONITORING CHRONIC NON BACTERIAL OSTEOMYELITIS? / G. Zanon* - S. Corradin -<br />
G. Martini - F.Vittadello - F. Zulian<br />
THU0314 BONE STATUS OF CHILDREN BORN FROM MOTHERS WITH AUTOIMMUNE DISEASES TREATED DURING PREGNANCY<br />
WITH LOW MOLECULAR WEIGHT HEPARIN AND/OR PREDNISONE / I. Pagnini* - G. Simonini - L. Cavalli - G. la Marca -<br />
S. Sollai - A. Iuliano - M. L. Brandi - F. Bellisai - M. Galeazzi - L. Cantarini - R. Cimaz<br />
THU0315 LONG-TERM OUTCOME OF JUVENILE IDIOPATHIC ARTHRITIS (JIA): A FRENCH MULTICENTER STUDY BASED ON 353<br />
PATIENTS / I. Melki* - C. Garcin - P. Quartier - C. Job Deslandre - I. Lemelle - P. Landais - B. Bader-Meunier - A.-M. Prieur<br />
THU0316 UPDATE ON THE JUVENILE SYSTEMIC SCLEROSIS INCEPTION COHORT. WWW.JUVENILESCLERODERMA.COM /<br />
I. Foeldvari* - C. Ehlers - C. Len - M. M. Katsicas - A. Tae - T. Kalinich - I. Kone-Paut - L. Mouthon - Y. Uziel on behalf of Juvenile<br />
Scleroderma Working Group of the PRES<br />
THU0317 LATENT CLASS ANALYSIS TO UNDERSTAND THE IMPACT OF RECENT-ONSET JIA ON PATIENT’S PERCEIVED HEALTH-<br />
RELATED QUALITY OF LIFE / J. Klotsche* - I. Liedmann - M. Niewerth - G. Horneff - J.-P. Haas - K. Minden<br />
THU0318 A PROSPECTIVE COMPARATIVE STUDY OF THREE METHODS OF ASSESSMENT OF THE KNEE JOINT IN JUVENILE<br />
IDIOPATHIC ARTHRITIS: CLINICAL EXAMINATION, ULTRASOUND AND MRI (A NEWLY DEVELOPED KNEE MRI<br />
SCORING SYSTEM) / L. Pascoli* - N. J. Napier - M. Wray - M. Mc Carron - C. Mc Allister - M. Rooney<br />
THU0319 DISEASE COURSE, OUTCOME AND PREDICTORS OF OUTCOME IN AN UNSELECTED COHORT OF INDIVIDUALS WITH<br />
JUVENILE CHRONIC ARTHRITIS FOLLOWED FOR 17 YEARS / L. Bertilsson* - B. Andersson-Gäre - A. Fasth - I. F. Petersson -<br />
H. Forsblad-d'Elia<br />
THU0320 DEVELOPMENT AND TESTING OF THE READINESS FOR ADULT CARE IN RHEUMATOLOGY (RACER) QUESTIONNAIRE<br />
FOR ADOLESCENTS WITH RHEUMATIC CONDITIONS / J. Stinson - L. Spiegel* - K. Watanabe Duffy - L. Tucker - E. Stringer<br />
- B. Hazel - J. Hochman - N. GIll - K. Spadafora - M. Kaufman<br />
THU0321 110 PATIENTS WITH ENTHESITIS RELATED ARTHRITIS: A DEMOGRAPHIC AND CLINICAL STUDY FROM A TERTIARY<br />
LEVEL PEDIATRIC RHEUMATOLOGY CENTRE IN INDIA / M. Agarwal* - M. Jariwala - S. Sawhney - R. Prakash<br />
* Presenting author<br />
Thursday, 7 June 2012<br />
65
Thursday, 7 June 2012<br />
66<br />
eular berlin 2012<br />
<strong>Scientific</strong> Poster Session 1 11:45 - 13:30<br />
THU0322 DOES INTENSE SYNOVIAL ENHANCEMENT IN TEMPOROMANDIBULAR JOINTS OF JUVENILE IDIOPATHIC ARTHRITIS<br />
PATIENTS CORRELATE WITH DISEASE ACTIVITY? / L. Zwir - M. T. Terreri* - S. Sousa - A. Fernandes - A. S. Guimarães -<br />
M. O. Hilário<br />
THU0323 ACHIEVEMENT OF CLINICAL REMISSION IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS AFTER A LONG-TERM<br />
(2 - 5 YEARS) ETANERCEPT EXPOSURE: A NATIONAL REFERRAL CENTER’S EXPERIENCE. (PRELIMINARY REPORT) /<br />
M. Trachana* - P. Pratsidou-Gertsi - G. Pardalos<br />
THU0324 RITUXIMAB FOR SEVERE DISEASE FLARES IN CHILDHOOD ANCA VASCULITIDES / M. Twilt* - R. Schneider - A. Bell-Peter<br />
- C.Yang - S. Dell - S. M. Benseler<br />
THU0325 OUTCOME OF PATIENTS WITH OLIGOARTICULAR ONSET OF JUVENILE IDIOPATHIC ARTHRITIS: DATA FROM THE<br />
GERMAN PAEDIATRIC RHEUMATOLOGIC DATABASE -A LONGITUDINAL STUDY / M. Niewerth* - J. Klotsche - A. Raab -<br />
A. Zink - G. Ganser - I. Foeldvari - K. Minden<br />
THU0326 DRUG SURVIVAL AND REASONS FOR DISCONTINUATION OF THE FIRST COURSE OF BIOLOGICAL THERAPY IN 301<br />
JUVENILE IDIOPATHIC ARTHRITIS PATIENTS / M. Romano* - I. Pontikaki - M. Gattinara - I. Ardoino - C. Donati - P. Boracchi<br />
- P. L. Meroni - V. Gerloni<br />
THU0327 RADIOLOGICAL PERIPHERAL INVOLVEMENT AT HANDS, FEET AND HIPS IN YOUNG ADULTS WITH POLYARTICULAR<br />
IDIOPATHIC JUVENILE ARTHRITIS / M. Elhai* - R. Bazeli - V. Freire - A. Feydy - A. Kahan - C. Job-Deslandre - J. Wipff<br />
THU0328 CHANGES IN HEALTH-RELATED QUALITY OF LIFE IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS PATIENTS AFTER<br />
SINGLE DOSE OF CANAKINUMAB / N. Wulffraat* - T. Kallinich - L. McCann - R. Brik - L. Rutkowska-Sak - M. Ferrandiz -<br />
K. Lheritier - D. Kim - A. Gnanasakthy - H. Ozdogan<br />
THU0329 OPG/RANK/RANKL IN PATHOGENESIS OF OSTEOPOROSIS OF JUVENILE IDIOPATHIC ARTHRITIS (JIA) SUBTYPES /<br />
N. Abdel-Wahab* - T. M. Khedr - E. A. Alkady - E. Mosad on behalf of Sonya Rashad<br />
THU0330 DAMAGE IN JUVENILE-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS / P. Costa Reis* - J. Isgro - S. Nativ - C.Yildirim-Toruner<br />
- A. Starr - L. Imundo - A. Eichenfield<br />
THU0331 MANAGEMENT OF OSTEOPOROSIS IN CHILDREN: EXPERIENCE FROM A PEDIATRIC RHEUMATOLOGY CENTER /<br />
R. Campanilho-Marques* - F. Ramos - J. Romeu - J. A. Pereira da Silva on behalf of Rheumatology Department, Hospital de Santa<br />
Maria - Lisbon; Rheumatology Research Unit, Instituto de Medicina Molecular<br />
THU0332 PREDICTORS OF POOR GROWTH IN CHILDREN WITH EARLY JUVENILE IDIOPATHIC ARTHRITIS: RESULTS FROM THE<br />
CHILDHOOD ARTHRITIS PROSPECTIVE STUDY (CAPS) / R. Carrasco* - L. R. Wedderburn - H. E. Foster - E. Baildam -<br />
J. Gardner-Medwin - A. Chieng - J. Davidson - W. Thomson - K. Hyrich<br />
THU0333 EFFECTIVENESS AND LONG-TERM FOLLOW UP OF RECOMBINANT IL-1RA AS FIRST LINE THERAPY IN NEWLY ONSET<br />
JUVENILE IDIOPATHIC ARTHRITIS / S. Vastert* - W. De Jager - B. J. Noordman - D. Holzinger - W. Kuis - B. Prakken -<br />
N. Wulffraat<br />
THU0334 DIFFERENCES IN THE FEATURES OF FAMILIAL MEDITERRANEAN FEVER AMONG PATIENTS FROM EUROPE AS<br />
COMPARED TO THOSE FROM THE EASTERN MEDITERRANEAN COUNTRIES / S. Ozen* - E. Demirkaya - G. Amaryan -<br />
I. Koné-Paut - P. Woo - Y. Uziel - M. Finetti - P. Quartier - C. Modesto - E. Papadopoulou-Alataki - S. Nielsen - M. Hofer - A. Polat<br />
- T. Turker - A. Insalaco - L. Cantarini - S. M. Al-Mayouf - J. Frenkel - H. Ozdogan - N. Ruperto - M. Gattorno<br />
THU0335 SUPPORT VECTOR MACHINES CLASSIFICATION OF TEXTURE PARAMETERS OF WHITE MATTER LESIONS IN CHILD-<br />
HOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS. POSSIBLE MECHANISM TO DISTINGUISH BETWEEN DEMYELI-<br />
NATION AND ISCHEMIA / A.T. Lapa - M. P. Bento - L. Rittner - H. H. Ruocco - G. Castellano - B. P. Damasceno - L.T. L. Costallat<br />
- R. Lotufo - F. Cendes - S. Appenzeller*<br />
THU0336 PREVALENCE AND CLINICAL SIGNIFICANCE OF WHITE MATTER HYPERINTENSITIES IN JUVENILE SYSTEMIC LUPUS<br />
ERYTHEMATOSUS (JSLE) / A. T. Lapa - L. Ferretti - N. A. Sinicato - M. Postal - R. Marini - F. Cendes - S. Appenzeller*<br />
THU0337 SUBCLINICAL FUNCTIONAL LUNG ABNORMALITIES IN JUVENILE ONSET SYSTEMIC LUPUS ERYTHEMATOSUS (JSLE)<br />
/ S. M. Rashad* - K. M. Darwish - E. A. Abbda - H. M. Abozaid - M. S. Khalil<br />
THU0338 INCIDENCE OF SELECTED OPPORTUNISTIC INFECTIONS AMONG CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS<br />
/ T. Beukelman* - F. Xie - J. W. Baddley - L. Chen - E. Delzell - C. Grijalva - N. Patkar - K. G. Saag - K. Winthrop - J. R. Curtis<br />
THU0339 POWER DOPPLER ULTRASONOGRAPIC FINDINGS IN HEALTHY PEDIATRIC ENTHESISES / V. Ravagnani* - S. Pieropan -<br />
G. Barausse - G. Sidoti - A. Boner - A.Volpe - P. Caramaschi - D. Biasi - S. Adami<br />
THU0340 CYTOKINES’ STUDY IN PATIENTS WITH DIFFERENT SUBTYPES OF JUVENILE IDIOPATHIC ARTHRITIS / Y. Boyko* -<br />
V. Chernyshov<br />
Fibromyalgia and pain in rheumatic diseases<br />
THU0341 ASSESSMENT OF ART THERAPY PROGRAM FOR WOMEN WITH FIBROMYALGIA: RANDOMIZED, CONTROLLED,<br />
BLINDED STUDY / A. S. Baptista - A. Jones* - F. P. Cardoso - B. Schaffir - E. R. W. Coelho - A. Orlandi - J. Natour<br />
THU0342 NEUROPATHIC PAIN IN PATIENTS WITH SYSTEMIC SCLEROSIS / F. Teixeira* - D. Peixoto - J. Costa - C. Afonso - D. Araujo<br />
THU0343 METABOLIC SYNDROME AND ITS COMPONENTS IN FIBROMYALGIA PATIENTS / F. Ursini* - S. Naty - M. Calabria -<br />
M. Labonia - R. D. Grembiale on behalf of Rheumatology Research Unit<br />
THU0344 DAS-28, SDAI AND CDAI IN THE PATIENTS WITH RHEUMATOID ARTHRITIS AND CONCOMITANT FIBROMYALGIA /<br />
J. Toms* - P. Bradna - T. Soukup - Z. Hrncir<br />
THU0345 SIMILARITIES BETWEEN FIBROMYALGIA AND CHRONIC FATIGUE SYNDROME: A SINGLE DISEASE? / J. Rivera* -<br />
A. Collado - J. Alegre - J. Blanch - J. Vidal - A. Arias - J. Carbonel on behalf of FSGCDB Group (Fibromyalgia and SFC Spanish<br />
Genetic and Clinical Data Bank). Foundation FF.<br />
* Presenting author
eular berlin 2012<br />
<strong>Scientific</strong> Poster Session 1 11:45 - 13:30<br />
THU0346 DEPRESSIVE SYMPTOMS AND HEART RATE VARIABILITY IN PATIENTS WITH FIBROMYALGIA / J. W. Lee* - S. G. Lee -<br />
Y. E. Park - S. H. Park - J. H. Lee - S. H. Baek - G. T. Kim<br />
THU0347 EFFICACY AND SAFETY OF WHOLE BODY CRYOTHERAPY IN FIBROMYALGIC PATIENTS / L. Bettoni* - F. G. Bonomi -<br />
V. Zani - A. Indelicato - G. Banfi<br />
THU0348 ADHERENCE AND EFFECTIVENESS OF A SIMPLE PROGRAM OF HOME-MADE STRETCHING IN FIBROMYALGIA /<br />
L. Cavagna* - R. Caporali - L. Lepri - S. Rossi - S. Balduzzi - E. Prisco - C. Montecucco<br />
THU0349 ASSESSMENT OF DRY EYE SYMPTOMS IN PRIMARY FIBROMYALGIA / M. Antivalle* - M. Battellino - A. Batticciotto - M. C. Ditto<br />
- A. Mutti - V.Varisco - F. Atzeni - P. Sarzi-Puttini<br />
THU0350 SMOKING IS ASSOCIATED WITH REDUCED IGF-1 LEVELS AND HIGHER PAIN EXPERIENCE IN PATIENTS WITH<br />
FIBROMYALGIA / M. Bokarewa* - J. Bjersing - H. Alhafed - M. Erlandsson - M. Dehlin - K. Mannerkorpi<br />
THU0351 NEGATIVE LIFE EVENTS BEFORE THE DISEASE ONSET AND DISEASE OUTCOME IN LONG TERM FOLLOW UP OF PAIN,<br />
SLEEP, FATIGUE AND GENERAL WELL-BEING / M. L. Kukkurainen* - M. Sallinen - M. Mikkelsson - U. M. Anderberg -<br />
H. Kautiainen on behalf of Marja Leena Kukkurainen<br />
THU0352 TROCHANTERIC BURSITIS: IS THERE ULTRASONOGRAPHIC EVIDENCE TO SUGGEST INFLAMMATION? / N. Schlesinger*<br />
- P. Dundeva-Baleva - A. Abdel-Megid - A. Borham<br />
THU0353 THE PREVALENCE OF VITAMIN D DEFICIENCY IN 55 NEW PATIENTS DIAGNOSED WITH FIBROMYALGIA AT FIRST VISIT<br />
TO RHEUMATOLOGY OUTPATIENT CLINICS IN CORK, IRELAND / O. E. Hussein* - W. J. Tee - M. J. Regan<br />
THU0354 ATTENTIONAL IMPAIRMENT IN CHRONIC CENTRAL AND PERIPHERAL PAIN: CONTROLLED STUDY / S. Akdogan -<br />
F. Ayhan - P. Borman*<br />
THU0355 MONOTHERAPY VERSUS COMBINATION THERAPY IN THE TREATMENT OF FIBROMYALGIA / S. Metyas* - M. Ibrahim -<br />
E. C. Ortiz - S. Maher - D. Arkfeld<br />
THU0356 BENEFITS OF A MULTIDISCIPLINARY TREATMENT IN WOMEN WITH FIBROMYALGIA AND OBESITY / S. Castro* -<br />
R. Fontova - M. J. Poveda - A. Castel - R. Qanneta - S. Montull - R. Periñan - I. Miralles - N. Aragonés - I. Salvat - R. Cascón<br />
- S. Monterde - A. Padrol - C. Añez - M. Rull on behalf of Multidimentional Pain Research Group. IISPV. Tarragona. Spain<br />
THU0357 PREDICTIVE VALUE OF EXERCISE STRESS TEST (24H TEST&RE-TEST) AND COGHEALTH© IN DIFFERENTIAL DIAGNOSIS<br />
OF CHRONIC FATIGUE SYNDROME VS. FIBROMYALGIA / S. Garcia-Blanco* - V. Poca-Dias - C. Santos - A. Cuscó-Segarra -<br />
V. Torrente-Segarra - F. J. Garcia-Fructuoso<br />
THU0358 THE GERMAN FIBROMYALGIA CONSUMER REPORTS – A CROSS-SECTIONAL SURVEY / W. Häuser*<br />
THU0359 A BIO-PSYCHO-SOCIAL APPROACH FOR ASSESSING ASSOCIATIONS WITH CHANGES IN PERCEIVED HEALTH IN<br />
RECENTLY DIAGNOSED FIBROMYALGIA PATIENTS / Y. Van Eijk-Hustings* - M. Kroese - A. Boonen - M. Bessems-Beks -<br />
R. Landewé<br />
Infection-related rheumatic diseases<br />
THU0360 INTERFERON-GAMMA RELEASE ASSAYS IN RHEUMATIC PATIENTS: BASELINE STUDY AND IN THE COURSE OF ANTI-<br />
TUMOR NECROSIS FACTOR-ALPHA AGENTS / M. Martínez-Morillo - S. Mínguez - L. Mateo - I. Latorre - J. Domínguez -<br />
D. Grados - B. Tejera - A. Riveros* - S. Holgado - A. Olivé - X. Tena<br />
THU0361 PARANEOPLASTIC ARTHRITIS: A MULTI-CENTERED EXPERIENCE / B. Kisacik* - A. M. Onat - T. Kasifoglu - Y. Pehlivan -<br />
O. N. Pamuk - E. Dalkilic - S. Dönmez - S.Y. Bilge - S.Yilmaz - H. Erdem - R. Mercan - M. A. Ozturk - C. Bes - M. Soy - S. Erten<br />
- V. Cobankara - S. Senel - F. A. Oner - H. Direskeneli - S.Yilmaz - S. Kul - G.Y. Cetin - M. Sayarlioglu<br />
THU0362 ISOLATED SACRAL TUBERCULOSIS: REPORT OF THREE CASES / F. Lazrak* - F.-Z. Elouazzani - F.-Z. Abourazzak - L. tahiri<br />
- M. benzagmout - M. El Faiz Chaoui - T. Harzy<br />
THU0363 LATENT TUBERCULOSIS INFECTION AND VIRAL HEPATITIS IN A COLOMBIAN COHORT OF PATIENTS WITH BIOLO-<br />
GICAL THERAPY / F. Gonzalez-Malaver* - C. M. Guzman-Vergara - J. M. Bello-Gualtero - J. Varela - A. M. Mesa-Betancourt<br />
- J. Londoño - R.Valle-Oñate<br />
THU0364 LONGTERM FOLLOW-UP FOR PATIENTS MIT RETROPERITNOEAL FIBROSIS AFTER MEDICAL AND SURGICAL TREAT-<br />
MENT / H. Cash* - C. Noack - T. F. Fuller - G. Riemekasten<br />
THU0365 SYPHILITIC UVEITIS: A MULTICENTER STUDY OF 50 CASES / I. Pérez-Martín* - R. Blanco - A. Fonollosa - M. Sorribas -<br />
D. Díaz-Valle - A. Adán - V. Llorens - L. Distefano - M. Cordero - A. Blanco - J. Cañal - M. A. González Gay<br />
THU0366 DOES BEING A HEPATITIS B VIRUS CARRIER DECREASE APPLYING TO HOSPITAL IN PATIENTS WITH RHEUMATOID<br />
ARTHRITIS AND ANKYLOSING SPONDYLITIS? / O. Karadag* - N.Yilmaz - A.Yazici - B. Kisacik - S.Yilmaz - T. Kasifoglu -<br />
U. Kalyoncu - H. Temiz - B. Baysal - A. M. Onat<br />
THU0367 JOINT ECHINOCOCCOSIS: A REPORT OF THREE NEW CASES / W. Hamdi* - M. M. Ghannouchi - M. Bouaziz - F. M. Ladeb<br />
- M. M. Kchir<br />
THU0368 RISK OF HERPES VIRUSES INFECTIONS (HSV,VZV) DURING ANTI-TNF THERAPY IN PATIENTS WITH INFLAMMATORY<br />
RHEUMATIC DISEASES. SYSTEMATIC REVIEW AND META-ANALYSIS / H. Che - J. Morel - B. Combe - C. Lukas*<br />
THU0369 SEPTIC ARTHRITIS: CHANGING TRENDS IN EPIDEMIOLOGY OVER TWO DECADES / R. Kalagate - A. Rivera - C. H. Pritchard<br />
- L. H. Brent*<br />
THU0370 RISK INFECTION ASSESSMENT IN RHEUMATOID ARTHRITIS PATIENTS FROM THE PORTUGUESE BIOREPORTAR AND<br />
REGISTAR DATABASES / I. Silva* - F. Araújo - M. Mateus - J. C. Branco<br />
* Presenting author<br />
Thursday, 7 June 2012<br />
67
Thursday, 7 June 2012<br />
68<br />
eular berlin 2012<br />
<strong>Scientific</strong> Poster Session 1 11:45 - 13:30<br />
Other orphan diseases<br />
THU0371 INCREASED EXPRESSION OF INFLAMMATORY CYTOKINES AND CHEMOKINES IN AN AUTOINFLAMMATORY<br />
DISORDER, NAKAJO-NISHIMURA SYNDROME / K. Arima* - N. Kanazawa - F. Furukawa - H. Ida - K.Yoshiura<br />
THU0372 MRI QUANTIFICATION OF FAT INFILTRATION IN SKELETAL MUSCLE OF PATIENTS WITH CAMPTOCORMIA / S. Guis* -<br />
J. P. Mattei - Y. Le Fur - N. Cuge - E. Soulier - P. Cozzone - D. Bendahan<br />
THU0373 CLINICAL PRESENTATION OF ERDHEIM-CHESTER DISEASE: DATA FROM A COHORT OF 10 PATIENTS AND REVIEW OF<br />
THE LITERATURE / G. Cavalli* - B. Guglielmi - C. Campochiaro - A. Berti - M. G. Sabbadini - L. Dagna<br />
THU0374 ARTICULAR SYMPTOMS IN CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME : A RETROSPECTIVE FRENCH STUDY /<br />
L. Houx* - X. Guennoc - E. Hachulla - I. Koné-Paut - P. Quartier - G. Grateau - P. Pillet - M. Hamidou - I. Lemelle - A. Pagnier -<br />
B. Neven - C. Richez - V. Devauchelle-Pensec<br />
THU0375 MALONDIALDEHYDE SERUM LEVELS AND MYCOARDIAL GLOBAL STRAIN IN IDIOPATHIC INFLAMMATORY<br />
MYOPATHY / K. Ramirez-Santillan* - M.Vazquez-Zaragoza - A. Camargo-Coronel - E. Gomez - B. Mendoza-Perez - L. Moreno-<br />
Ruiz - A. Chavez-Negrete - L. Barile-Fabris<br />
THU0376 SERUM LEPTIN, RESISTIN, VISFATIN AND ADIPONECTIN LEVELS IN TUMOR NECROSIS FACTOR RECEPTOR-ASSOCI-<br />
ATED PERIODIC SYNDROME (TRAPS) / L. Cantarini* - L. Obici - G. Simonini - R. Cimaz - M. R. Bacarelli - G. Merlini - A.Vitale<br />
- O. M. Lucherini - M. G. Brizi - M. Galeazzi - A. Fioravanti<br />
THU0377 EFFICACY, SAFETY AND PHARMACOKINETICS OF THE ANTI-INTERLEUKIN-1 BETA ANTIBODY CANAKINUMAB IN<br />
PATIENTS WITH SCHNITZLER SYNDROME / H. D. De Koning* - J. Schalkwijk - J. van der Ven-Jongekrijg - M. Stoffels -<br />
J. W. van der Meer - A. Simon<br />
THU0378 INTERLEUKIN-6 BLOCKING THERAPY BY TOCILIZUMAB IN PATIENTS WITH MULTICENTRIC CASTLEMAN’S DISEASE<br />
RESULTS IN A SIGNIFICANT DECREASE IN SERUM LEVELS OF IGG4 AND IGE / M. Murakami* - T. Matsutani - C. Aoki -<br />
H.-M. Lee - Y. Li - N. Nishimoto<br />
THU0379 A 20 YEAR SINGLE CENTRE EXPERIENCE OF AA AMYLOIDOSIS DEMONSTRATING CHANGES IN ITS EPIDEMIOLOGY /<br />
H. J. Lachmann* - J. D. Gillmore - A. D. Wechalekar - S. D. Gibbs - J. H. Pinney - D. M. Rowczenio - H. Trojer - T. Lane - C. P.<br />
Venner - S. M. Banypersad - J. A. Gilbertson - F. T. Hunt - D. Gopaul - D. F. Hutt - N. Wassef - M. B. Pepys - P. N. Hawkins<br />
THU0380 ENTHESOPATHY IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER AND ITS ASSOCIATION WITH MEFV GENE<br />
M694V VARIANT / A. Tufan - R. Mercan - M. E. Tezcan - A. Kaya - B. Bitik - M. A. Ozturk* - S. Haznedaroglu - B. Goker<br />
THU0381 CLINICAL DETERMINANTS OF ATTACK PRODROME IN PATIENTS WIHT FAMILIAL MEDITERRANEAN FEVER / A. Tufan-<br />
R. Mercan - M. E. Tezcan - A. Kaya - B. Bitik - M. A. Ozturk* - S. Haznedaroglu - B. Goker<br />
THU0382 FAMILIAL MEDITERRANEAN FEVER (FMF) - DISEASE ACTIVITY AND QUALITY OF LIFE IN ADULT PATIENTS OF TURKISH<br />
ANCESTRY LIVING IN TURKEY OR GERMANY / A. Giese* - A. Örnek - M. Kurucay - L. Kiliç - S. S?endur - S. Kiraz - E. Lainka<br />
- B. F. Henning<br />
THU0383 KIKUCHI’S DISEASE AND SYSTEMIC LUPUS ERYTHEMATOUS: A SYSTEMATIC LITERATURE REVIEW / B. Sopeña * -<br />
A. Chamorro - L. Gonzalez - A. Rivera - B. Maure - M. Freire - C. Martínez-Vázquez<br />
THU0384 SPONTANEOUS PANNICULITIS (WEBER-CHRISTIAN DISEASE): CLINICAL COURSE VARIANTS / B. S. Belov* - O. N. Egorova<br />
- O.V. Pushkova - Y. A. Karpova - S. G. Radenska-Lopovok<br />
THU0385 COGAN SYNDROME: A PORTUGUESE SINGLE CENTER COHORT REPORT / C. Ponte A. Castro* - C. Macieira - C. Miranda<br />
Rosa - J. A. Pereira da Silva<br />
THU0386 EFFICACY OF LONG-TERM TREATMENT WITH BIOLOGIC AGENTS IN REFRACTORY ADULT ONSET STILL’S DISEASE: A<br />
SINGLE CENTRE EXPERIENCE ON 16 PATIENTS / E. Della Torre* - S. Franchini - E. Baldissera - G. Cavalli - E. P. Bozzolo -<br />
M. G. Sabbadini<br />
THU0387 RELATIONSHIP BETWEEN PATTERNS OF CLINICAL PRESENTATION UVEITIS AND FINAL IMMUNOLOGIC DIAGNOSIS<br />
/ E. Toledano* - Z. Rosales - Ó. Fontseré - C.Vadillo - R. Méndez - M. Á. Descalzo - E. Loza - E. Pato<br />
THU0388 TOCILIZUMAB STRONGLY SUPPRESSES THE SERUM AMYLOID A LEVEL IN REFRACTORY ADULT – ONSET STILL’S<br />
DISEASE ASSOCIATED AMYLOIDOSIS / H. M. Al Attia* - M. A. Ibrahim<br />
THU0389 ERYTHEMA OVER THE JOINT MAY HELP TO DISTINGUISH FAMILIAL MEDITERRANEAN FEVER FROM OTHER RHEUMA-<br />
TOLOGIC CONDITIONS / S. Ugurlu - F. Mehmedali - F. Nalci - A. Gurbuz - B. Canbay - Y. Sengul - G. Hatemi - H. Ozdogan*<br />
THU0390 PROLONGED DISEASE-FREE INTERVAL IN FAMILIAL MEDITERRANEAN FEVER: A DISTINCT SUBSET WITH UNIQUE<br />
CLINICAL, DEMOGRAPHIC AND MOLECULAR CHARACTERISTICS / I. Ben-Zvi* - T. Krichely-Vachdi - O. Feld - M. Lidar -<br />
S. Kivity - A. Livneh<br />
THU0391 ANTI-TNF THERAPY IN SEVERE AND REFRACTORY SARCOIDOSIS: MULTICENTER STUDY OF 25 PATIENTS / I. Pérez-<br />
Martín* - R. Blanco - N. Ortego - V. Llorens-Bellés - A. Adán - A. Olivé - W. A. Sifuentes Giraldo - S. González - C. Bejerano -<br />
M. C. González-Vela - M. A. González-López - H. Fernández-Llaca - A. Oterino - M. J. Sedano - M. Agudo - A. Corrales -<br />
V. M. Martínez-Taboada - M. A. Gónzalez-Gay<br />
THU0392 BETA-CONFIDENT-REGISTRY: EFFICACY AND SAFETY OF CANAKINUMAB IN CRYOPYRIN ASSOCIATED PERIODIC<br />
SYNDROME - 18 MONTH FOLLOW-UP / J. Kuemmerle-Deschner* - P. Hawkins - H. Hoffman - T. Van der Poll - U. Walker -<br />
H. Tilson<br />
THU0393 THE CLINICAL OBSERVATIONAL STUDY OF ADULT ONSET STILL’S DISEASE IN A LARGE COHORT OF KOREAN<br />
PATIENTS / J. J. Kim* - K. H. Jung - Y. B. Joo - C. B. Choi - Y. K. Sung - J. B. Jun - T. H. Kim - S. C. Bae - D. H.Yoo<br />
THU0394 MACROPHAGE ACTIVATION SYNDROME IN ADULT ONSET STILL’S DISEASE: A SINGLE CENTER EXPERIENCE /<br />
L. O. Damian* - I. Felea - S.-P. Simon - M. Lupse - C. Bodolea - L. Ghib - R. Mocanu - S. Rednic<br />
* Presenting author
eular berlin 2012<br />
<strong>Scientific</strong> Poster Session 1 11:45 - 13:30<br />
THU0395 TUMOUR NECROSIS FACTOR-ALPHA AS A MASTER REGULATOR OF INFLAMMATION IN ERDHEIM-CHESTER<br />
DISEASE: RATIONALE FOR THE SUCCESSFUL TREATMENT OF TWO PATIENTS WITH INFLIXIMAB / L. Dagna* - A. Corti -<br />
S. Langheim - B. Guglielmi - G. Cavalli - F. De Cobelli - C. Doglioni - G. Fragasso - M. G. Sabbadini - M. Ferrarini<br />
THU0396 EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH TNF RECEPTOR ASSOCIATED PERIODIC SYNDROME<br />
(TRAPS) / M. Gattorno* - L. Obici - A. Meini - V. Tormey - K. Abrams - N. Davis - C. Andrews - H. Lachmann<br />
THU0397 EFFICACY OF PAMIDRONATE IN CHILDREN WITH OSTEOGENESIS IMPERFECTA : AN OPEN PROSPECTIVE STUDY /<br />
M. El Rakaawi* - N. Hammoumraoui - S. Mellal - F. Sadouki - S. Lehtihet - W. Kerri - H. Djoudi<br />
THU0398 EFFICACY OF RITUXIMAB AND OTHER IMMUNOSUPPRESSANTS FOR IGG4-RELATED DISEASE / M. Yamamoto* -<br />
H. Takahashi - Y. Naishiro - T. Tabeya - K. Ishigami - Y. Shimizu - H.Yajima - M. Matsui - C. Suzuki - H.Yamamoto - S. Honda -<br />
T. Abe - Y. Suzuki - T. Himi - K. Imai - Y. Shinomura<br />
THU0399 IS PERNIO A MICROVASCULAR DISEASE? / M. Ozmen* - V. Kurtoglu - G. Can - E. F. Tarhan - D. Soysal - S. L. Aslan<br />
THU0400 INHIBITION OF IL-6 SIGNALLING: A NOVEL THERAPEUTIC APPROACH FOR FAMILIAL MEDITERRANEAN FEVER /<br />
N. Stein* - M. Witt - M. Baeuerle - H. Schulze-Koops - M. Gruenke<br />
THU0401 SUCCESSFUL USE OF CANAKINUMAB IN ADULT-ONSET STILL’S DISEASE REFRACTORY TO SHORT ACTING IL-1<br />
INHIBITORS / P. Efthimiou* - O. Petryna - B. Mehta - A. Kontzias - J. Cush<br />
THU0402 EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH NOMID/CINCA / R. Goldbach-Mansky* - C. Sibley - S. D. Felix<br />
- C. Brewer - K. King - C. Zalewski - H. J. Kim - R. Bishop - A. Chakraborty - L. Colin - A. Chioato<br />
THU0403 SINONASAL SARCOIDOSIS: REVIEW OF CLINICAL AND IMAGING FEATURES: 7 YEAR EXPERIENCE / R. Joshi* - J. Zenga<br />
- A. Getz - N. Debnath<br />
THU0404 VITAMIN D LEVEL IN PATIENTS WITH EARLY ARTHRITIS. A PRELIMINARY REPORT / R. Sokolik* - M. Madej - B. Nowak -<br />
L. Korman - P. Wiland<br />
THU0405 CHARACTERIZATION OF THE GROUP OF PATIENTS WITH IGG4-RELATED SYSTEMIC DISEASE IN RUSSIAN POPULA-<br />
TION / S. Sedyshev* - V.Vasilyev - A. Kovrigina<br />
THU0406 EVALUATION OF PERIODONTAL PARAMETERS IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER / S. Senel* -<br />
V. Bostanci - H. Toker - S. Safak<br />
THU0407 SERUM GHRELIN AND OBESTATIN LEVELS IN BEHÇET’S DISEASE / S. S. Koca* - M. Ozgen - R. Dayanan - M. Kara - N. Ilhan<br />
- A. Isik<br />
THU0408 DEEP INSPIRATORY BREATH HOLD PET/CT IS USEFUL FOR MONITORING OF ACTIVITY IN RHEUMATIC DISEASE<br />
ASSOCIATED LUNG INTERSTITIAL PNEUMONITIS / T. Uehara* - M.Takeno - K.Terauchi - D. Kishimoto - K.Takase - M. Hama<br />
- A. Ihata - A. Ueda - Y. Ishigatsubo<br />
THU0409 MIXED CONNECTIVE TISSUE DISEASE AND UNDIFFERENTIATED CONNECTIVE TISSUE DISEASE: DO DOCTORS<br />
CLASSIFY CORRECTLY? / Y. B. Joo* - J. H. Kim - C.-B. Choi - T.-H. Kim - J.-B. Jun - S.-C. Bae - D.-H.Yoo - Y.-K. Sung<br />
THU0410 CHARACTERISATION OF INTERSTITIAL LUNG DISEASE ASSOCIATED WITH ADULT STILL'S DISEASE / Y. Takakuwa* -<br />
H.Yamada - H. Ito - S. Ooka - Y.Yamasaki - H. Nakano - M. Hiida - Y. Kurihara - S. Ozaki<br />
Diagnostics and imaging procedures<br />
THU0411 UTILITY OF ULTRASOUND SCORES IN ASSESSMENT ENTHESITIS ON ANTI-TNF THERAPY OF SPONDYLOARTHRITIS<br />
PATIENTS / A. M. Istrate* - E. de Miguel on behalf of Ioana Felea, Miguel Ángel Caracuel Ruíz, Eduardo Collantes-Estevéz<br />
THU0412 REACTIVE HYPEREMIA INDEX (RHI) IS ASSOCIATED WITH MACROVASCULAR DISEASE AND LUNG DISEASE IN<br />
SYSTEMIC SCLEROSIS / A. Meyer* - A. Theulin - A. Theulin - E. Chatelus - E. Chatelus - C. Sordet - R.-M. Javier - B. Geny -<br />
J.-E. Gottenberg - J. Sibilia<br />
THU0413 MAGNETIC RESONANCE IMAGING OF HANDS AND FEET JOINTS OF ACPA POSITIVE PERSONS WITHOUT CLINICAL<br />
ARTHRITIS / A. Krabben* - W. Stomp - L. K. P. M. Brakenhoff - D. M. F. M. van der Heijde - J. L. Bloem - T. W. J. Huizinga -<br />
M. Reijnierse - A. H. M. van der Helm-van Mil<br />
THU0414 DETERMINATION AND QUANTIFICATION OF SYNOVIAL INFLAMMATION BY MAGNETIC RESONANCE IMAGING IN<br />
SYSTEMIC SCLEROSIS / B. N. Stamenkovic* - A. M. Stankovic - A. N. Dimic - J. M. Nedovic - N. Damjanov - S. K. Stojanovic -<br />
D. Menkovic<br />
THU0415 INCREASED RIGIDITY OF SALIVARY GLANDS AS INDICATED BY SONOELASTOGRAPHY IS ASSOCIATED WITH<br />
REDUCED SALIVA PRODUCTION IN PRIMARY SJÖGREN’S SYNDROME / C. Dejaco* - T. DeZordo - D. Heber - R. Lipp - A. Lutfi<br />
- M. Magyar - D. Zauner - W. B. Graninger - J. Hermann<br />
THU0416 THE USEFULNESS OF A MUSCULOSKELETAL ULTRASOUND (MUS) SCORING SYSTEM FOR 22 HAND JOINTS EXAMI-<br />
NATION FOR THE DETECTION OF EARLY UNDIFFERENTIATED INFLAMMATORY ARTHRITIS AND TREATMENT<br />
DECISIONS MAKING IN ESTABLISHED INFLAMMATORY ARTHRITIS / C. Ciurtin* - M. Ehrenstein - M. Leandro - D. Dey -<br />
A. Nandagudi - V. Morris - I. Giles - J. Ioannou - D. Sen - M. Shipley - D. Isenberg<br />
THU0417 EXPOSURE, LATENT TUBERCULOSIS, OR DISSEMINATED INFECTION? THE ROLE OF TST, QUANTIFERON, AND MULTI-<br />
SITE CULTURES IN HIGH RISK PATIENTS ON TNF-INHIBITORS / D. Cooray - R. Moran - P. P. C. Chen - J. A. Louie - G.<br />
A. Karpouzas*<br />
THU0418 AUTOMATED INTERPRETATION OF ANCA PATTERNS – A NEW APPROACH IN THE SEROLOGY OF ANCA ASSOCIATED<br />
VASCULITIS / D. Roggenbuck* - I. Knütter - R. Hiemann - T. Brumma - T. Büttner - K. Großmann - K. Conrad - D. Reinhold -<br />
E. Csernok<br />
* Presenting author<br />
Thursday, 7 June 2012<br />
69
Thursday, 7 June 2012<br />
70<br />
* Presenting author<br />
eular berlin 2012<br />
<strong>Scientific</strong> Poster Session 1 11:45 - 13:30<br />
THU0419 A NOVEL TECHNIQUE TO QUANTIFY BONE EROSIONS IN PATIENTS WITH RHEUMATOID DISEASES USING HIGH-<br />
RESOLUTION PQCT IMAGES / D. Toepfer* - S. Finzel - O. Museyko - G. Schett - K. Engelke<br />
THU0420 A CITRULLINATED AND MMP DEGRADATED VIMENTIN NEOEPITOPE AS A NOVEL RHEUMATIC BIOMARKER / E.Vassiliadis*<br />
- W. P. Maksymowych - C. Zhang - K. L. Duffin - C. Christiansen - D. J. Leeming - M. A. Karsdal - A. C. Bay-Jensen<br />
THU0421 INFLUENCE OF CLINICAL, LABORATORY AND IMAGE FINDINGS ON THE CRITERIA-BASED DIAGNOSIS AND CLASSI-<br />
FICATION OF PATIENTS IN NEW-ONSET SPONDYLOARTHRITIS UNITS: RESULTS FROM THE ESPERANZA COHORT /<br />
E. G. Tomero * - L. Carmona - J. Mulero - E. De Miguel - M. Gobbo - C. Martínez on behalf of ESPERANZA GROUP<br />
THU0422 ICG-ENHANCED FLUORESCENCE OPTICAL IMAGING REVEALS SUBCLINICAL DISEASE ACTIVITY IN RHEUMATOID<br />
AND PSORIATIC ARTHRITIS PATIENTS WHO HAVE ACHIEVED CLINICAL REMISSION / F. Spiecker* - S. G. Werner -<br />
C. Hermsen - M. Bahner - M. Backhaus - H.-E. Langer<br />
THU0423 CCL18 – A POTENTIAL BIOMARKER OF FIBRO-INFLAMMATORY ACTIVITY IN CHRONIC PERIAORTITIS / F. Kollert* - M. Binder<br />
- C. Probst - M. Uhl - A. Zirlik - G. Kayser - R. E.Voll - H.-H. Peter - G. Zissel - A. Prasse - K. Warnatz<br />
THU0424 NEAR-INFRARED SPECTROSCOPY DURING EXERCISE AND RECOVERY IN CHILDREN WITH JUVENILE DERMATO-<br />
MYOSITIS / G. E. A. Habers* - R. de Knikker - M. van Brussel - E. Hulzebos - D. F. Stegeman - A. van Royen - T. Takken<br />
THU0425 ASSOCIATIONS BETWEEN RADIOGRAPHIC AND CLINICAL OSTEOARTHRITIS FEATURES AND MRI-DEFINED BONE<br />
MARROW LESIONS IN THE FINGER JOINTS / I. K. Haugen* - P. Bøyesen - B. Slatkowsky-Christensen - S. Sesseng - D. van der<br />
Heijde - T. K. Kvien<br />
THU0426 IS CONTRAST MATERIAL NEEDED FOR THE MRI SCORING OF SYNOVITIS OF THE HAND IN PATIENTS WITH RHEUMA-<br />
TOID ARTHRITIS? – A SYSTEMATIC COMPARISON OF 0.23, 0.6, 1.5 AND 3.0 TESLA MRI / I. Eshed* - S. Krabbe -<br />
M. Østergaard - P. Bøyesen - J. Møller - F. Therkildsen - O. R. Madsen - S. Juhl Pedersen<br />
THU0427 NAIL FOLD CAPILLAROSCOPY IN LUPUS ERYTHEMATOSUS – EFFECT OF CLINICAL MANIFESTATIONS AND GENDER<br />
/ J. Richter* - P. Klein-Weigel - H. Acar - R. Fischer-Betz - M. Schneider - O. Sander<br />
THU0428 VALIDITY AND RELIABILITY OF 3D US FOR DETECTION OF EROSIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS<br />
USING MRI AS GOLD STANDARD / K. Ellegaard* - H. Bliddal - U. Døhn Møller - M. Henriksen - M. Boesen - R. Bouert -<br />
B. Danneskiold-Samsøe - S. Torp-Pedersen<br />
THU0429 WHICH DIAGNOSIS IN CASE OF POSITIVITY OF ANTI-CCP IN RHEUMATOLOGICAL DAILY PRACTICE? (EVALUATION<br />
OF THE PERFORMANCES OF ANTI-CCP IN 517 CONSECUTIVE PATIENTS) / L. Bialé* - C. Goulvestre - N. Kavian - M. Dougados<br />
THU0430 IMAGE PATTERN IN FLUORESCENCE OPTICAL IMAGING OF THE HANDS: DOES XIRALITE SUPPORT DIFFERENTIAL<br />
DIAGNOSIS? – A FEASIBILITY STUDY / M. Bahner* - C. Schwenke - M. Schirner<br />
THU0431 LOCALISATION OF BONE MARROW EDEMA IN SACROILIAC JOINTS IN SPONDYLOARTHRITIS PATIENTS: DOES THE<br />
SITE OF LESIONS CHANGE OVER A 3-MONTH PERIOD? / M. de Hooge* - R. van den Berg - M. Reijnierse - V. Navarro-<br />
Compán - F. van Gaalen - T. Huizinga - D. van der Heijde<br />
THU0432 BONE EROSIONS IN RHEUMATOID ARTHRITIS: ULTRASOUND FINDINGS IN THE EARLY STAGE OF THE DISEASE /<br />
M.-M. Tamas* - E. Filippucci - A. Becciolini - M. Gutierrez - L. Di Geso - K. Bonfiglioli - P.V.Voulgari - F. Salaffi - W. Grassi<br />
THU0433 PREVALENCE OF SUB-CLINICAL CAROTID ATHEROSCLEROSIS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND<br />
PSORIATIC ARTHRITIS: A NEW AUTOMATED RADIOFREQUENCY-BASED ULTRASOUND MEASUREMENT OF COMMON<br />
INTIMA-MEDIA THICKNESS / M. Gutierrez* - E. Naredo - L. Di Geso - I. Moller - A. Iagnocco - F. Salaffi - E. Filippucci - W.<br />
Grassi<br />
THU0434 THREE-DIMENSIONAL POWER DOPPLER SONOGRAPHIC EVALUATION OF FINGER JOINTS IN PATIENTS WITH<br />
RHEUMATOID ARTHRITIS / M. SATO* - M. TAKEMURA - K. SHIMIZU - T. WATANABE - D. FUKUOKA - R. SHINOHE -<br />
Y. SHINOHE<br />
THU0435 DETECTION OF SYNOVITIS, BONE EROSIONS, AND BONE MARROW OEDEMA IN PATIENTS WITH INFLAMMATORY<br />
HAND PAIN - A COMPARISON OF LOW FIELD MRI AND HIGH FIELD MRI / M. S. Saltzherr* - J. J. Luime - B. J. Ejbjerg -<br />
M. Østergaard - P. G. Conaghan - R. Ouwendijk - J. M. Hazes - G. S. Muradin<br />
THU0436 USEFULNESS OF SALIVARY GLANDS ULTRASONOGRAPHY IN THE NON INVASIVE EARLY DETECTION OF SUBCLIN-<br />
ICAL GLANDULAR INVOLVEMENT IN PSS / N. Luciano* - C. Baldini - R. Pascale - A. Paolicchi - F. Ferro - D. Caramella -<br />
S. Bombardieri<br />
THU0437 EVALUATION OF SEPARATE QUANTITATIVE RADIOGRAPHIC FEATURES ADDS TO THE PREDICTION OF INCIDENT<br />
RADIOGRAPHIC OSTEOARTHRITIS IN INDIVIDUALS WITH RECENT ONSET OF KNEE PAIN: FIVE-YEAR FOLLOW-UP IN<br />
THE CHECK COHORT / P. M. Welsing* - M. B. Kinds - A. C. Marijnissen - K. L.Vincken - M. A.Viergever - K. W. Drossaers-Bakker<br />
- J. W. Bijlsma - S. M. Bierma-Zeinstra - F. P. Lafeber<br />
THU0438 PREDICTIVE VALUE OF ULTRASOUND ON THE RESPONSE TO STEROID INFILTRATIONS IN THE PAINFUL SHOULDER:<br />
A PROSPECTIVE CONTROLLED SINGLE-BLIND STUDY OF 70 PATIENTS / P. Zufferey* - E. Naredo - Y. Henchoz - A. So<br />
THU0439 AN EVALUATION OF A NOVEL TECHNIQUE FOR FULLY AUTOMATIC SYNOVITIS QUANTIFICATION FROM PRE- AND<br />
POST-CONTRAST WRIST MRI / P. Mysling* - E. Dam - S. Zaim - H. K. Genant - T. Fuerst - M. Lillholm<br />
THU0440 EFFECTIVENEEFFECTIVENESS OF ULTRASOUND GUIDED CORTICOSTEROIDS INJECTIONS IN INTERDIGITAL<br />
MORTON'S NEUROMA A SURVEY OF 23 PATIENTS / R. Ghozlan* - F. zeitoun<br />
THU0441 ENTHESIS INFLAMMATION IN INFLAMMATORY BOWEL DISEASES WITHOUT SPONDYLOARTHRITIS / R. Martínez<br />
Pérez* - E. Rejón - S. Rodríguez Montero - J. L. Marenco de la Fuente<br />
THU0442 MR-DEFINED FAT INFILTRATION OF THE LUMBAR PARAVERTEBRAL MUSCLES DIFFERS BETWEEN NON-<br />
RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS AND ESTABLISHED ANKYLOSING SPONDYLITIS / O. Akgul -<br />
S. Ozgocmen*
eular berlin 2012<br />
<strong>Scientific</strong> Poster Session 1 11:45 - 13:30<br />
THU0443 DIFFERENTIAL DIAGNOSIS BETWEEN RHEUMATOID ARTHRITIS AND PERIPHERAL SPONDYLARTHROPATHIES:<br />
USEFULNESS OF SHOULDERS ULTRASONOGRAPHY / S. Ottaviani* - K. Dawidowicz - E. Palazzo - G. Gill - G. Hayem -<br />
O. Meyer - P. Dieudé<br />
THU0444 REVIEW OF ULTRASOUND FINDINGS IN PATIENTS WITH SHOULDER PAIN. SONOGRAFIC STUDY IN 735 PATIENTS /<br />
S. Muraja* - B. Markulinčič<br />
THU0445 HIGH ULTRASONOGRAPHIC SCORES PERSIST AMONG PATIENTS WITH RHEUMATOID ARTHRITIS IN CLINICAL<br />
REMISSION WITH NORMAL SERUM MMP-3 VALUES / T. Okano* - T. Koike - M. Tada - Y. Sugioka - K. Mamoto - S. Wakitani<br />
- H. Nakamura<br />
THU0446 TRABECULAR BONE TEXTURE PARAMETERS ARE CORRELATED WITH MAGNETIC RESONANCE IMAGING (MRI) BONE<br />
EDEMA AT HAND AND WRIST IN ACTIVE RHEUMATOID ARTHRITIS (RA) / T. Pham* - S. Trijau - R. Chapurlat - D. Loeuille<br />
- T. Schaeverbeke - C. Roux - C. L. Benhamou - O.Vittecoq - J. Sibilia - F. Mistretta - C. Hacquard Bouder<br />
THU0447 CALCULATION OF THE SMALLEST DETECTABLE CHANGE (SDC) OF RADIOGRAPHIC PROGRESSION IN CLINICAL<br />
TRIALS WITH MULTIPLE TIME POINTS: THE MEAN SDC IS A VALID APPROXIMATION OF THE OVERALL SDC / V. Navarro-<br />
Compán* - D. van der Heijde - H. Ahmad - C. Miller - R. Landewé<br />
Education<br />
THU0448 SAFETY COMPETENCES KNOWLEDGE AND BEHAVIOURAL SKILLS OF PATIENTS TREATED BY BIOLOGICS IN RHEUMA-<br />
TOLOGY / A.-C. Rat* - B. Fautrel - E. Flipon - L. Gossec - B.-D. Caritey - L. Margerie - H. Nataf - M. Piperno - B. Pallot Prades -<br />
R. M. Poilvert - V. Royant, - F. Sadji - C. Sordet - C. Thevenot - C. Beauvais<br />
THU0449 INTERNET USE BY PATIENTS AND RHEUMATOLOGISTS: RESULTS OF TWO PARALLEL INVESTIGATIONS IN FRANCE /<br />
D. Poivret* - I. Griffoul - D. Oziel - N. Legoupil - S. Perrot - G. Chales - J.-S. Giraudet-Le Quintrec<br />
THU0450 THERAPEUTIC PATIENT EDUCATION PROGRAM FOR OSTEOPOROSIS DISEASE: DEVELOPMENT, EVALUATION IN<br />
ASSOCIATION WITH A PATIENT GROUP / D. Poivret* - M.-E. Saint-Eve - V. Noirez - L. Carton - C. Cardon - F. Zito<br />
THU0451 IMPLEMENTATION OF THE OSTEOARTHRITIS CLINICAL GUIDELINE: RESULTS OF A CLUSTER RANDOMIZED TRIAL IN<br />
PRIMARY CARE / D. Maximov - O. Lesnyak*<br />
THU0452 DEVELOPING A LONGITUDINAL CURRICULUM TO IMPROVE RHEUMATOLOGICAL SKILLS IN UNDERGRADUATE<br />
MEDICAL STUDENTS / E. L. Bezerra* - F. A. Bezerra Neto - M. J.Vilar - G. D. Azevedo<br />
THU0453 A PICTORIAL INFORMATION LEAFLET IS USEFUL FOR GIANT CELL ARTERITIS PATIENTS TAKING PREDNISOLONE /<br />
K. Mankia* - M. Munir - D. Collins - E. Price - L. Williamson<br />
THU0454 QUESTIONNAIRE SURVEY FOR GOUT-RELATED KNOWLEDGE LEVEL IN 185 CHINESE PHYSICIANS / Q. H. Li - Z. X. Li<br />
- H. J. Liu - M. Lu - Y. H. Li - X. Ou-Yang - T. Li - C. J. Zou - H. R. Schumacher - L. Dai*<br />
THU0455 SURVEY OF PRIMARY CARE PHYSICIANS’ ATTITUDES TO CO-MANAGEMENT MEDICAL COLLABORATION IN TREAT-<br />
MENT OF RHEUMATOID ARTHRITIS: COMPARISON BETWEEN PHYSICIANS WITH AND WITHOUT RHEUMATOLOGY<br />
BOARD CERTIFICATION / S. Mizuki* - T. Murakami - K. Oryoji - K. Kamada - E.Yokota<br />
THU0456 A COMPARATVIE STUDY OF RHEUMATOLOGY TRAINING ACROSS THREE EUROPEAN COUNTRIES / S. Panchal* -<br />
S. Ramiro - A. Moorthy - F. Sivera<br />
THU0457 EVALUATION OF RHEUMATOLOGY ADMISSIONS IN A TEACHING HOSPITAL: A TRAINEE’S PERSPECTIVE / R. Khan -<br />
V. Kr Rao* - K. Chaudhuri<br />
THU0458 ASSESSMENT OF DIETARY CALCIUM INTAKE AMONG RHEUMATOLOGY PATIENTS / X. Grapton* - D. Leclere - P. Lemesle<br />
- L. Poulain - P. Renard<br />
* Presenting author<br />
Thursday, 7 June 2012<br />
71